{"docstore/data": {"bd9c8945-0f61-43a4-a05a-98f04983f080": {"__data__": {"id_": "bd9c8945-0f61-43a4-a05a-98f04983f080", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fe2206e-cade-4790-bea9-72a6d79b8cdc", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "original_text": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year. "}, "hash": "f73a96995a8e66c4464d117e4ea2119b24a2c2cc09aec68ce3151fcd6bf45065", "class_name": "RelatedNodeInfo"}}, "text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion. ", "start_char_idx": 0, "end_char_idx": 669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fe2206e-cade-4790-bea9-72a6d79b8cdc": {"__data__": {"id_": "7fe2206e-cade-4790-bea9-72a6d79b8cdc", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "original_text": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd9c8945-0f61-43a4-a05a-98f04983f080", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6ff26a9a1671185fb400653e8752f9d5ab9aa242177ae9377ee9a8b45d8f2d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "original_text": "On the basis of U.S. "}, "hash": "648b87018a39692d449ed8a39c0abdf7230e74bbe9178c1603ce8420c64b9175", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year. ", "start_char_idx": 669, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511": {"__data__": {"id_": "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fe2206e-cade-4790-bea9-72a6d79b8cdc", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "original_text": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a3e93f414ff178b2e108fcaef23d5a1a217752dd71d4e2c8571ba474dc4692a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c863004e-c2df-4eb7-b406-d25e4e24c40d", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. "}, "hash": "3aaf7bdd32c1e6d0a4c2c6cbb0c29d5bfea84dc067ead6db966e2ec53a90b97e", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 738, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c863004e-c2df-4eb7-b406-d25e4e24c40d": {"__data__": {"id_": "c863004e-c2df-4eb7-b406-d25e4e24c40d", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3bd51cc8ab3dc6a86004dd4625d74979e9bad49bc7ae0b53c6a030859d0d616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ee7199-20bd-428b-8d8f-e8f51dcd268d", "node_type": "1", "metadata": {"window": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. "}, "hash": "7332bc47d167125dedcf7947e07189b347a83706f44a85ac56fddfb5db6b643e", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "start_char_idx": 759, "end_char_idx": 941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ee7199-20bd-428b-8d8f-e8f51dcd268d": {"__data__": {"id_": "d1ee7199-20bd-428b-8d8f-e8f51dcd268d", "embedding": null, "metadata": {"window": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c863004e-c2df-4eb7-b406-d25e4e24c40d", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "601517cbba7902f11a20664fcda9cd0fcdb750c23c21f3c9fa3301a139a7d07d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e619bf4-1178-4c12-a56a-39f3afff092d", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "original_text": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n"}, "hash": "e00147d8adac0e0f58f395a154a9bb4bb3d776f7c8aaa0e33f5c44307dd0616a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "start_char_idx": 941, "end_char_idx": 1160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e619bf4-1178-4c12-a56a-39f3afff092d": {"__data__": {"id_": "6e619bf4-1178-4c12-a56a-39f3afff092d", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "original_text": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ee7199-20bd-428b-8d8f-e8f51dcd268d", "node_type": "1", "metadata": {"window": "Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e1768e8d59ba10575ba33ffcac21380b83386ca2b986add52d27dc12c4f9c32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9d0e3e4-1ee5-4446-b42b-493a19fa1586", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. "}, "hash": "49bfb63a9b5add1079346339a3b0844182c10c72ece26fe6f4e5044000895dd9", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "start_char_idx": 1160, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9d0e3e4-1ee5-4446-b42b-493a19fa1586": {"__data__": {"id_": "c9d0e3e4-1ee5-4446-b42b-493a19fa1586", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e619bf4-1178-4c12-a56a-39f3afff092d", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "original_text": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b2dba2523a382a5726913020a367f2b223639a6951f81f8a8c923a103a29de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dae1d640-4b0c-4614-8046-eff77ea08555", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr. ", "original_text": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. "}, "hash": "d4fa1799b199ef3ceb6aef4e82953580081932373cbe54e62b6c89d0910b8852", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "start_char_idx": 1236, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dae1d640-4b0c-4614-8046-eff77ea08555": {"__data__": {"id_": "dae1d640-4b0c-4614-8046-eff77ea08555", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr. ", "original_text": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9d0e3e4-1ee5-4446-b42b-493a19fa1586", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "761f573e8eded99e17231b60e26280a6743fd614216f6c300ac4df4058ebda22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a40f42ca-8ad8-485f-9fad-7f97a40ecba7", "node_type": "1", "metadata": {"window": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued. ", "original_text": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. "}, "hash": "38f1a2b134d933dda2fe1438cfe41ab710ffc87499a03bbf1d7830ab0bc2a2e9", "class_name": "RelatedNodeInfo"}}, "text": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "start_char_idx": 1333, "end_char_idx": 1483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a40f42ca-8ad8-485f-9fad-7f97a40ecba7": {"__data__": {"id_": "a40f42ca-8ad8-485f-9fad-7f97a40ecba7", "embedding": null, "metadata": {"window": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued. ", "original_text": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dae1d640-4b0c-4614-8046-eff77ea08555", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, including a $6.6 billion expense accrual related to opioid lawsuits, increased\n17.4 percent to $1.89 in the fiscal fourth quarter.  For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr. ", "original_text": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7c884dd6c2c87fa7186ad671909d6322cc2232b74408585cdb768d6e433336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f740528-ed5c-4cd7-adf4-55f71c3f7545", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "original_text": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "9f1ebca6db0d8000aec653308cfc9265e16b059d55ce07b86fb5afc802b5f928", "class_name": "RelatedNodeInfo"}}, "text": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "start_char_idx": 1483, "end_char_idx": 1637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f740528-ed5c-4cd7-adf4-55f71c3f7545": {"__data__": {"id_": "0f740528-ed5c-4cd7-adf4-55f71c3f7545", "embedding": null, "metadata": {"window": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "original_text": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a40f42ca-8ad8-485f-9fad-7f97a40ecba7", "node_type": "1", "metadata": {"window": "For fiscal year 2020, adjusted diluted EPS increased 11.4 percent to $7.90.\n \u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued. ", "original_text": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76dbd1d9878a6048aa5cb1b6f8e63797fb93ba193709e01506c54d5d1a3b19d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db457551-07ce-4033-af2f-3dbaab0f83ee", "node_type": "1", "metadata": {"window": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "original_text": "\"We are well-positioned as we enter fiscal 2021,\" Mr. "}, "hash": "64a552a00f7fa546280bd1092811ee252506b98a683265f0e9eae1686b723445", "class_name": "RelatedNodeInfo"}}, "text": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1637, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db457551-07ce-4033-af2f-3dbaab0f83ee": {"__data__": {"id_": "db457551-07ce-4033-af2f-3dbaab0f83ee", "embedding": null, "metadata": {"window": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "original_text": "\"We are well-positioned as we enter fiscal 2021,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f740528-ed5c-4cd7-adf4-55f71c3f7545", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong revenue and adjusted diluted EPS growth in fiscal year 2020.  Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "original_text": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "373683d858d28ce1bc3d947cb07af8ac33ff278f0bfd1676ace318333cec8e6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7cea242-b704-4816-95b7-4ad2e1e960bd", "node_type": "1", "metadata": {"window": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Collis continued. "}, "hash": "5f27d2ff422ecc2722323ff85bb3ee68e226fb18c3d9996606f9ee08bb30b88c", "class_name": "RelatedNodeInfo"}}, "text": "\"We are well-positioned as we enter fiscal 2021,\" Mr. ", "start_char_idx": 1857, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7cea242-b704-4816-95b7-4ad2e1e960bd": {"__data__": {"id_": "d7cea242-b704-4816-95b7-4ad2e1e960bd", "embedding": null, "metadata": {"window": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db457551-07ce-4033-af2f-3dbaab0f83ee", "node_type": "1", "metadata": {"window": "Working in an unprecedented\nenvironment, our associates rallied around our purpose of being united in our responsibility to create healthier futures.  They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "original_text": "\"We are well-positioned as we enter fiscal 2021,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e84f4609a1cf920891d8c54cf9f831c6ba9dd96ddcb6d6d3f18aa1fddc957224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27911437-bb74-415a-84ca-b624092d5b20", "node_type": "1", "metadata": {"window": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "\"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. "}, "hash": "a0d6de0ce2302071cb3369c7f21d1f64a45fb46e9bd4dff4a24bb3d0e1a4c940", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1911, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27911437-bb74-415a-84ca-b624092d5b20": {"__data__": {"id_": "27911437-bb74-415a-84ca-b624092d5b20", "embedding": null, "metadata": {"window": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "\"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7cea242-b704-4816-95b7-4ad2e1e960bd", "node_type": "1", "metadata": {"window": "They proved\nthe resilience of our business by continuously innovating to meet customer needs and delivering unparalleled execution to meet\npatient needs.  By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "145c850b87b8d69547e0fc0e2a15d95a07f3ec2fbafad4d1f5a6ed9f5864638d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74089d77-d17a-4c63-ab9a-cbbbaf69ffed", "node_type": "1", "metadata": {"window": "\"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n"}, "hash": "ded28c543f5bdee5daa4196a801a11626e86b8c152c3aec36ea905e1f804dd13", "class_name": "RelatedNodeInfo"}}, "text": "\"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "start_char_idx": 1929, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74089d77-d17a-4c63-ab9a-cbbbaf69ffed": {"__data__": {"id_": "74089d77-d17a-4c63-ab9a-cbbbaf69ffed", "embedding": null, "metadata": {"window": "\"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27911437-bb74-415a-84ca-b624092d5b20", "node_type": "1", "metadata": {"window": "By focusing on our values, we ensured a stable supply chain and demonstrated the vital nature of our role in the\nhealth system,\" said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "\"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22c169fa571bc65ed2ace51ab0a45382cfff1b022dab6614f67d904e7e104125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de", "node_type": "1", "metadata": {"window": "Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1"}, "hash": "c0ca143348fbea202b08c9a96990dee947215ae510d6112b2e5d9335f624d921", "class_name": "RelatedNodeInfo"}}, "text": "We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "start_char_idx": 2238, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de": {"__data__": {"id_": "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de", "embedding": null, "metadata": {"window": "Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88211834d16bcc73cfd8af43c57fd75b72c0707a9a56eb408fd2361f724f9dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74089d77-d17a-4c63-ab9a-cbbbaf69ffed", "node_type": "1", "metadata": {"window": "\"We are well-positioned as we enter fiscal 2021,\" Mr.  Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "480a93a46447a47ba0f1cb2861eee368f6bec9efa6524401b3566b9ee0c606ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24daad0f-2890-4b79-9bb7-785941a91e58", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "original_text": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. "}, "hash": "379da2a617141bba591efb30e14381efec133af9eed0d7ab92267795f81469fd", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "start_char_idx": 2386, "end_char_idx": 2649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24daad0f-2890-4b79-9bb7-785941a91e58": {"__data__": {"id_": "24daad0f-2890-4b79-9bb7-785941a91e58", "embedding": null, "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "original_text": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de", "node_type": "1", "metadata": {"window": "Collis continued.  \"We will leverage our strong customer base, leadership in\nspecialty, dedication to innovation, and successful corporate stewardship to grow our portfolio of pharmaceutical-centric services\nand solutions, further our execution excellence, advance our talent, and become an even more unified AmerisourceBergen.  We also\nremain committed to delivering long-term growth and creating value for our shareholders, partners, customers, and the patients\nthey serve.\"\n Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $49.2B $49.2B\nGross Pr ofit $1.3B $1.3B\nOperating Expenses $7.5B $795M\nOperating (Loss) Income $(6.1)B $530M\nInterest Expense, Net $35M $35M\nEffectiv e Tax Rat e 21.1% 21.7%\n1", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53edd5bbb4f76308cac86eb3b8d51d6eb361d1463b1fa8f51557e58527d7a01e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa870e0-e8ed-4c3a-b8da-51a7de61021d", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "ecaf717897fd41f19abb276f19ccbc5be0f945564878bc1d399731e72d7d0cbb", "class_name": "RelatedNodeInfo"}}, "text": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "start_char_idx": 0, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa870e0-e8ed-4c3a-b8da-51a7de61021d": {"__data__": {"id_": "0aa870e0-e8ed-4c3a-b8da-51a7de61021d", "embedding": null, "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24daad0f-2890-4b79-9bb7-785941a91e58", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "original_text": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af53727a7645c22ec494abb802ce8998523b9f95e8b5622db6003e8dd8f6d1b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n"}, "hash": "75e6dc5026a1a033bba73289c9621a5b21e49d39986af4816d674adb38149e7c", "class_name": "RelatedNodeInfo"}}, "text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 279, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce": {"__data__": {"id_": "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce", "embedding": null, "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa870e0-e8ed-4c3a-b8da-51a7de61021d", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b82aaee2ee20849ed05ec935bd6324b013959cb671f360f6fc33a7a9dbdf629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137ef58a-ac1a-4da7-81f8-af9d95634ee1", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n"}, "hash": "64539c0d9cd853eaebaccb9d208b9949f1f8e4769261238936725a231eb207d7", "class_name": "RelatedNodeInfo"}}, "text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "start_char_idx": 371, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137ef58a-ac1a-4da7-81f8-af9d95634ee1": {"__data__": {"id_": "137ef58a-ac1a-4da7-81f8-af9d95634ee1", "embedding": null, "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56538633050861189744a9c0f73bb5fe684c86b82ecbfecee3e68d91a6c37712", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. "}, "hash": "6cc080299b32b5931fdc6cbfa68c748b0d4bc507f2ccc79d8d297a6bc89be8cb", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "start_char_idx": 590, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7": {"__data__": {"id_": "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7", "embedding": null, "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137ef58a-ac1a-4da7-81f8-af9d95634ee1", "node_type": "1", "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8060c4947f9d603ba98c753eee13a83f9c65f9a296bcd3d3ff2d60a5e0503a45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22c7e601-577f-49cb-8ed8-c30ec89692fc", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "original_text": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. "}, "hash": "9e69e24011a9687424a2cb6a03b82b292e50b031bc7792f875f95cf4f0a5d73a", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 904, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22c7e601-577f-49cb-8ed8-c30ec89692fc": {"__data__": {"id_": "22c7e601-577f-49cb-8ed8-c30ec89692fc", "embedding": null, "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "original_text": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3355ecb92139df4b310daaac68ec0e5301fd4fa4ece3a34b3f5b6d0c2406a082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "853b7cb6-a361-474e-8570-325da0038bca", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. "}, "hash": "39f3b77fd12569b47dfc2db69cc9340521e7b6fc98168573a8a42f94110cbbb3", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "start_char_idx": 1065, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "853b7cb6-a361-474e-8570-325da0038bca": {"__data__": {"id_": "853b7cb6-a361-474e-8570-325da0038bca", "embedding": null, "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22c7e601-577f-49cb-8ed8-c30ec89692fc", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "original_text": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1560b5aa0429b27762122abf3bc5bce2b7a3ea3b0b376ef76eb79ba6e9c9e371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "703f156d-862c-4d3c-86e1-fe8cc9082600", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "original_text": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n"}, "hash": "030b33e9a3bdbce69d73be92cad114a5a0b2da7c3298fdd716939ca495d90242", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "start_char_idx": 1221, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "703f156d-862c-4d3c-86e1-fe8cc9082600": {"__data__": {"id_": "703f156d-862c-4d3c-86e1-fe8cc9082600", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "original_text": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "853b7cb6-a361-474e-8570-325da0038bca", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8de759e8a7fc46a12a030c58e73d36dfdd91ae11004d69951744a1aba55870e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b8e792-cd8f-4953-9151-be3bba46648e", "node_type": "1", "metadata": {"window": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. "}, "hash": "789f9e3d46fd867576281d6a883a715ff9bc2ea24f1aa71708612f0b48e393cb", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "start_char_idx": 1383, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b8e792-cd8f-4953-9151-be3bba46648e": {"__data__": {"id_": "19b8e792-cd8f-4953-9151-be3bba46648e", "embedding": null, "metadata": {"window": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "703f156d-862c-4d3c-86e1-fe8cc9082600", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 fourth quarter was $1.3 billion, a 13.7 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "original_text": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac584563aa46c8731ca76e23eb9477173a00fbb41cae1b7ffd9e6903942260a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efa888d4-7245-4a31-86a6-6e150d54c524", "node_type": "1", "metadata": {"window": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "original_text": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n"}, "hash": "a40bed113d136cc2d1f4d69dc53064fc530018397e9311ba069e3de3614af1ca", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "start_char_idx": 1501, "end_char_idx": 1737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efa888d4-7245-4a31-86a6-6e150d54c524": {"__data__": {"id_": "efa888d4-7245-4a31-86a6-6e150d54c524", "embedding": null, "metadata": {"window": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "original_text": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b8e792-cd8f-4953-9151-be3bba46648e", "node_type": "1", "metadata": {"window": "Gross profit in the current fiscal quarter was favorably impacted by the increases in gross\nprofit for both Pharmaceutical Distribution Services and Other.  Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97a9de6f884ddf1b7ec68f4990b91746e26b08e263dc483a666d331ca8820111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1317e049-f628-47d4-975c-a8f2cccf1f18", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "original_text": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. "}, "hash": "34e49e39fa72e757dd4b778dda3e748b2fa677452fd6ec8bc5f37ab290a310e7", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "start_char_idx": 1737, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1317e049-f628-47d4-975c-a8f2cccf1f18": {"__data__": {"id_": "1317e049-f628-47d4-975c-a8f2cccf1f18", "embedding": null, "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "original_text": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efa888d4-7245-4a31-86a6-6e150d54c524", "node_type": "1", "metadata": {"window": "Gross profit was also favorably impacted by a $35.8 million\nLIFO credit in the current year quarter versus a $57.2 million LIFO expense in the prior year period.  Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "original_text": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce56cd200178d628e28678c920a48fc20258b7a6a7fc81291cf2da5314406627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "811378d9-6c2f-4b92-8f6b-23abc41d1bc2", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "original_text": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n"}, "hash": "7675e9d06bd61806c06cc66abd20b90ca57067b6a4298e155c727fee3be93eb8", "class_name": "RelatedNodeInfo"}}, "text": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "start_char_idx": 1911, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "811378d9-6c2f-4b92-8f6b-23abc41d1bc2": {"__data__": {"id_": "811378d9-6c2f-4b92-8f6b-23abc41d1bc2", "embedding": null, "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "original_text": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1317e049-f628-47d4-975c-a8f2cccf1f18", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.74 percent, an increase of 14 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "original_text": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00723d5576a5ed47f0d5a714c03228fe0592bf61d3817b0d16d011e785afaa3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77dda154-9f67-46c3-888f-84d4c097adb4", "node_type": "1", "metadata": {"window": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "original_text": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n"}, "hash": "40e8e42607177f9e01df5c76407ecd6e72f19abb2a077c10833351682ee7f8f8", "class_name": "RelatedNodeInfo"}}, "text": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "start_char_idx": 2064, "end_char_idx": 2156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77dda154-9f67-46c3-888f-84d4c097adb4": {"__data__": {"id_": "77dda154-9f67-46c3-888f-84d4c097adb4", "embedding": null, "metadata": {"window": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "original_text": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "811378d9-6c2f-4b92-8f6b-23abc41d1bc2", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2020, operating expenses were $7.5 billion, compared to $1.0 billion in the\nsame prior year period primarily due to a $6.6 billion expense accrual in connection with opioid lawsuits.  Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "original_text": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c895c5b66de4d15a320e7536412dddf54b8a4163836c705d7fde08254d9bbd3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3193c05-42bb-4696-b21b-32c94195a431", "node_type": "1", "metadata": {"window": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n"}, "hash": "9a96bb7c509af875789a83481389208d2717a6bbd98a5bb5941cb5c4b3ce46d5", "class_name": "RelatedNodeInfo"}}, "text": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "start_char_idx": 2156, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3193c05-42bb-4696-b21b-32c94195a431": {"__data__": {"id_": "c3193c05-42bb-4696-b21b-32c94195a431", "embedding": null, "metadata": {"window": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77dda154-9f67-46c3-888f-84d4c097adb4", "node_type": "1", "metadata": {"window": "Operating expenses\nas a percentage of revenue in the fiscal 2020 fourth quarter were 15.15 percent, compared to 2.20 percent for the same\nperiod in the previous fiscal year.\n Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "original_text": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4568ffff360f930ee9cb8e8eb7568e9be8d2059f7ed997d305fbd76426a8ca0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28228a07-16f7-47aa-99be-946156a6be6e", "node_type": "1", "metadata": {"window": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n"}, "hash": "e9afe262689aa8d489cb2402563072981afe37cd98c5cdc11dd312e77241d98f", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "start_char_idx": 2335, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28228a07-16f7-47aa-99be-946156a6be6e": {"__data__": {"id_": "28228a07-16f7-47aa-99be-946156a6be6e", "embedding": null, "metadata": {"window": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3193c05-42bb-4696-b21b-32c94195a431", "node_type": "1", "metadata": {"window": "Operating (Loss) Income:  In the fiscal 2020 fourth quarter, operating (loss) income was $(6.1) billion versus $179.8 million in\nthe prior year quarter.  Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95a93f2b6eb299c418e0546bfc8478bb4731b5b4deb954d618ea4efa77b7d487", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2", "node_type": "1", "metadata": {"window": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. "}, "hash": "2b6e331a8342ad0bb46eb18c8a3f4db2da8db7151b096afa9583dce034293f26", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "start_char_idx": 2631, "end_char_idx": 2809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2": {"__data__": {"id_": "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2", "embedding": null, "metadata": {"window": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28228a07-16f7-47aa-99be-946156a6be6e", "node_type": "1", "metadata": {"window": "Operating income was negatively impacted by the previously mentioned legal expense accrual.\n Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64a92fc479cb6be27ccc850f717ac5feff9f2bf02fe5447e62d5ca1206a88582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0953262-5102-4766-a52a-88e5d3a74d93", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "original_text": "This decrease was primarily due to the legal expense accrual.\n"}, "hash": "2e5f12ef28e61888e3fc188bc06c4103b03156f391e967146c4b78e2418205c3", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "start_char_idx": 2809, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0953262-5102-4766-a52a-88e5d3a74d93": {"__data__": {"id_": "e0953262-5102-4766-a52a-88e5d3a74d93", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "original_text": "This decrease was primarily due to the legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2", "node_type": "1", "metadata": {"window": "Operating (loss) income as a percentage of revenue in the fiscal 2020 fourth quarter was (12.41) percent compared to 0.39\npercent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a57c90a597f2022d02ab64bb11a78e216e204663b313c8780c3d2dd3b887fa4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "753e5b41-f83f-4a6f-a21c-7757eb54cbb6", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n"}, "hash": "7f667235eb64f9fcb27dabe68f7932c3f2ef53b602c56ee58e19f01c72188e99", "class_name": "RelatedNodeInfo"}}, "text": "This decrease was primarily due to the legal expense accrual.\n", "start_char_idx": 2977, "end_char_idx": 3039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "753e5b41-f83f-4a6f-a21c-7757eb54cbb6": {"__data__": {"id_": "753e5b41-f83f-4a6f-a21c-7757eb54cbb6", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0953262-5102-4766-a52a-88e5d3a74d93", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 fourth quarter, net interest expense of $34.7 million was down 4.7 percent versus the\nprior year quarter due to a decrease in interest expense, substantially offset by a decrease in interest income as a result of a\ndecline in investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "original_text": "This decrease was primarily due to the legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6fe1bc2de94781d13b953fb863a6a95b0e4e7e7e90ab8f95961612c216c65c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e08d95df-585d-4b6b-9538-a95f2bb28bc4", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. "}, "hash": "293fb98dfcb2297b81550657ca8a076250ca42423685e237447830bca26caa9c", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "start_char_idx": 3039, "end_char_idx": 3335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e08d95df-585d-4b6b-9538-a95f2bb28bc4": {"__data__": {"id_": "e08d95df-585d-4b6b-9538-a95f2bb28bc4", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "753e5b41-f83f-4a6f-a21c-7757eb54cbb6", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.1 percent for the fourth quarter of fiscal 2020 reflecting the legal expense\naccrual and a credit related to Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce2dbbef2c6aa892aace5acdde74db4111ef935d8361b2cc490b1ce9d5fdab04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6060e495-18c1-4b8a-8294-eef50ef76848", "node_type": "1", "metadata": {"window": "This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. "}, "hash": "f3b604f86f0da040400835b1d065be9e27f5a22211c5cc4ce1725e7338c0a827", "class_name": "RelatedNodeInfo"}}, "text": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "start_char_idx": 3335, "end_char_idx": 3612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6060e495-18c1-4b8a-8294-eef50ef76848": {"__data__": {"id_": "6060e495-18c1-4b8a-8294-eef50ef76848", "embedding": null, "metadata": {"window": "This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e08d95df-585d-4b6b-9538-a95f2bb28bc4", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $(23.74) in the fourth quarter of fiscal 2020 compared to $0.63 in\nthe previous fiscal year fourth quarter.  This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd0ab9e6ffae6313d392cf397db56d48bb9c18c0459df9acf0c3716981538820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b966424-52e8-4901-80c6-249c7e6c4bb6", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. "}, "hash": "d491b93b19b5d03264ac0ecdb45c85bd1ccc986a38ed5987808670e27b6c8f8f", "class_name": "RelatedNodeInfo"}}, "text": "The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "start_char_idx": 3612, "end_char_idx": 3886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b966424-52e8-4901-80c6-249c7e6c4bb6": {"__data__": {"id_": "5b966424-52e8-4901-80c6-249c7e6c4bb6", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6060e495-18c1-4b8a-8294-eef50ef76848", "node_type": "1", "metadata": {"window": "This decrease was primarily due to the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb2d2b1079bccac88a9f5dc3c99ba49ca05c2bc044cb2182e5f725bc36945311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a90a22f-e1dd-4627-a240-cd0120f510b1", "node_type": "1", "metadata": {"window": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2"}, "hash": "563092f5e323988c2ea4bd0e5c542c5a1cd6679cc1ad8348ffeeb1db10832f60", "class_name": "RelatedNodeInfo"}}, "text": "The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "start_char_idx": 3886, "end_char_idx": 4013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a90a22f-e1dd-4627-a240-cd0120f510b1": {"__data__": {"id_": "0a90a22f-e1dd-4627-a240-cd0120f510b1", "embedding": null, "metadata": {"window": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e2e2375-2056-44d1-9211-acb187caa717", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6411e175b34e8513691ea832f9bea1c37eb4e283535c51aeed05b45472b6a76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b966424-52e8-4901-80c6-249c7e6c4bb6", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2020 were 204.1\nmillion, a 2.7 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases made earlier in the\nfiscal year, net of stock option exercises.\n Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "095f97aaf56032938be3f097b7f6ac6bb96cba4738eda0cb713ce9885f2e0ece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b1fe49a-b2b9-454f-b50c-63a831ac8f61", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "original_text": "forward.\n"}, "hash": "ce6b69228c3399307bc1045e3d291e84c1e2d531d375b2166af33340620bd169", "class_name": "RelatedNodeInfo"}}, "text": "A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "start_char_idx": 4013, "end_char_idx": 4131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b1fe49a-b2b9-454f-b50c-63a831ac8f61": {"__data__": {"id_": "7b1fe49a-b2b9-454f-b50c-63a831ac8f61", "embedding": null, "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "original_text": "forward.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a90a22f-e1dd-4627-a240-cd0120f510b1", "node_type": "1", "metadata": {"window": "Opioid Litigation\nIn the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, the\nCompany recorded a $6.6 billion ($5.5 billion after tax) charge, which is excluded from its adjusted (non-GAAP) results.  The\nCompany is in advanced discussions, which are ongoing, to reach a global settlement to be paid over an 18-year period to resolve\ncases currently filed and that could be filed by states, counties, municipalities and other governmental entities covered by the\nsettlement.  The Company has recorded the charge now that it has determined that a loss is probable and the amount is reasonably\nestimable.  A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "original_text": "A global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move\n2", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "495a24aae7bf9278ee790744fbe3b64af28ced20047c41163b8c12f3d3272d0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04e3da42-b9d5-4e07-b739-23b3b628f366", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "e6fddb252f41a4f12304a53cd24622f01a0da508cbfde3d20d003727987ac862", "class_name": "RelatedNodeInfo"}}, "text": "forward.\n", "start_char_idx": 0, "end_char_idx": 9, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04e3da42-b9d5-4e07-b739-23b3b628f366": {"__data__": {"id_": "04e3da42-b9d5-4e07-b739-23b3b628f366", "embedding": null, "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b1fe49a-b2b9-454f-b50c-63a831ac8f61", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "original_text": "forward.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a25f7be28e08c66cb04ee0c13a716116ba1dcb14f845db58aed857fd70279546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99e179fe-68db-4e44-a38c-acb7bcb75617", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "original_text": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n"}, "hash": "f4734d61840947abe2abeb1e79233c40f1fea3ef61cf40a905ad7166fa372b98", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 9, "end_char_idx": 128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99e179fe-68db-4e44-a38c-acb7bcb75617": {"__data__": {"id_": "99e179fe-68db-4e44-a38c-acb7bcb75617", "embedding": null, "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "original_text": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04e3da42-b9d5-4e07-b739-23b3b628f366", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2caad1b8959442c0e9c9dedce036d62199f3a35c7da03979ec925377268f7257", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb10ce1e-8d0a-456e-a978-64bc1d579b06", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. "}, "hash": "bbd0ff41432821332a93c0856db675f0e92d20e051e87636a5d879dcd51e37c1", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n", "start_char_idx": 128, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb10ce1e-8d0a-456e-a978-64bc1d579b06": {"__data__": {"id_": "eb10ce1e-8d0a-456e-a978-64bc1d579b06", "embedding": null, "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99e179fe-68db-4e44-a38c-acb7bcb75617", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "original_text": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76f8cd049b052c06861e28d957b93a328095a6c1c9b773dede38c322397abdb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n"}, "hash": "d2f6a4ceb478ce2d551adfd4a1cda2b2f28002f3ccb4279d71d07b22e23900de", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "start_char_idx": 401, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1": {"__data__": {"id_": "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1", "embedding": null, "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb10ce1e-8d0a-456e-a978-64bc1d579b06", "node_type": "1", "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a89cc437f2c908313502921b81d2b671b4695255a49de57b16bf5038a2b75d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d75f35-e706-4bb9-9430-6e9062754085", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. "}, "hash": "44964cf4852ed2cb13af244f928349888b729ff79efcc9a6201540ab492e713b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "start_char_idx": 706, "end_char_idx": 865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d75f35-e706-4bb9-9430-6e9062754085": {"__data__": {"id_": "81d75f35-e706-4bb9-9430-6e9062754085", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35f1d0db46db5ea25bbc15491d073354fdbd344361294307e83f52eddafffe2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "998631c3-b098-42e5-91d5-768746b3a302", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n"}, "hash": "efdf822ac142f48207c04492c8ecebe485a38ecb39982377c800f878d4d30c08", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "start_char_idx": 865, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "998631c3-b098-42e5-91d5-768746b3a302": {"__data__": {"id_": "998631c3-b098-42e5-91d5-768746b3a302", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d75f35-e706-4bb9-9430-6e9062754085", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518d65b8de40426fc4418988a47e7d1d71eb9261dceab5dfbd01d7e49bc061aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd00dd1-4e58-4a2d-b793-9b75af047e8c", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. "}, "hash": "d1bcd11b42c420622a3cf6ca5b967e661b413656a6bf697122387c6a7df2e99f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "start_char_idx": 1066, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd00dd1-4e58-4a2d-b793-9b75af047e8c": {"__data__": {"id_": "bbd00dd1-4e58-4a2d-b793-9b75af047e8c", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "998631c3-b098-42e5-91d5-768746b3a302", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue.  Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c031f8e6da06b0892e1a6b124dd630262a3b119d5f738ff4fdc1402e465441e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n"}, "hash": "eef9a66f4009c328c1271f6223ed06c04782528fce0bef2ae38387092d1fcc94", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "start_char_idx": 1247, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4": {"__data__": {"id_": "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd00dd1-4e58-4a2d-b793-9b75af047e8c", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.69\npercent in the fiscal 2020 fourth quarter, a decrease of 4 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b439c0ce00c9f74be87d6db4e180c772beb4bdc3ea8c1dec911e0de2d89e84d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "bb39ba819f9d55f3c9b1f2343b8e4f9522a75b83bd78fb78f19e3159ccc5348a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "start_char_idx": 1561, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb": {"__data__": {"id_": "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2020, adjusted operating expenses were $795.4 million, an\nincrease of 0.8 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37be534a09d7c492e4915b4a94a2a373a1f7cd330304d2a44143f7d5a8ad09b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e75a5724-6375-4162-95c1-70dcc0c69310", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "original_text": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n"}, "hash": "a2c8174206bd2dc662118e903572b2626970c7a029342dadc823bb283006a5d8", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1689, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e75a5724-6375-4162-95c1-70dcc0c69310": {"__data__": {"id_": "e75a5724-6375-4162-95c1-70dcc0c69310", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "original_text": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage\nof revenue in the fiscal 2020 fourth quarter was 1.62 percent, compared to 1.73 percent for the same period in the previous\nfiscal year.\n Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88d0585488dd0e3a497c447741695c2b64f9e2ad60e14ce04a5de20958eb603c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d60c2ad-0116-478e-b81b-196add31126a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. "}, "hash": "131797e729362f40882cfde8a11d896c7e17afbfbfb0fe6f949944a51f4e9c55", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "start_char_idx": 1788, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d60c2ad-0116-478e-b81b-196add31126a": {"__data__": {"id_": "5d60c2ad-0116-478e-b81b-196add31126a", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e75a5724-6375-4162-95c1-70dcc0c69310", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 fourth quarter, adjusted operating income of $530.0 million increased 16.2\npercent from the prior year period due to a 15.2 percent increase in operating income within Pharmaceutical Distribution\nServices and a 20.5 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "original_text": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08f749a142e359bbb43bb1a3c540b33fd0a5848e03205e540d6a8364e9ab38bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1937eb6-0d16-4339-99f5-2d6a21c20b36", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n"}, "hash": "a379906ce7e646b1241aa4ebc37a658bcf760cf4491cbb77bb7a931b3b45a351", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "start_char_idx": 2060, "end_char_idx": 2219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1937eb6-0d16-4339-99f5-2d6a21c20b36": {"__data__": {"id_": "b1937eb6-0d16-4339-99f5-2d6a21c20b36", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d60c2ad-0116-478e-b81b-196add31126a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.08 percent, which was up 8 basis points from the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8052ab208e226d3d3093b30d82b14d3643f329517cdf24c1f513966f0a04b8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e29ef5e-5a02-4e05-b21d-fdd155b4b239", "node_type": "1", "metadata": {"window": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n"}, "hash": "87dadccac8441a9e581568ac85acc1934fb875eda7c3c7424050e306cdc5664c", "class_name": "RelatedNodeInfo"}}, "text": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "start_char_idx": 2219, "end_char_idx": 2325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e29ef5e-5a02-4e05-b21d-fdd155b4b239": {"__data__": {"id_": "2e29ef5e-5a02-4e05-b21d-fdd155b4b239", "embedding": null, "metadata": {"window": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1937eb6-0d16-4339-99f5-2d6a21c20b36", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62b4175719f9304707f35faee406d8157c79042617398d2f52b6028c6ecccd52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49a57206-6a64-4021-97a1-4465ac16c9c2", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "original_text": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n"}, "hash": "d179a102fb66e0f43f0e6e3d74b7453b7137f5def644b779b922e9908df3cb3e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "start_char_idx": 2325, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49a57206-6a64-4021-97a1-4465ac16c9c2": {"__data__": {"id_": "49a57206-6a64-4021-97a1-4465ac16c9c2", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "original_text": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e29ef5e-5a02-4e05-b21d-fdd155b4b239", "node_type": "1", "metadata": {"window": "In the fiscal 2020 fourth\nquarter, net interest expense of $34.7 million was down 4.7 percent versus the prior year quarter due to a decrease in interest\nexpense, substantially offset by a decrease in interest income as a result of a decline in investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9587ef3691778d949669d601c2cabaaa53f2c1d23a30d62359847152405c2a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2ffb482-19c0-4a52-af31-5448e8784b92", "node_type": "1", "metadata": {"window": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. "}, "hash": "3d64d229a286a450fca771ecc28dd32833492bed5d5b81cd62a9a6a43a49771e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "start_char_idx": 2631, "end_char_idx": 2940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2ffb482-19c0-4a52-af31-5448e8784b92": {"__data__": {"id_": "f2ffb482-19c0-4a52-af31-5448e8784b92", "embedding": null, "metadata": {"window": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49a57206-6a64-4021-97a1-4465ac16c9c2", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.7 percent for the fourth quarter of fiscal 2020 and included\na discrete unfavorable item.  The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "original_text": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c34af694783ad27aa7e5064e11c9574ac51e08fb8b5ce4d42bf3720bc3ea74c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "233093d7-e34a-41c9-b82e-0afe621fdb7e", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "80b0d9c8c1f3b597787fe54c383f2a401e6937a5c0d4e6c5bdcfb329937eef9a", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "start_char_idx": 2940, "end_char_idx": 3268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "233093d7-e34a-41c9-b82e-0afe621fdb7e": {"__data__": {"id_": "233093d7-e34a-41c9-b82e-0afe621fdb7e", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2ffb482-19c0-4a52-af31-5448e8784b92", "node_type": "1", "metadata": {"window": "The prior year fourth quarter effective tax rate was 19.6 percent and included a favorable discrete\nitem.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9694ebd35c6dacb02470a130380fe2e5a075cb8bc71a4f8de1b4ce04b399d700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93", "node_type": "1", "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. "}, "hash": "b7fb58a5d082140cc9cb74a3670c6ff27961d20a5cb79b2dc9b8f4710c4673fb", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 3268, "end_char_idx": 3473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93": {"__data__": {"id_": "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93", "embedding": null, "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "233093d7-e34a-41c9-b82e-0afe621fdb7e", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 17.4 percent to $1.89 in the fourth quarter\nof fiscal 2020 compared to $1.61 in the previous fiscal year fourth quarter, primarily driven by the increase in adjusted\noperating income and a slightly lower diluted share count.\n Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ed0015a109419c77ca68d3c448cfc4f23ad34e2ba3a20eb3c723d92c4b83e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "697037c2-9329-44c0-bf10-e08a208c408e", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n"}, "hash": "ee2e28f85f3438d51f0a96b1f0c873cb642f74bf1293e0a06c2c305d0d8ea97c", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "start_char_idx": 3473, "end_char_idx": 3803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "697037c2-9329-44c0-bf10-e08a208c408e": {"__data__": {"id_": "697037c2-9329-44c0-bf10-e08a208c408e", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93", "node_type": "1", "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Adjusted diluted weighted average shares outstanding for the fourth quarter of fiscal\n2020 were 206.4 million, a 1.6 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases\nearlier in the fiscal year, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales. ", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49c21b2eb726277eadf3da98e2b2b61e3703307e3e1ee2b3550f35bf94ffc622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "3"}, "hash": "c4d039b837c7d613b3a59b6bd14deda28d5beb50c26741ad1bed508d7aef02d5", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "start_char_idx": 3803, "end_char_idx": 4083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195": {"__data__": {"id_": "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99f35340-e798-462c-b301-84023a5e8668", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3a2846040a001bd5228240c1cd4c943162accd179e012caecfebfd566fb64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "697037c2-9329-44c0-bf10-e08a208c408e", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c178d476ceea10b713fa091f7cc76762d6f31c271c1703a7ac04c6ad2f83167a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29e955cb-e530-481d-bbef-55d17d883fee", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "original_text": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. "}, "hash": "bdf77164de4adcb4f831c81919d12daf45010584a398116c53b69dd76f8cbf21", "class_name": "RelatedNodeInfo"}}, "text": "3", "start_char_idx": 488, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29e955cb-e530-481d-bbef-55d17d883fee": {"__data__": {"id_": "29e955cb-e530-481d-bbef-55d17d883fee", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "original_text": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.3 billion, an increase of 7.8 percent compared to the same quarter in the prior\nfiscal year primarily due to increased volume associated with the growth of some of its largest customers and continued strong\nspecialty product sales.  Segment operating income of $425.6 million in the fourth quarter of fiscal 2020 was up 15.2 percent\ncompared to the same period in the previous fiscal year, primarily due to the increase in gross profit, the exit of the PharMEDium\ncompounding business, and modest expense growth.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "687c7f7c988aa56c1757beff955e3d265110e5a4f9c20de6860edc37f09918f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e06309f5-3821-4dda-bf3e-62ad4e02f0f9", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "original_text": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n"}, "hash": "713913c1949fd8bdfcc6d6f092c23e04a1bfcdfc3bc75726cfee8a2b8b045604", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "start_char_idx": 0, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e06309f5-3821-4dda-bf3e-62ad4e02f0f9": {"__data__": {"id_": "e06309f5-3821-4dda-bf3e-62ad4e02f0f9", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "original_text": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29e955cb-e530-481d-bbef-55d17d883fee", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "original_text": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "270316b629b331223b27be89a5f27ebc762454e6aed8aff797aa2381dfb100ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1e7885d-ada5-48da-a274-c3b5cdad066e", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "original_text": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year. "}, "hash": "1962b08ab09a6ad90c1174e0e5849948da2ad22a349b555e8471a4c6db827feb", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n", "start_char_idx": 236, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1e7885d-ada5-48da-a274-c3b5cdad066e": {"__data__": {"id_": "b1e7885d-ada5-48da-a274-c3b5cdad066e", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "original_text": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e06309f5-3821-4dda-bf3e-62ad4e02f0f9", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "original_text": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae10328861bef94933167af01f66381766660931eb1d382e870f1f0c23d8c651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea3bb1ee-ebf2-435e-86a3-7f314ba46755", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "original_text": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. "}, "hash": "980857a941106ea58fb4ba592cc89841fe8358ad882bd15def7542e0f4026c02", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year. ", "start_char_idx": 387, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea3bb1ee-ebf2-435e-86a3-7f314ba46755": {"__data__": {"id_": "ea3bb1ee-ebf2-435e-86a3-7f314ba46755", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "original_text": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1e7885d-ada5-48da-a274-c3b5cdad066e", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "original_text": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abc80a5cb4139c4669feb21f0d1259d21de790f2cba8923967dcb4dc1a36e77a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e5e62e-0326-4aac-b93b-51983f257c7b", "node_type": "1", "metadata": {"window": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "original_text": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. "}, "hash": "3b94127efc8068119ca1f401daf5c260aeab5a035e0648de886c6b737b1a60bd", "class_name": "RelatedNodeInfo"}}, "text": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "start_char_idx": 901, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e5e62e-0326-4aac-b93b-51983f257c7b": {"__data__": {"id_": "62e5e62e-0326-4aac-b93b-51983f257c7b", "embedding": null, "metadata": {"window": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "original_text": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea3bb1ee-ebf2-435e-86a3-7f314ba46755", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "original_text": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18c213b3c2e903e776b0a747d66d26db93370a46d102d501e326294523bdd146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "original_text": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n"}, "hash": "418a3de7b659bc8320247fb2ca997431c23a7a57d5d828d17104e29f78e64913", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "start_char_idx": 973, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368": {"__data__": {"id_": "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368", "embedding": null, "metadata": {"window": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "original_text": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e5e62e-0326-4aac-b93b-51983f257c7b", "node_type": "1", "metadata": {"window": "Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "original_text": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc88d25b2f3735381a611a607d5caf59819a5f4a2d8a9d9fa7e7eaa59576fada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00a31cca-1242-4d5e-bcf6-9dcba5899389", "node_type": "1", "metadata": {"window": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n"}, "hash": "057bfff2ac971fb340a0f948c3a3f96a3b15fa1ecf2debc81a7a554d777e74b1", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "start_char_idx": 1278, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00a31cca-1242-4d5e-bcf6-9dcba5899389": {"__data__": {"id_": "00a31cca-1242-4d5e-bcf6-9dcba5899389", "embedding": null, "metadata": {"window": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "original_text": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a147038e28583a27b39b77546a9b7d56853653562bcf3236d975f029eed1a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1", "node_type": "1", "metadata": {"window": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. "}, "hash": "afe5db11496fdc4be16a01f729e7c0473eb3470b543e7ac1aa79526222df7090", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "start_char_idx": 1466, "end_char_idx": 1590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1": {"__data__": {"id_": "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1", "embedding": null, "metadata": {"window": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00a31cca-1242-4d5e-bcf6-9dcba5899389", "node_type": "1", "metadata": {"window": "Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year.  Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aac9e1ba5d6d6316e6c568293064dcb48ec116143c29884c17295430726d507e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8460cdfe-2644-4618-a626-71c31f6f72b4", "node_type": "1", "metadata": {"window": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "original_text": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. "}, "hash": "f11856bf41109e6c09825709d1d7efa195ce35fb9fb8b73977e5643677605f12", "class_name": "RelatedNodeInfo"}}, "text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "start_char_idx": 1590, "end_char_idx": 1868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8460cdfe-2644-4618-a626-71c31f6f72b4": {"__data__": {"id_": "8460cdfe-2644-4618-a626-71c31f6f72b4", "embedding": null, "metadata": {"window": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "original_text": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1", "node_type": "1", "metadata": {"window": "Gross profit increased 1.0 percent to $5.2 billion primarily due to increases in gross profit within\nPharmaceutical Distribution Services and Other and was partially offset by lower gains from antitrust litigation settlements and a\nLIFO expense in the current year versus a LIFO credit in the prior year.  Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89bb3d96785f82bda8b5d9d4b5f538687d4dafbc95220c2b292d1fc5f356610d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03930657-2bab-400f-8f04-2239491ddf1c", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "original_text": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. "}, "hash": "b0e8ed7768a35aed66d17e73ff2fb8b229ba29fa251f4d8f8587a78d6a8ac139", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "start_char_idx": 1868, "end_char_idx": 1939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03930657-2bab-400f-8f04-2239491ddf1c": {"__data__": {"id_": "03930657-2bab-400f-8f04-2239491ddf1c", "embedding": null, "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "original_text": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8460cdfe-2644-4618-a626-71c31f6f72b4", "node_type": "1", "metadata": {"window": "Operating expenses increased 156.5 percent and operating\nincome decreased 561.8 percent over the prior fiscal year primarily due to the expense accrual in connection with opioid lawsuits.\n Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "original_text": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba99e8cfd36344489c0d3d587054ca0f45e30168e496338657b2439f476252f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d05beb9-cd19-42a8-be58-379f86d222fe", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. "}, "hash": "6b5ea61950f1408a67fdff3581c3af582c36c4178f37ea39728c60ddb2161094", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "start_char_idx": 1939, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d05beb9-cd19-42a8-be58-379f86d222fe": {"__data__": {"id_": "2d05beb9-cd19-42a8-be58-379f86d222fe", "embedding": null, "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03930657-2bab-400f-8f04-2239491ddf1c", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2020 were 204.8 million, down 3.3 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "original_text": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "954ecf6d6880fc4f83db9ce116355a7659591aff4b92efb8fd53c71e42d5394a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68e2f6e8-32b2-466c-aa25-c2f5824234e6", "node_type": "1", "metadata": {"window": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. "}, "hash": "cd930e84893da637d6ba2da69c717017a539b55ec08fc5432b4775cf4306b41f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "start_char_idx": 2141, "end_char_idx": 2334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68e2f6e8-32b2-466c-aa25-c2f5824234e6": {"__data__": {"id_": "68e2f6e8-32b2-466c-aa25-c2f5824234e6", "embedding": null, "metadata": {"window": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d05beb9-cd19-42a8-be58-379f86d222fe", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2020, adjusted diluted EPS was $7.90, an increase of 11.4 percent over the prior fiscal year primarily due to an increase\nin operating income, and a decrease in adjusted diluted weighted average shares outstanding.  Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f0aaa675202b3ced54ed82a6414d656e1685f3c305846f0d7ea51b5d99772fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f703977b-1992-460f-bcdf-52877cce03e0", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n"}, "hash": "324a82351f27d01d35e6c59b99dd6f9008925180a591af21cce43bac3e8d3c81", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "start_char_idx": 2334, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f703977b-1992-460f-bcdf-52877cce03e0": {"__data__": {"id_": "f703977b-1992-460f-bcdf-52877cce03e0", "embedding": null, "metadata": {"window": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68e2f6e8-32b2-466c-aa25-c2f5824234e6", "node_type": "1", "metadata": {"window": "Revenue increased 5.7 percent from\nlast fiscal year to $189.9 billion.  Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5eb807010f5f3d3ab2265bb2131277ca291b4b33c5c0272c8f6a78e6ca225db5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b595c98b-2a4b-47f3-9a39-dd224ed59c4a", "node_type": "1", "metadata": {"window": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Recent Comp any Highlights & Milest ones\n4"}, "hash": "c88aff31df2fec824ceb9e366ba23822e329c66f37d9d42d05cb75a37201d1bd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "start_char_idx": 2427, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b595c98b-2a4b-47f3-9a39-dd224ed59c4a": {"__data__": {"id_": "b595c98b-2a4b-47f3-9a39-dd224ed59c4a", "embedding": null, "metadata": {"window": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Recent Comp any Highlights & Milest ones\n4", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122ca9b72ea13c473fcac72e050592f8448ea1e16c6ea337c9a340cade99968d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f703977b-1992-460f-bcdf-52877cce03e0", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $221.1 million, or 4.4 percent, from the prior fiscal year to $5.2\nbillion due to the increases in gross profit within Pharmaceutical Distribution Services and Other.  Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fbd6d2c2e83990e8bf614e52e417183ea5c5cd8261644d661880edf0ffce441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79033148-2632-4cd2-9863-a4402bc06bae", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "original_text": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n"}, "hash": "6b9b599cf19b3e77c815bc396d700ce045b11fc1d6ff16aacc5e0ed45ae32418", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\n4", "start_char_idx": 2560, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79033148-2632-4cd2-9863-a4402bc06bae": {"__data__": {"id_": "79033148-2632-4cd2-9863-a4402bc06bae", "embedding": null, "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "original_text": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b595c98b-2a4b-47f3-9a39-dd224ed59c4a", "node_type": "1", "metadata": {"window": "Adjusted operating income\nincreased 7.5 percent due to an increase in gross profit and a favorable comparison due to the exit of the PharMEDium\ncompounding business, and modest expense growth.  Adjusted operating income margin increased 2 basis points from 1.14 percent\nto 1.16 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2020 were 206.6 million, down 2.5 percent from the\nprior fiscal year.\n Recent Comp any Highlights & Milest ones\n4", "original_text": "Recent Comp any Highlights & Milest ones\n4", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e25cb52b3faf57fde1d6e72d5aafe08fb7d10414fcf44eea715b36111e739e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6409f3c-ff47-462a-a7ec-66cf92f2fd95", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow. "}, "hash": "8ee11b6164cd783d3fe721c56b90563724f9c29a97eeb80dff763006d56024b4", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6409f3c-ff47-462a-a7ec-66cf92f2fd95": {"__data__": {"id_": "f6409f3c-ff47-462a-a7ec-66cf92f2fd95", "embedding": null, "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79033148-2632-4cd2-9863-a4402bc06bae", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "original_text": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d282e887e38b0a5754ce7645a5ccb7dcde83371057a9148147b91424c26431cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6674f685-60a1-40f6-9f9d-b7b99a8cace2", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "original_text": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n"}, "hash": "3200ed5c40693296dc7487a3c550a6ba42b35b8a56e77e2825901a4a14ddaf18", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow. ", "start_char_idx": 165, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6674f685-60a1-40f6-9f9d-b7b99a8cace2": {"__data__": {"id_": "6674f685-60a1-40f6-9f9d-b7b99a8cace2", "embedding": null, "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "original_text": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6409f3c-ff47-462a-a7ec-66cf92f2fd95", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc10e8e5d966da7acdaef7005262224e256704e059e63dd7dda53dca2384ff0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6acb175c-fb63-45e2-8608-e3f0de0d211d", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "original_text": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. "}, "hash": "aefd88f00b02e0c9fec8b65173057f73a6687794dbaa3ab3702189f55c588f09", "class_name": "RelatedNodeInfo"}}, "text": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n", "start_char_idx": 305, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6acb175c-fb63-45e2-8608-e3f0de0d211d": {"__data__": {"id_": "6acb175c-fb63-45e2-8608-e3f0de0d211d", "embedding": null, "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "original_text": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6674f685-60a1-40f6-9f9d-b7b99a8cace2", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "original_text": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eaaa82d6b8eb8fcaf465e423177b0d78095de919d25ed15d00404255680eeba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3de57fb-6252-4b24-9ecc-5593485b4bf3", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "original_text": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n"}, "hash": "6d87cfe3d720f844b4b9b5e29fab6523b46a5add7e494df225d4080da8be741d", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "start_char_idx": 582, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3de57fb-6252-4b24-9ecc-5593485b4bf3": {"__data__": {"id_": "a3de57fb-6252-4b24-9ecc-5593485b4bf3", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "original_text": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6acb175c-fb63-45e2-8608-e3f0de0d211d", "node_type": "1", "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "original_text": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cad1cc10f96661219c7743d7c07ebcd2e9c838bc1569606d9ed2c702cf4dc73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6428ae8a-19f4-467f-a065-c5f63f2f572b", "node_type": "1", "metadata": {"window": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n"}, "hash": "b781eb70c5f50a37ddb2d77db663d87f8413108011eeec924464617b2d5249a8", "class_name": "RelatedNodeInfo"}}, "text": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "start_char_idx": 737, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6428ae8a-19f4-467f-a065-c5f63f2f572b": {"__data__": {"id_": "6428ae8a-19f4-467f-a065-c5f63f2f572b", "embedding": null, "metadata": {"window": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3de57fb-6252-4b24-9ecc-5593485b4bf3", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "original_text": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91b4d2f3d9f8d5870762698cf4488ee411e51e3ffa12ca9355ef750c046d66f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49d5fba-1923-40c3-9e17-9ec4fa31e63b", "node_type": "1", "metadata": {"window": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. "}, "hash": "827e10c134871746509dd6b831a0fbc062a44d89702463914133ab583ea4b7a0", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "start_char_idx": 1008, "end_char_idx": 1337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b49d5fba-1923-40c3-9e17-9ec4fa31e63b": {"__data__": {"id_": "b49d5fba-1923-40c3-9e17-9ec4fa31e63b", "embedding": null, "metadata": {"window": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6428ae8a-19f4-467f-a065-c5f63f2f572b", "node_type": "1", "metadata": {"window": "Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bda45d7f20649b34247a894453ed396985778d59b05daea3a548d506ed59c46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "500faac5-cf18-41c0-9231-516d8856c4a4", "node_type": "1", "metadata": {"window": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "original_text": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n"}, "hash": "df2294554032bc7911b1956eed843c42bb57d086ee591353ccb9c8b3854b35bb", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "start_char_idx": 1337, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "500faac5-cf18-41c0-9231-516d8856c4a4": {"__data__": {"id_": "500faac5-cf18-41c0-9231-516d8856c4a4", "embedding": null, "metadata": {"window": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "original_text": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49d5fba-1923-40c3-9e17-9ec4fa31e63b", "node_type": "1", "metadata": {"window": "AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers.  The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50fa7272045fb490608d21f51b3eb8bab319ee6509b0fafb81c446eac56d9e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866e6947-6464-4a49-a482-f1c957f57805", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "e7e054d6aae3f7a58bfde7dc48e07bfe953224831346030d8580cbe5f38da031", "class_name": "RelatedNodeInfo"}}, "text": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "start_char_idx": 1522, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866e6947-6464-4a49-a482-f1c957f57805": {"__data__": {"id_": "866e6947-6464-4a49-a482-f1c957f57805", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "500faac5-cf18-41c0-9231-516d8856c4a4", "node_type": "1", "metadata": {"window": "The event addressed current industry challenges and how AmerisourceBergen will\ncollaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development\nand delivery of pharmaceuticals and healthcare products in the future.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "original_text": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb4c6047f21a4c39e4010d076a41455d86ea9c9c0c80cdbd0789850375c149c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a8441d-4b4b-42fe-80de-7b6f096851f2", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "a0f1625d97ceedefbb1ccda80632140ebb9e440b10096ba58efd72bdae911213", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 1679, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31a8441d-4b4b-42fe-80de-7b6f096851f2": {"__data__": {"id_": "31a8441d-4b4b-42fe-80de-7b6f096851f2", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866e6947-6464-4a49-a482-f1c957f57805", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, has continued making grants to\norganizations that promote social justice, health access and equity, and organizations that are providing relief to those\nimpacted by the pandemic, Hurricane Sally, and wildfires throughout the West Coast.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a423297da32194d1150e182a7f610679a2b287d37534add1c856c84d606bc384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. "}, "hash": "fe27c6347531c12095fc189770d4055a4908799ff943d073b335b74b8e8f8935", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1924, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09": {"__data__": {"id_": "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09", "embedding": null, "metadata": {"window": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a8441d-4b4b-42fe-80de-7b6f096851f2", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly dividend of $0.44 per common share, a 5% increase in its quarterly dividend\nrate from $0.42 per common share.  The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1136d75c23e020a373b02ab9a0fe4ef60370ddc8e2ce4c6e92d24b043c499a02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87ddd624-a21e-4c76-8276-eadc950e1f7d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "original_text": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. "}, "hash": "ffc9db24f797d2ab3f2c1f3f447fd3ca98465181af31b08ba74c0b5da19c0140", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "start_char_idx": 2056, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87ddd624-a21e-4c76-8276-eadc950e1f7d": {"__data__": {"id_": "87ddd624-a21e-4c76-8276-eadc950e1f7d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "original_text": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.44 per common share will be payable November 30, 2020, to\nstockholders of record at the close of business on November 16, 2020.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55d11ea64090ea35e88988bb0242c48a6b53f02e66952d8c68ee446e09e4c801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee2ad3f9-75ce-4c66-8b12-b4227face72f", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020. ", "original_text": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n"}, "hash": "6165b3b60edbd3386df28f8d2aab2f28c4d8ee61a22587b4b10723ed0c5d1021", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "start_char_idx": 2338, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee2ad3f9-75ce-4c66-8b12-b4227face72f": {"__data__": {"id_": "ee2ad3f9-75ce-4c66-8b12-b4227face72f", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020. ", "original_text": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87ddd624-a21e-4c76-8276-eadc950e1f7d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "original_text": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bca4eba75e6d2ce337a08c3c42b04acadc268f15698639c0228e85c5e5ce6ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cecc850b-e060-488d-b771-80dbce91a03d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n"}, "hash": "a04510493df76ebdb79df141d87a12b5170c80275e21ef524fcbf40c1b555613", "class_name": "RelatedNodeInfo"}}, "text": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "start_char_idx": 2454, "end_char_idx": 2607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cecc850b-e060-488d-b771-80dbce91a03d": {"__data__": {"id_": "cecc850b-e060-488d-b771-80dbce91a03d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee2ad3f9-75ce-4c66-8b12-b4227face72f", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020. ", "original_text": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e874fbb77a40c101c515040bb7e11c3528f38d49ed368176b120c0b7c8992ec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4be0d65a-6f85-4270-a079-3512e2c95ccf", "node_type": "1", "metadata": {"window": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. "}, "hash": "01a4c1fc4089c2d402699bceb74060378965702e879ea77fa087806b4800ee36", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "start_char_idx": 2607, "end_char_idx": 3355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4be0d65a-6f85-4270-a079-3512e2c95ccf": {"__data__": {"id_": "4be0d65a-6f85-4270-a079-3512e2c95ccf", "embedding": null, "metadata": {"window": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cecc850b-e060-488d-b771-80dbce91a03d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2021 financial guidance, which reflects growth in both Pharmaceutical Distribution\nServices and businesses focused on Global Commercialization Services & Animal Health.  AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41b8e680bc62983c9c5931861220f4dfd232e7a28fe63375731daf96ae8f1593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83626644-f406-4e61-99dd-b68510e8f5fc", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "ET on November 5, 2020. "}, "hash": "cbdb664fda187a4fb07d6b0fcdc3d568e43bf26e02b8e044a74f6d9dea453523", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "start_char_idx": 3355, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83626644-f406-4e61-99dd-b68510e8f5fc": {"__data__": {"id_": "83626644-f406-4e61-99dd-b68510e8f5fc", "embedding": null, "metadata": {"window": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "ET on November 5, 2020. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be0d65a-6f85-4270-a079-3512e2c95ccf", "node_type": "1", "metadata": {"window": "AmerisourceBergen does not include\nunidentified capital allocation opportunities into its forward-looking guidance.  The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "677b62521cb3821d1e2259aafa6b7857845cb87863aef75decd344eb01e8570b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f25c9f8-14b6-43f9-8626-15527dd2e5c8", "node_type": "1", "metadata": {"window": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "7d9cbf12cf25c3a78ea084d5048e9ed3b03225e1bd02da707ccac9bf0e421941", "class_name": "RelatedNodeInfo"}}, "text": "ET on November 5, 2020. ", "start_char_idx": 3470, "end_char_idx": 3494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f25c9f8-14b6-43f9-8626-15527dd2e5c8": {"__data__": {"id_": "1f25c9f8-14b6-43f9-8626-15527dd2e5c8", "embedding": null, "metadata": {"window": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83626644-f406-4e61-99dd-b68510e8f5fc", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth in the mid-single digit percent range; and\nAdjusted diluted earnings per share to be in the range of $8.20 to $8.45.\n Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "ET on November 5, 2020. ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7573612fdbea70b71bf4c68e83e0475a9ca0a26fe6cb5b037bf234b882ca9d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "765a1777-bcd2-469f-ae04-a6805f4df07e", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Participating in the conference call\nwill be:\n5"}, "hash": "cd27de8b9f21384eced130affa385e2c402ee8c11f37d7aac56c1fb7c3829764", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 3494, "end_char_idx": 3611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "765a1777-bcd2-469f-ae04-a6805f4df07e": {"__data__": {"id_": "765a1777-bcd2-469f-ae04-a6805f4df07e", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Participating in the conference call\nwill be:\n5", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab3e4eb9550dc457b048e59be0093eeb6fb927cc081f2d1d24f580ce0d8f4f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f25c9f8-14b6-43f9-8626-15527dd2e5c8", "node_type": "1", "metadata": {"window": "Additional expectations include:\nAdjusted operating expenses to increase in the mid-single digit percent range;\nAdjusted operating income growth in the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the mid-single digit percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $1.5 billion;\nCapital expenditures in the $400 million range; and\nWeighted average diluted shares are expected to be between 206 million to 207 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf1e60702bd23c2962e841d970c95473eab972774f32cc220bf6b79766e9a381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dde9fd5f-f402-46b6-a9fa-424facae070f", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. "}, "hash": "b4628a90b35383a79ba17e3ce6a288cd7d4e34a25f8907555c3cd59029f92294", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call\nwill be:\n5", "start_char_idx": 3611, "end_char_idx": 3658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dde9fd5f-f402-46b6-a9fa-424facae070f": {"__data__": {"id_": "dde9fd5f-f402-46b6-a9fa-424facae070f", "embedding": null, "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "765a1777-bcd2-469f-ae04-a6805f4df07e", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:00 a.m.  ET on November 5, 2020.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\n5", "original_text": "Participating in the conference call\nwill be:\n5", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5a1275c72713360fab73bc0c89aaf28309b6c18ee887c33e4d8afd33a3b2838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07585bae-966a-470e-bd35-e22a0030963b", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. "}, "hash": "723a6d4b05623c1dabdac3963d8f148efa154882805af33e6435e30b39d80484", "class_name": "RelatedNodeInfo"}}, "text": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 0, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07585bae-966a-470e-bd35-e22a0030963b": {"__data__": {"id_": "07585bae-966a-470e-bd35-e22a0030963b", "embedding": null, "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dde9fd5f-f402-46b6-a9fa-424facae070f", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80d3652cad590dfde9d8e3e41d547f6ed81c016883e84977b0716ccd7a9265b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81e94f23-93ee-42db-96a0-04e6516c4447", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . "}, "hash": "f832ac81e7e6a8e26407b836de9b0f70ae97d61f4c3ac09f7118b1161c262b54", "class_name": "RelatedNodeInfo"}}, "text": "No access code is required. ", "start_char_idx": 193, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81e94f23-93ee-42db-96a0-04e6516c4447": {"__data__": {"id_": "81e94f23-93ee-42db-96a0-04e6516c4447", "embedding": null, "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07585bae-966a-470e-bd35-e22a0030963b", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b78730783a23755e0e46210c6281e69934cd8890fefd4d8d5ef0284d670f4d97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9cd29b5-2317-4b85-9ab5-34dea7819d47", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n"}, "hash": "3d0a53e382bd09162cbc28c274581cda9e60410a2facac08d82412d317598a8d", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 221, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9cd29b5-2317-4b85-9ab5-34dea7819d47": {"__data__": {"id_": "a9cd29b5-2317-4b85-9ab5-34dea7819d47", "embedding": null, "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81e94f23-93ee-42db-96a0-04e6516c4447", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d6c67aa97355ae7f90679b123a80f7f64780c6e838f5fca94ea67ae92106941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60f65129-7de7-4671-87c8-f434bfc260f6", "node_type": "1", "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "d20a12bf5141e231ce6396b4718faa1ae0173cabab528a6d90dd08d57b8b3383", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "start_char_idx": 318, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60f65129-7de7-4671-87c8-f434bfc260f6": {"__data__": {"id_": "60f65129-7de7-4671-87c8-f434bfc260f6", "embedding": null, "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9cd29b5-2317-4b85-9ab5-34dea7819d47", "node_type": "1", "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed532b412ab5f7d39b0e6bc985ed0ebb06a254725ec57279e068f10395d1c45f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8e9fdef-2257-4b0b-bae8-0730b5700343", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. "}, "hash": "5b34a3ecd121ce228a1affba3dde474c8b3af7f28b9aa0412daa416f69963188", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 441, "end_char_idx": 511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8e9fdef-2257-4b0b-bae8-0730b5700343": {"__data__": {"id_": "f8e9fdef-2257-4b0b-bae8-0730b5700343", "embedding": null, "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60f65129-7de7-4671-87c8-f434bfc260f6", "node_type": "1", "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "482e8ab9ff2ea2e9a783add99fc443b10e138fff0af09e29a58d80ef153b9038", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4036928-dbf0-4ebe-b527-6a92e7fe5991", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. "}, "hash": "10faf8ba366595591b72cdc2805e643ec496bb35907904fd3b60d820f3e81dcf", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "start_char_idx": 511, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4036928-dbf0-4ebe-b527-6a92e7fe5991": {"__data__": {"id_": "d4036928-dbf0-4ebe-b527-6a92e7fe5991", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8e9fdef-2257-4b0b-bae8-0730b5700343", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258a656bc56ceba5fbcd455c7a93df9f2fdd016d49155b63c25242e3aa3c7c80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84729ce8-2556-4a14-a8fc-cbd0c034ab0a", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "c49f512020322a88388eae00b96fe71a38fbba2229c7624709727281bbaaf268", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 681, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84729ce8-2556-4a14-a8fc-cbd0c034ab0a": {"__data__": {"id_": "84729ce8-2556-4a14-a8fc-cbd0c034ab0a", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4036928-dbf0-4ebe-b527-6a92e7fe5991", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66a9ba66522d446dfe19e2b491b27ead3e67ffc0e9c0f8b11d19b360060adb0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. "}, "hash": "8f6da8d2e770de66025373655ab956bca452c97748a264d8d6cf835aef725ebe", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 824, "end_char_idx": 898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4": {"__data__": {"id_": "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84729ce8-2556-4a14-a8fc-cbd0c034ab0a", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "942ba4169ac4fc328ebcaa4b1e92dc4aa207df68021c8611bd5d0e1099af1cda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10148255.\n"}, "hash": "11f6fc300a33206aa9b85f75bfd5173d202a22f97fea9c06b8db5ac41da35e7c", "class_name": "RelatedNodeInfo"}}, "text": "From outside the U.S., dial +1 (412) 317-0088. ", "start_char_idx": 898, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30": {"__data__": {"id_": "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10148255.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f2401437b3a2066659ce8450823f3d3338b249f077adca26e43f22151215298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc43260a-110e-4d63-b6ad-187cae692264", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. "}, "hash": "3613648c8c369f1af9fcc3966c3ae6523d1ba3fbd580970c8f517479fad98f4d", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the replay is 10148255.\n", "start_char_idx": 945, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc43260a-110e-4d63-b6ad-187cae692264": {"__data__": {"id_": "bc43260a-110e-4d63-b6ad-187cae692264", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10148255.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce9e631471851f6eda2f8768c5895e47bf87796e8815985d463b9d0b04536f84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2d2cc54-21a1-4da2-a446-4d3c904f3292", "node_type": "1", "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Morgan Healthcare Conference, January 10-14.\n"}, "hash": "5edcc645317a3883960d95805d5b0d0b5e3bdc822b9033dc7be2d45878553856", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "start_char_idx": 989, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2d2cc54-21a1-4da2-a446-4d3c904f3292": {"__data__": {"id_": "f2d2cc54-21a1-4da2-a446-4d3c904f3292", "embedding": null, "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Morgan Healthcare Conference, January 10-14.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc43260a-110e-4d63-b6ad-187cae692264", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb50c5d11598b7332f7931f906a548f9cba931b72daccd4db692227ef4985660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff3864ea-ad97-45ec-81cb-8c98d659e985", "node_type": "1", "metadata": {"window": "The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "6b441c5485f4226f81dcc58c11c8b88dc7f6715ee444eb60dd224c6e73cf6862", "class_name": "RelatedNodeInfo"}}, "text": "Morgan Healthcare Conference, January 10-14.\n", "start_char_idx": 1124, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff3864ea-ad97-45ec-81cb-8c98d659e985": {"__data__": {"id_": "ff3864ea-ad97-45ec-81cb-8c98d659e985", "embedding": null, "metadata": {"window": "The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2d2cc54-21a1-4da2-a446-4d3c904f3292", "node_type": "1", "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Morgan Healthcare Conference, January 10-14.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3edcbe89c78998ec1b1a525b0ef8694357123473c7e6a8aa85cbdcf18467454d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f374e57-cf72-405e-a78a-2a72ab0617da", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n"}, "hash": "1e10b3a0e284c438f3b0abe40308f3a3c1ee70f2e91d0dff125362b884c3a813", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1169, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f374e57-cf72-405e-a78a-2a72ab0617da": {"__data__": {"id_": "9f374e57-cf72-405e-a78a-2a72ab0617da", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff3864ea-ad97-45ec-81cb-8c98d659e985", "node_type": "1", "metadata": {"window": "The\naccess code for the replay is 10148255.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5c0081ba631fc3029a2f729af852cdf0427ad875ad80776bd85a897f2f984d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6078699d-35c6-46c8-afa9-1a4b71e86aa9", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. "}, "hash": "c07659fdd938dddad215bdef2d5588da326de7df352b50fef149aa785724c144", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "start_char_idx": 1298, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6078699d-35c6-46c8-afa9-1a4b71e86aa9": {"__data__": {"id_": "6078699d-35c6-46c8-afa9-1a4b71e86aa9", "embedding": null, "metadata": {"window": "Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f374e57-cf72-405e-a78a-2a72ab0617da", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96c3f16741f376ee19be37bd4312318bdec8e4358e448037c52baf9b0a420a2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28bf0b91-05e3-48fb-8ee9-72ff5042b156", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n"}, "hash": "4469e963c2e097174c33a23774c6fbec18967fbd5008dbc199e57c6d50f36c11", "class_name": "RelatedNodeInfo"}}, "text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "start_char_idx": 1451, "end_char_idx": 1601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28bf0b91-05e3-48fb-8ee9-72ff5042b156": {"__data__": {"id_": "28bf0b91-05e3-48fb-8ee9-72ff5042b156", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6078699d-35c6-46c8-afa9-1a4b71e86aa9", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 10-14.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "670428972d4ac31eaf12a4eb2340ac66994a95842db8553cc1ca3ea725e7d880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c4f8d91-83a4-4ad1-8aee-98280e608a63", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n"}, "hash": "e0c1dc850a48bd8fc4f0c1fcd6ad003072265fcfb2d5ecb8a1a8e82e4ae8c887", "class_name": "RelatedNodeInfo"}}, "text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "start_char_idx": 1601, "end_char_idx": 1698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c4f8d91-83a4-4ad1-8aee-98280e608a63": {"__data__": {"id_": "9c4f8d91-83a4-4ad1-8aee-98280e608a63", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28bf0b91-05e3-48fb-8ee9-72ff5042b156", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea153f01bb3c0673421a543dc2d4797b0aa116bf23ce89abf5c1ad576650347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f25f6784-733e-42c5-9155-010533818f64", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. "}, "hash": "f0c9f174a977dd523942e86e5b338d105078c9594cc49b168d3bbe1bf048444a", "class_name": "RelatedNodeInfo"}}, "text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "start_char_idx": 1698, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f25f6784-733e-42c5-9155-010533818f64": {"__data__": {"id_": "f25f6784-733e-42c5-9155-010533818f64", "embedding": null, "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c4f8d91-83a4-4ad1-8aee-98280e608a63", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02c509f946d7edd2435620a136ae023105bef2cd1aefb9da9d1d84de89e699ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee2999e-f602-4bd0-b336-c3b158f01198", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. "}, "hash": "291d148404e850965351b3f9ef9378a14bb07dcc696a117b11261a7a17caf315", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "start_char_idx": 1823, "end_char_idx": 1922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee2999e-f602-4bd0-b336-c3b158f01198": {"__data__": {"id_": "bee2999e-f602-4bd0-b336-c3b158f01198", "embedding": null, "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f25f6784-733e-42c5-9155-010533818f64", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "763303493a39dce6fa60201aec19d30c647da7f3ad459734ad5dad2914820a50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48205464-ecaa-4855-bd83-fc93bc2f3fd1", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. "}, "hash": "b1ac73eb76b0566d07aff1caff7e4f4ce48434ba2859af92cdb91a18ae42f49a", "class_name": "RelatedNodeInfo"}}, "text": "The company is\nheadquartered in Valley Forge, Pa. ", "start_char_idx": 1922, "end_char_idx": 1972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48205464-ecaa-4855-bd83-fc93bc2f3fd1": {"__data__": {"id_": "48205464-ecaa-4855-bd83-fc93bc2f3fd1", "embedding": null, "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee2999e-f602-4bd0-b336-c3b158f01198", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deac45fa5c070f4c535556c5f39142e13bbf4e7f4ff21ec2dec68d50db46ddc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7aecefb-1258-4e55-9eb1-cea2b184246f", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "fe9a2ba5bf1bdb4c4b9a6a30cda6ad272598b1e4d152ac33280ab7256d376423", "class_name": "RelatedNodeInfo"}}, "text": "and has a presence in 50+ countries. ", "start_char_idx": 1972, "end_char_idx": 2009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7aecefb-1258-4e55-9eb1-cea2b184246f": {"__data__": {"id_": "f7aecefb-1258-4e55-9eb1-cea2b184246f", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48205464-ecaa-4855-bd83-fc93bc2f3fd1", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3faa95387f5679af9db8ec72f158a7d2debbf2ae74c4874febad8b6b24036d41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44a32c10-3c5a-48a6-b529-ede5dfe9d401", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. "}, "hash": "fe71244f6b2c67e469ddd315eaac25f556f330c506ea28300e3eb2f7e15e93ac", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 2009, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44a32c10-3c5a-48a6-b529-ede5dfe9d401": {"__data__": {"id_": "44a32c10-3c5a-48a6-b529-ede5dfe9d401", "embedding": null, "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7aecefb-1258-4e55-9eb1-cea2b184246f", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba3c2414fdb129b53b319dcff7e127583d9cbf19b9f9d9430f78ded7ce2a2fae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e956ebc2-ce30-4736-b167-993c78d3d6ea", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. "}, "hash": "8de532a828fd3ee7f007a52bb6877662ea4d5aada04aa3147d0eefea4ef635c8", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "start_char_idx": 2056, "end_char_idx": 2346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e956ebc2-ce30-4736-b167-993c78d3d6ea": {"__data__": {"id_": "e956ebc2-ce30-4736-b167-993c78d3d6ea", "embedding": null, "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44a32c10-3c5a-48a6-b529-ede5dfe9d401", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e66f7c4ff794f78775f8ae2629f1c1ad768feb408c766e37ad2f938850b8de39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. "}, "hash": "10a6093aabd962b50b47ed528be4c450c975f63722f09f20ddd4f8a7bb9ecefb", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "start_char_idx": 2346, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9": {"__data__": {"id_": "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e956ebc2-ce30-4736-b167-993c78d3d6ea", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f532dcd9f21230b5b7bafd8c3e17706dc392311bb19547cd1c889072b96a7e8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82b2e5c6-29bc-40d4-8c01-74821aba62ce", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. "}, "hash": "12de9b3ac0f51426b9384a58fdb0f99b185e26925d4fb97d12bc3e80f3376b20", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "start_char_idx": 2696, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82b2e5c6-29bc-40d4-8c01-74821aba62ce": {"__data__": {"id_": "82b2e5c6-29bc-40d4-8c01-74821aba62ce", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9dc1d095439a1523ae9bfba524363daaa7fa6f3b7d684a21663293e14bea4aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6146dc7f-1150-4c10-92da-17d421bb698c", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6"}, "hash": "e153481aace8f49a96620ce1cd2c184b2fca995d19e9579c3eaa31fa343bb8da", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 2858, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6146dc7f-1150-4c10-92da-17d421bb698c": {"__data__": {"id_": "6146dc7f-1150-4c10-92da-17d421bb698c", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "991b5740-edca-4251-803c-f1bd2f8fbe44", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "030a50af5aefcf1e029ccb78dee21083873d8a3b7ee35d35f8be10686f7e4f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82b2e5c6-29bc-40d4-8c01-74821aba62ce", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57d2b42ce15f2a6a9cbed634715715ffcae997fe0e7bbdbc11f9253012384bd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e06cdf83-31db-4e84-9ed9-9cead65c9a82", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "5147599869cb0e5a0eeb98b86a1d899257165a52b141cf91b03a9c2f98540f4d", "class_name": "RelatedNodeInfo"}}, "text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "start_char_idx": 3057, "end_char_idx": 4745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e06cdf83-31db-4e84-9ed9-9cead65c9a82": {"__data__": {"id_": "e06cdf83-31db-4e84-9ed9-9cead65c9a82", "embedding": null, "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6146dc7f-1150-4c10-92da-17d421bb698c", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\n6", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21211131b60e71ddc0c0be6ab44effbacb841ad31c20249c6dae543d11f02d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce95df4d-f082-42ba-b9a2-6a67e51b7343", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S. "}, "hash": "b61c47138ce0281a1c5773f778c183ab5a7e322392bf21835900b46c9c9b32fa", "class_name": "RelatedNodeInfo"}}, "text": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce95df4d-f082-42ba-b9a2-6a67e51b7343": {"__data__": {"id_": "ce95df4d-f082-42ba-b9a2-6a67e51b7343", "embedding": null, "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e06cdf83-31db-4e84-9ed9-9cead65c9a82", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a15120eec6e23974efe19a2247759c44a70fb0f34bcd0202cd9bd7cb5c32f674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca5de92a-a310-4b8a-8c78-ee81c10362ae", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally. "}, "hash": "b78eaf777410d48e554600d3b6a7552ea190052741a78f29763062d55cd3b0df", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S. ", "start_char_idx": 322, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca5de92a-a310-4b8a-8c78-ee81c10362ae": {"__data__": {"id_": "ca5de92a-a310-4b8a-8c78-ee81c10362ae", "embedding": null, "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce95df4d-f082-42ba-b9a2-6a67e51b7343", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dbfd5bad3ab41c03f790a4a3379eb326aa65506db52cbe516d489e1f2203a69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6752793-e8e7-42ec-975d-e10c701bdad7", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "7254a49d13d6654db2973d950d990a0fb37a6b9dfc8bed4629d45c16e6a89d50", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally. ", "start_char_idx": 753, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6752793-e8e7-42ec-975d-e10c701bdad7": {"__data__": {"id_": "a6752793-e8e7-42ec-975d-e10c701bdad7", "embedding": null, "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca5de92a-a310-4b8a-8c78-ee81c10362ae", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30b0c413648934a7394ba8e111f0207f3532278ac749ad574852f16af73f5729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea19e11a-5561-4789-8adb-ab3d226c3b1a", "node_type": "1", "metadata": {"window": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n"}, "hash": "91320c13cb4f37060c1ee785834c6c240f6533482849688e6efefbbfaced5fe7", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 2430, "end_char_idx": 2845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea19e11a-5561-4789-8adb-ab3d226c3b1a": {"__data__": {"id_": "ea19e11a-5561-4789-8adb-ab3d226c3b1a", "embedding": null, "metadata": {"window": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6752793-e8e7-42ec-975d-e10c701bdad7", "node_type": "1", "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bb648e52b2e11f09b9b7950c368a76796f6c49e548bdb122efa54ea74230e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b018d3c-554c-4a9b-ada4-7638c41ecf48", "node_type": "1", "metadata": {"window": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7"}, "hash": "973e5f66077648db7b170c585c82b544d41b24285c7a3c0a57317d7d32535310", "class_name": "RelatedNodeInfo"}}, "text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "start_char_idx": 2845, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b018d3c-554c-4a9b-ada4-7638c41ecf48": {"__data__": {"id_": "1b018d3c-554c-4a9b-ada4-7638c41ecf48", "embedding": null, "metadata": {"window": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "79a4aa0b-df42-4135-848a-9dd211bde65c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11902a996e2a947786cf3a284bbacf52a9a41797c800714ed20d9065deeea41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea19e11a-5561-4789-8adb-ab3d226c3b1a", "node_type": "1", "metadata": {"window": "and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a7caa0c1eb9f05c0fd32f25086d3c25563f2287b4bafdfec09515413a3f9ac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d8433e-2694-4a57-9fc4-d9b9908e8780", "node_type": "1", "metadata": {"window": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "original_text": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8"}, "hash": "e7d97226d7c3aa1d5dc3ea13316d6c2de26b9998c090a920403fba98a453eeb8", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "start_char_idx": 2994, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d8433e-2694-4a57-9fc4-d9b9908e8780": {"__data__": {"id_": "d7d8433e-2694-4a57-9fc4-d9b9908e8780", "embedding": null, "metadata": {"window": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "original_text": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e77b5f4-6b57-426c-af63-3312e27915f5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b1da877b06faebb41993d571ab4ebb745cb8bd7b3ac052798ace4cd91871a4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b018d3c-554c-4a9b-ada4-7638c41ecf48", "node_type": "1", "metadata": {"window": "Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a0$45,637,802 \u00a0\u00a0\u00a0 \u00a07.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a044,453,065 \u00a0\u00a0\u00a0 \u00a07.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,346,847 \u00a0\u00a02.74 %\u00a01,184,737 \u00a0\u00a02.60 %\u00a013.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0720,966 \u00a0\u00a01.46 %\u00a0721,944 \u00a0\u00a01.58 %\u00a0(0.1 )%\n7", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab3136f8b90d74d509a8d263d5f8f811a54b21b474f45431bb80f39a644e0bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020. "}, "hash": "976611f765ce08b1f3e163116efe52f66946b84f259180ee78f275442fa14d4e", "class_name": "RelatedNodeInfo"}}, "text": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "start_char_idx": 0, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49": {"__data__": {"id_": "d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d8433e-2694-4a57-9fc4-d9b9908e8780", "node_type": "1", "metadata": {"window": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "original_text": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4df646c7be7c7d670fc8cf243342d280ea0a08847fd85316e87c3943bfa67f21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1239d4d9-95e0-4f90-bb4f-866fca49fa81", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "original_text": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n"}, "hash": "e017a24b7ce984842b7b087dadc6009cdca09bb9e13b8c8f68692f954052c7c1", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020. ", "start_char_idx": 0, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1239d4d9-95e0-4f90-bb4f-866fca49fa81": {"__data__": {"id_": "1239d4d9-95e0-4f90-bb4f-866fca49fa81", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "original_text": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34d6bfc2403daf5526bb10cc9bda839f8367a4034093d9b33fb4fc36af7faddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdcd009d-4abc-42e5-88d3-b514fe89b91d", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020. "}, "hash": "6ad6fe3dcdc0dbe93b27a86571eada43f01f2be9e949c9855e263e0ade68a734", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n", "start_char_idx": 349, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdcd009d-4abc-42e5-88d3-b514fe89b91d": {"__data__": {"id_": "bdcd009d-4abc-42e5-88d3-b514fe89b91d", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1239d4d9-95e0-4f90-bb4f-866fca49fa81", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "original_text": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2cd43cd1b071fbe08e2ec8e6f15ed519bac15a4fdabcd574033a3a213fbf509", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2d590ae-7639-416f-b2df-d6ddc00a7e12", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "original_text": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n"}, "hash": "23a14185c8613319a6a471c44347fbcd737059d594a117279c0412a73e27504c", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020. ", "start_char_idx": 544, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2d590ae-7639-416f-b2df-d6ddc00a7e12": {"__data__": {"id_": "b2d590ae-7639-416f-b2df-d6ddc00a7e12", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "original_text": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdcd009d-4abc-42e5-88d3-b514fe89b91d", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acac24f42b6e330dd8ac915ac35a6915589aba92406bf8eb54bf92c5712a35e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adf39649-b52f-44d3-b623-d5d75944c70c", "node_type": "1", "metadata": {"window": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. "}, "hash": "3c3341436b0835be504c455b3a5b47d4ad61ca966337b60457174ba78c70b537", "class_name": "RelatedNodeInfo"}}, "text": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "start_char_idx": 651, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adf39649-b52f-44d3-b623-d5d75944c70c": {"__data__": {"id_": "adf39649-b52f-44d3-b623-d5d75944c70c", "embedding": null, "metadata": {"window": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2d590ae-7639-416f-b2df-d6ddc00a7e12", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "original_text": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e21c8ec39a4ac5100e448d5d002b8a5eb214499e462b449d01fa7fe248ae4f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4a3b046-2445-4a61-8ce6-1c432806072b", "node_type": "1", "metadata": {"window": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n"}, "hash": "e8c9d02158efcf496230808ad46039858ce9e355a04e21401c0dcc828e3561ea", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "start_char_idx": 753, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4a3b046-2445-4a61-8ce6-1c432806072b": {"__data__": {"id_": "e4a3b046-2445-4a61-8ce6-1c432806072b", "embedding": null, "metadata": {"window": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adf39649-b52f-44d3-b623-d5d75944c70c", "node_type": "1", "metadata": {"window": "Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2aeb2b99a5c1f0bb77949930ae29dda012fb249eee9abd82d8b0f6278aaf4753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e", "node_type": "1", "metadata": {"window": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n"}, "hash": "91bc93f706f54ae280511122f29694ee38fe5b31a9a2298fd57719a096df5a24", "class_name": "RelatedNodeInfo"}}, "text": "Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "start_char_idx": 1133, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e": {"__data__": {"id_": "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e", "embedding": null, "metadata": {"window": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4a3b046-2445-4a61-8ce6-1c432806072b", "node_type": "1", "metadata": {"window": "2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43e9d42b13ef8c41ce359ea474f131d6f7abcfe7a6eb8d2cd1f36ddb0d1f11c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9", "node_type": "1", "metadata": {"window": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9"}, "hash": "cca657d901bdf17b33b8309e423d07f10b8c3fc16d656af0c2eea4ea2feb79c9", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "start_char_idx": 1573, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9": {"__data__": {"id_": "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9", "embedding": null, "metadata": {"window": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f5070f85ed3c4e2b3f7c7403877a017f04a856d20262267042d33cd204da4bf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e", "node_type": "1", "metadata": {"window": "Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n 3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3dcb37c231caad3e26a59953fb89e3ab04d0a36b7df744043da654d923f63f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a6f189-e253-4cf7-be1c-216e3f675a49", "node_type": "1", "metadata": {"window": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10"}, "hash": "bc198c681b6ee3252da4a3f2ad6a7f5fd0ef3568d51d68e630ee4c010952af24", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "start_char_idx": 2001, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a6f189-e253-4cf7-be1c-216e3f675a49": {"__data__": {"id_": "18a6f189-e253-4cf7-be1c-216e3f675a49", "embedding": null, "metadata": {"window": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67637666-07f6-46ca-95ff-6e0322dfdf1f", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98a5aed98e65e36231a41fe966bdab092ba70d154f6bf5a809d307663674d756", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9", "node_type": "1", "metadata": {"window": "3Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and $28.5 million of legal fees in connection with\nopioid lawsuits and investigations, and $4.2 million of other costs in connection with business transformation efforts,\nacquisition-related deal and integration costs, and other restructuring initiatives in the three months ended September 30,\n2020.  Includes $4.5 million of employee severance, $116.7 million of legal settlements, $21.3 million of litigation and opioid-\nrelated costs primarily related to legal fees in connection with opioid lawsuits and investigations, and $31.9 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2019.\n\u00a0\n 4Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a\n$360.7 million tax benefit relating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously\nrecognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium\nbusiness in the three months ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \nRevenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a0$179,589,121 \u00a0\u00a0\u00a0 \u00a05.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a0174,450,809 \u00a0\u00a0\u00a0 \u00a05.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a05,191,884 \u00a0\u00a02.73 %\u00a05,138,312 \u00a0\u00a02.86 %\u00a01.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c5aa59385aafd85a54dac150e5e4e2a8983cc33a57ad0fbbe2066b0f66555c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c31585bb-0952-4944-afe8-79e7825b740c", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020. "}, "hash": "93b7120f734ed0ef8d33f22592e6b7703f4068f540b40e30070f79a84cae9f32", "class_name": "RelatedNodeInfo"}}, "text": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "start_char_idx": 0, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c31585bb-0952-4944-afe8-79e7825b740c": {"__data__": {"id_": "c31585bb-0952-4944-afe8-79e7825b740c", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a6f189-e253-4cf7-be1c-216e3f675a49", "node_type": "1", "metadata": {"window": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deca29841d641e84a22d5ff82a56b71e3efa4b280158afc2471a2265b8f559a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c28c0c6b-18ca-4530-a187-63a3ed8f09d0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n"}, "hash": "2706b1ddec6e5598a4997f1a73fcb3f77f59ffb5374e347cc7fab4fa7cb73c8c", "class_name": "RelatedNodeInfo"}}, "text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020. ", "start_char_idx": 0, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c28c0c6b-18ca-4530-a187-63a3ed8f09d0": {"__data__": {"id_": "c28c0c6b-18ca-4530-a187-63a3ed8f09d0", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c31585bb-0952-4944-afe8-79e7825b740c", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28c2b9119186796cf90a1be56e0c8e040fd4bb8b83bd2c684c56c7f83c106917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77db1781-36f1-4da5-835f-642ef764dff0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020. "}, "hash": "38dc8cbe4f6ae519cf6954c0e1416f2aa725768ee1e5f6ba8d0281e0228cda4b", "class_name": "RelatedNodeInfo"}}, "text": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n", "start_char_idx": 551, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77db1781-36f1-4da5-835f-642ef764dff0": {"__data__": {"id_": "77db1781-36f1-4da5-835f-642ef764dff0", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c28c0c6b-18ca-4530-a187-63a3ed8f09d0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b4c265f8a006afb04d566d0240ad42e7f47fc3a80d81f57c842541a32b801c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n"}, "hash": "18cb0d03d4f1a98f973391fc5e06e01b7b2b310c3b4872453970be0ccc6be70a", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020. ", "start_char_idx": 866, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0": {"__data__": {"id_": "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77db1781-36f1-4da5-835f-642ef764dff0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0f8c6db752c45612ca4900e246524fdcb3f3f70d2de52ef450fb778ab3f8818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df81b0ff-8496-4d0a-89eb-c99a33fdfea3", "node_type": "1", "metadata": {"window": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "original_text": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n"}, "hash": "415d32cd055134f81516423366fa4191a248cdc2e19d3e0f3e7c2e09d4a1186e", "class_name": "RelatedNodeInfo"}}, "text": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "start_char_idx": 1134, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df81b0ff-8496-4d0a-89eb-c99a33fdfea3": {"__data__": {"id_": "df81b0ff-8496-4d0a-89eb-c99a33fdfea3", "embedding": null, "metadata": {"window": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "original_text": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf40cadac81d24a08f9bd30df9c5e73020ed6c21edd45aea7f253629d54b3f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "626f011a-0058-44cf-9b87-5b26be8490ca", "node_type": "1", "metadata": {"window": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "original_text": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n"}, "hash": "0afc52433fe1bc71830eff30ec723d20fca3f8fa34b2c8619b9379ccabd7a0e6", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "start_char_idx": 1236, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "626f011a-0058-44cf-9b87-5b26be8490ca": {"__data__": {"id_": "626f011a-0058-44cf-9b87-5b26be8490ca", "embedding": null, "metadata": {"window": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "original_text": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df81b0ff-8496-4d0a-89eb-c99a33fdfea3", "node_type": "1", "metadata": {"window": "Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "original_text": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834d69c3261890d8b7a733a8620bf924cb8022a85e5a4917affe60a7a24b895e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "953a2da6-014f-45cf-97a6-2f19b54731da", "node_type": "1", "metadata": {"window": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n"}, "hash": "ad96e0515d6a572d29a43f6502e785bb7c8400c7cafd3f855d3bc3de59a97fe0", "class_name": "RelatedNodeInfo"}}, "text": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "start_char_idx": 1618, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "953a2da6-014f-45cf-97a6-2f19b54731da": {"__data__": {"id_": "953a2da6-014f-45cf-97a6-2f19b54731da", "embedding": null, "metadata": {"window": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "626f011a-0058-44cf-9b87-5b26be8490ca", "node_type": "1", "metadata": {"window": "2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "original_text": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa8aa6a58a27f938d76f5984b28cd2a9062d17177dca17321990f0447ac7549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5", "node_type": "1", "metadata": {"window": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. "}, "hash": "120b6263552f0c8aad213868475ce79c434e40f142a981a00f0362ca39d7a2bc", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "start_char_idx": 2058, "end_char_idx": 2172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5": {"__data__": {"id_": "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5", "embedding": null, "metadata": {"window": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "953a2da6-014f-45cf-97a6-2f19b54731da", "node_type": "1", "metadata": {"window": "Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n 3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7c39810053d207958f717ace4fb99ca352182d425b5efcbb517b922609790c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d59d0c7-96c3-4074-97f7-c453383a3420", "node_type": "1", "metadata": {"window": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n"}, "hash": "f35ce6c5f3a62f73bbe9584d1fe0425e02ac7fe66ac8a68ab4ca7c1e311ecc12", "class_name": "RelatedNodeInfo"}}, "text": "5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "start_char_idx": 2172, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d59d0c7-96c3-4074-97f7-c453383a3420": {"__data__": {"id_": "3d59d0c7-96c3-4074-97f7-c453383a3420", "embedding": null, "metadata": {"window": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5", "node_type": "1", "metadata": {"window": "3Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and $115.4 million of legal fees in connection\nwith opioid lawsuits and investigations, and $50.6 million of other costs in connection with business transformation efforts,\nother restructuring initiatives, and acquisition-related deal and integration costs in the fiscal year ended September 30, 2020.\n Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dae7a71d30fc583e364e6380fb412834ac51043d4458277920168ce14bbe42b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b02135bc-b68e-4eba-97f1-b1c218ff1914", "node_type": "1", "metadata": {"window": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11"}, "hash": "04fe0bf8341800a4ed6cbd507a3b13c4ca523722ef22ce9c26ee7ad942fd8575", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "start_char_idx": 2565, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b02135bc-b68e-4eba-97f1-b1c218ff1914": {"__data__": {"id_": "b02135bc-b68e-4eba-97f1-b1c218ff1914", "embedding": null, "metadata": {"window": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d3dc6679-af14-4823-bb3a-9e97e000459a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06fc952cc4d6d0670ff53bea35552faf7c20cfb104284fc364558793e206857", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d59d0c7-96c3-4074-97f7-c453383a3420", "node_type": "1", "metadata": {"window": "Includes $34.1 million of employee severance, $116.7 million of legal settlements, $68.5 million of litigation and opioid-related\ncosts primarily related to legal fees in connection with opioid lawsuits and investigations, and $111.2 million of other costs in\nconnection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the fiscal year ended September 30, 2019.\n\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5960feeddebde5372c0531c9fe2f25500c3294b39348f89193095758580a7850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5114b368-cc2e-4189-9a49-72b3a73431f6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12"}, "hash": "d5449ae56d039eb0f01624f3988ad4a56da1ddf7e8525c7cae5b1ecab3f912b6", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "start_char_idx": 2765, "end_char_idx": 2934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5114b368-cc2e-4189-9a49-72b3a73431f6": {"__data__": {"id_": "5114b368-cc2e-4189-9a49-72b3a73431f6", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8687204e-d0a7-4da4-9432-1f376b32802d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e6334fc2d460eb48d4abe1c41c7327ffc9bd8a7357da04fe7e5aa7d891fc188", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b02135bc-b68e-4eba-97f1-b1c218ff1914", "node_type": "1", "metadata": {"window": "4Includes a $13.7 million gain on the sale of an equity investment in the fiscal year ended September 30, 2019.\n\u00a0\n 5Includes a $1,078.6 million tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits,\n$720.6 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business, and a $360.7 million tax benefit relating to Swiss tax reform in the fiscal year ended\nSeptember 30, 2020.  Includes a $37.0 million measurement period adjustment of the one-time transition tax on historical\nforeign earnings and profits through December 31, 2017 in the fiscal year ended September 30, 2019.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020\n(Loss)\nld\n11", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e679936466cf975d5af58d4015a318bd6654436f41c9b94d65a91608d037b6ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "57ebce4fd606fe78fe70bcb841865a46a5dda9b7de81d7b448c71df6ff471732", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "start_char_idx": 0, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1": {"__data__": {"id_": "e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1", "embedding": null, "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e870ba2f-9b27-47a8-894e-26192a7e6020", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e9b7ca2ca5295c7dae607147b502b9f913b79907b742f0311f085e435a9562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5114b368-cc2e-4189-9a49-72b3a73431f6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bec4eecf7db665e84b55a2e587637b3c0ee5ade80b0ba40709bd789415f71e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "584d9df2-6136-47df-ab81-481061fe64e6", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n"}, "hash": "048df533cccf0e75c46c9fc700dda3c8671f96ca89307e1964c5028eb8448399", "class_name": "RelatedNodeInfo"}}, "text": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "584d9df2-6136-47df-ab81-481061fe64e6": {"__data__": {"id_": "584d9df2-6136-47df-ab81-481061fe64e6", "embedding": null, "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e870ba2f-9b27-47a8-894e-26192a7e6020", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e9b7ca2ca5295c7dae607147b502b9f913b79907b742f0311f085e435a9562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "976f66d536526cde61ee2dd682b38baf1a66da5d4125fad794f4db25607cae5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1037c6f5-913a-4149-87e3-81628ac1288a", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n"}, "hash": "b0e13f758a57806b594747d0e1623be658ef4abcb2723db807005d31f0c2df43", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "start_char_idx": 452, "end_char_idx": 803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1037c6f5-913a-4149-87e3-81628ac1288a": {"__data__": {"id_": "1037c6f5-913a-4149-87e3-81628ac1288a", "embedding": null, "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e870ba2f-9b27-47a8-894e-26192a7e6020", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e9b7ca2ca5295c7dae607147b502b9f913b79907b742f0311f085e435a9562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "584d9df2-6136-47df-ab81-481061fe64e6", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9f2c686232b925abd1ad1546d60508214e51dee0fd2d0d41dc5526341767ce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64d4fbaa-3b73-4868-bc38-fd58c44822bd", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n"}, "hash": "fd4e4de8baaab4cc121068c54fc9ebeeb4b5a5df4bda8a63ae3d3552b112e9da", "class_name": "RelatedNodeInfo"}}, "text": "2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n", "start_char_idx": 803, "end_char_idx": 996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64d4fbaa-3b73-4868-bc38-fd58c44822bd": {"__data__": {"id_": "64d4fbaa-3b73-4868-bc38-fd58c44822bd", "embedding": null, "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e870ba2f-9b27-47a8-894e-26192a7e6020", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e9b7ca2ca5295c7dae607147b502b9f913b79907b742f0311f085e435a9562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1037c6f5-913a-4149-87e3-81628ac1288a", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fc992efc500e76b28b1271a43c4996f2515fb6f00ffe0a264d160b0617108e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "938ee48a-47f2-4c4e-84e7-0db3571470fb", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "13"}, "hash": "9c72ed29bf4c3e8350ac87581ac0039012f339fbe89f4de997b32617534da3b6", "class_name": "RelatedNodeInfo"}}, "text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "start_char_idx": 996, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "938ee48a-47f2-4c4e-84e7-0db3571470fb": {"__data__": {"id_": "938ee48a-47f2-4c4e-84e7-0db3571470fb", "embedding": null, "metadata": {"window": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "13", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e870ba2f-9b27-47a8-894e-26192a7e6020", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e9b7ca2ca5295c7dae607147b502b9f913b79907b742f0311f085e435a9562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64d4fbaa-3b73-4868-bc38-fd58c44822bd", "node_type": "1", "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4785297fca091df1477c34954715ec523e3526742dadababdcd51547310d3ad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9bc7192-8d8f-4256-a1f4-9ac2e396b394", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "23fb0389ce81d26e7d2e19c0097c2a17ad06a6757d23f669564249ab5d136322", "class_name": "RelatedNodeInfo"}}, "text": "13", "start_char_idx": 1054, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9bc7192-8d8f-4256-a1f4-9ac2e396b394": {"__data__": {"id_": "a9bc7192-8d8f-4256-a1f4-9ac2e396b394", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09e81d7a-2548-4447-9283-300df9fa2a91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffa2d7e0562cd88ce85fe039d57b999242e4afbad1825078881a9ac69f7ba78c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "938ee48a-47f2-4c4e-84e7-0db3571470fb", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 13", "original_text": "13", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96df47657f022b0394db7a13331a79817560f4bdce0c0c73848a53e3f2a5742b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "593093f1-7746-4452-b0f6-b027dd72e045", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14"}, "hash": "da9e5504f015ce5dafc9076526db32ccff2b7e888ee6fef3f6fa731046ab2571", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "593093f1-7746-4452-b0f6-b027dd72e045": {"__data__": {"id_": "593093f1-7746-4452-b0f6-b027dd72e045", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09e81d7a-2548-4447-9283-300df9fa2a91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffa2d7e0562cd88ce85fe039d57b999242e4afbad1825078881a9ac69f7ba78c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9bc7192-8d8f-4256-a1f4-9ac2e396b394", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55b69803bf3f2db508b6a78a595bc5a2191b2ce11d7b185c75a6b6a8c173c5d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b1b2fe609bf26d75e3d175b9a52144dd747a34d85af721ea04a9ad53d8fff0d5", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "start_char_idx": 177, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7": {"__data__": {"id_": "a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "520772ff-bae5-432b-bead-06f23fabe510", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2e302e08ae8c60ed73bc97e12c0bacd8e588c31b9cae2bba0eaaaf5cdfcbb3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "593093f1-7746-4452-b0f6-b027dd72e045", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "381c08538f7a29693c2e06aaea62070931409779afa1d1c0f33e663e190fe778", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69906f47-04e7-410b-a4eb-9ab883932e32", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15"}, "hash": "26880d342f2769cc8865ee0498ac4e6d36b1dea37ac15a26e58979eb378058df", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69906f47-04e7-410b-a4eb-9ab883932e32": {"__data__": {"id_": "69906f47-04e7-410b-a4eb-9ab883932e32", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "520772ff-bae5-432b-bead-06f23fabe510", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2e302e08ae8c60ed73bc97e12c0bacd8e588c31b9cae2bba0eaaaf5cdfcbb3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bae420d5a826802a0ffaf7766f898a960135b27f70b37a81c187691b832119f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "195f806c-1005-48d0-9817-5c5dc51c8b40", "node_type": "1", "metadata": {"window": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16"}, "hash": "e373de0f3124a57c09ca0a90f02e3e961e454cd1ee4905d2f6d689257f416b19", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "start_char_idx": 362, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "195f806c-1005-48d0-9817-5c5dc51c8b40": {"__data__": {"id_": "195f806c-1005-48d0-9817-5c5dc51c8b40", "embedding": null, "metadata": {"window": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bff91b8c-9e20-4fae-9c1c-7b15b45748fa", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c74d70ccdb17be01c37f677c8ed92e8b9aa1b35a4a4eabbeb6f79a5719a1256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69906f47-04e7-410b-a4eb-9ab883932e32", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9677db30597d4a49460e19094e41250d3785ebbd79054332c92d4a78b85e92d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "008b954c-ebdd-44b7-86b2-42648c81b6cd", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Adjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "204a23d8c7c5cfeca23d3a349263e8daab803ba48b03d02649c55fb92bbb3aab", "class_name": "RelatedNodeInfo"}}, "text": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "start_char_idx": 0, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "008b954c-ebdd-44b7-86b2-42648c81b6cd": {"__data__": {"id_": "008b954c-ebdd-44b7-86b2-42648c81b6cd", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Adjusted\nNon-GAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "195f806c-1005-48d0-9817-5c5dc51c8b40", "node_type": "1", "metadata": {"window": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6281902f7982657029d824f7da20cf388dbdff70f4109d58fc096ff77719fa92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d154778-ddf4-4be8-a6ac-472d32ec92eb", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n"}, "hash": "1e3a9dc1103b20461d26a131ec2a5cced2fa2890c2cf11edf06d268f246607f4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 31, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d154778-ddf4-4be8-a6ac-472d32ec92eb": {"__data__": {"id_": "1d154778-ddf4-4be8-a6ac-472d32ec92eb", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "008b954c-ebdd-44b7-86b2-42648c81b6cd", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Adjusted\nNon-GAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "797f7014de6b6deb28d84d42a4bbf87a35feba19f7022d5a3df3044878b37393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00838776-fb73-4c0a-8ec0-257d95e87699", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n"}, "hash": "4c319a845bb4f53010baa6e538a74130dace8312682afcba48cf49fcba4f2678", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "start_char_idx": 31, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00838776-fb73-4c0a-8ec0-257d95e87699": {"__data__": {"id_": "00838776-fb73-4c0a-8ec0-257d95e87699", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d154778-ddf4-4be8-a6ac-472d32ec92eb", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0815e608cdc5a8ad4d5bfaeae64a1af36a313babcc34d83f3461cdc7e4aba22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b7ac312-11b2-4f0b-8c2d-c944f7884b76", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n"}, "hash": "ed61bf5b7e39615e6235e30d037d3147ae9888c0beafbafba6618c72c1140c11", "class_name": "RelatedNodeInfo"}}, "text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "start_char_idx": 370, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b7ac312-11b2-4f0b-8c2d-c944f7884b76": {"__data__": {"id_": "4b7ac312-11b2-4f0b-8c2d-c944f7884b76", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00838776-fb73-4c0a-8ec0-257d95e87699", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d344fdc44facf642fceab2584086925c5a684cc8353db2374f26b4140cd25c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16eba2a1-0d4f-4284-ae85-be5d91c485db", "node_type": "1", "metadata": {"window": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "5756be2ed61cfd9a6f5d17cf7552ef75bb8c8c4be79e948a5d1793fa2d9d933e", "class_name": "RelatedNodeInfo"}}, "text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "start_char_idx": 524, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16eba2a1-0d4f-4284-ae85-be5d91c485db": {"__data__": {"id_": "16eba2a1-0d4f-4284-ae85-be5d91c485db", "embedding": null, "metadata": {"window": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b7ac312-11b2-4f0b-8c2d-c944f7884b76", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67ea4e6d39de81ec96e7d540c001c1f313e2d2549819a61eb218a2bda4a43408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "686b71b0-c938-47bb-add6-b4efca6ae1cd", "node_type": "1", "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "007b4627f5a1b0717572be92b4e6e67b8d4966edccfb8ca770ba94f0a17f606a", "class_name": "RelatedNodeInfo"}}, "text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 582, "end_char_idx": 653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "686b71b0-c938-47bb-add6-b4efca6ae1cd": {"__data__": {"id_": "686b71b0-c938-47bb-add6-b4efca6ae1cd", "embedding": null, "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16eba2a1-0d4f-4284-ae85-be5d91c485db", "node_type": "1", "metadata": {"window": "prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41616f1b24a2e0fc138b4c95945a954e82f42a4579db172ec7061f0874ef029c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e933621-0bc5-4d60-ab78-9d8803e4473b", "node_type": "1", "metadata": {"window": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17"}, "hash": "0b2e8e9481cdc2be38424fe2bff9f636a1f34d9aea28b486e48f48751dde3891", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 653, "end_char_idx": 830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e933621-0bc5-4d60-ab78-9d8803e4473b": {"__data__": {"id_": "7e933621-0bc5-4d60-ab78-9d8803e4473b", "embedding": null, "metadata": {"window": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef07e74b6d7d76fc31f100cf043d1865e418b4138bf134a99ebf9c8ba92f304", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "686b71b0-c938-47bb-add6-b4efca6ae1cd", "node_type": "1", "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d51df37019e32f335893fc3d47d0bbab0e95673e23dc4380356c8196780b626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6c393c3-c8f3-48c0-98e1-deed4f005d81", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18"}, "hash": "f8a22d54f9128fac46951b8464a5af0a8b6771862dc94d7db9ead9ca2cf15efd", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "start_char_idx": 830, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6c393c3-c8f3-48c0-98e1-deed4f005d81": {"__data__": {"id_": "e6c393c3-c8f3-48c0-98e1-deed4f005d81", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "page_label": "18", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "999b7c0b-7db0-4420-af0a-464508fe1c2f", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4cefd90b40659663e1dc2561e4ab8d017787a88b31127f32dcd283af5aed0d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e933621-0bc5-4d60-ab78-9d8803e4473b", "node_type": "1", "metadata": {"window": "3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2019\nIncome\nBefor e IncomeNet Loss \n (Income) \nAttributable toNetIncomeDilut ed \nEarnings\n17", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f9da51945b4a02d8384360bc04126f5c771a5297ba208db4bfbccdf27f224ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "587cea1a-8fd6-43bb-9684-79e46bead2b2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n"}, "hash": "7a4cf5869a20366520756fee61dbd90831d23531a563cccd198861c477513e80", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "start_char_idx": 0, "end_char_idx": 1398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "587cea1a-8fd6-43bb-9684-79e46bead2b2": {"__data__": {"id_": "587cea1a-8fd6-43bb-9684-79e46bead2b2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7590c3c228a1ea088be5a4d95770bcc9dd6600ed8c0d52ad2964e1a35db16fb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6c393c3-c8f3-48c0-98e1-deed4f005d81", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "page_label": "18", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce2c1c10e8445bbaf13fa084ccaaeb0b027ae7c896f45a910f792f316cf231ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4e17012-e68d-4ada-a614-f725bf534812", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "0a1d890a8402120e8691ad137f57a4f97780870f31cd99cf6b4b3c7de31a81f3", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4e17012-e68d-4ada-a614-f725bf534812": {"__data__": {"id_": "b4e17012-e68d-4ada-a614-f725bf534812", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7590c3c228a1ea088be5a4d95770bcc9dd6600ed8c0d52ad2964e1a35db16fb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "587cea1a-8fd6-43bb-9684-79e46bead2b2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd5758aae1ccd5db5da719a557311a31ae6e3b9d9fcd16b5e1f19511b818597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db92de59-0145-479e-8f9d-ce49d37fba70", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19"}, "hash": "ce4d8cfc1a5229f92ab7cda687296a7e0bde86a69106e24d9e486192ca7d1c0a", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 468, "end_char_idx": 645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db92de59-0145-479e-8f9d-ce49d37fba70": {"__data__": {"id_": "db92de59-0145-479e-8f9d-ce49d37fba70", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7590c3c228a1ea088be5a4d95770bcc9dd6600ed8c0d52ad2964e1a35db16fb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4e17012-e68d-4ada-a614-f725bf534812", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd96fcc9651af3b930706b4ebf21434ebb063a9383f638f5ca2da207da721ea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f113148-d3d7-4043-a9eb-0a6c7e543a09", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n"}, "hash": "d843a86eca413d1a62e97515dfcf0c2d5b94e8967c4254239e83f127d671db77", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "start_char_idx": 645, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f113148-d3d7-4043-a9eb-0a6c7e543a09": {"__data__": {"id_": "0f113148-d3d7-4043-a9eb-0a6c7e543a09", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2340d502-3472-4d1d-822e-89910f10693e", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e814d51d978755a8d00d0ca46df7fd67708076754ae198e8dbf2c8c29dcdbf98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db92de59-0145-479e-8f9d-ce49d37fba70", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31226054468bac8d253ace36d5ee1fc160ecd6dd04466dc8c569eb976fe5d4dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24def10d-99c8-4d09-94e4-dbd2846b7bd3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c3efb52d0d35dae7b8f88b88ab1a85e130da688803b04877245667a4a52e35cc", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24def10d-99c8-4d09-94e4-dbd2846b7bd3": {"__data__": {"id_": "24def10d-99c8-4d09-94e4-dbd2846b7bd3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2340d502-3472-4d1d-822e-89910f10693e", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e814d51d978755a8d00d0ca46df7fd67708076754ae198e8dbf2c8c29dcdbf98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f113148-d3d7-4043-a9eb-0a6c7e543a09", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa87746e46993e60a0345d2355ddec907d185231326c43a282b4e10761a6b506", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cff161fb-93fd-484e-9282-ba9d179d248f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20"}, "hash": "21b27953649b83e14bda40e51b6f0cb2f7c6ecc64f152154c191a94a79329705", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 401, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cff161fb-93fd-484e-9282-ba9d179d248f": {"__data__": {"id_": "cff161fb-93fd-484e-9282-ba9d179d248f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2340d502-3472-4d1d-822e-89910f10693e", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e814d51d978755a8d00d0ca46df7fd67708076754ae198e8dbf2c8c29dcdbf98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24def10d-99c8-4d09-94e4-dbd2846b7bd3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64519c7c117e36f70c1fe85e98d902fe99f95b65ea0a9f3db0d7170deeb0651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f3f1de8-4617-49ca-ac00-72ceec4b48e5", "node_type": "1", "metadata": {"window": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21"}, "hash": "762da90b8ee6ee094b147af497a7f0d44cd871ffc512802daca2100385174329", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "start_char_idx": 578, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f3f1de8-4617-49ca-ac00-72ceec4b48e5": {"__data__": {"id_": "9f3f1de8-4617-49ca-ac00-72ceec4b48e5", "embedding": null, "metadata": {"window": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a250ca7-4948-488e-bec3-03bd2a36811b", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6577594a775a76a301142220d70e2550949c5cd1f54d018528bd931c9ee1e456", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cff161fb-93fd-484e-9282-ba9d179d248f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15c323043b53be4b036a8ab7d3160e5e9482e0aff0f86abf5bcb3e610749823b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9643655f-e3c1-4718-984b-b503530db308", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "fdcbc3e95f99909bba107149796cbc98878c3779ff38864ddd01bd21c6615ac0", "class_name": "RelatedNodeInfo"}}, "text": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "start_char_idx": 0, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9643655f-e3c1-4718-984b-b503530db308": {"__data__": {"id_": "9643655f-e3c1-4718-984b-b503530db308", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84e1ca6a-98f0-412b-8f2a-39fca4af8589", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56b1669ec85ddecee1df9cca615185cdb16ed2a4c94d4c58e300ee028b6a36f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f3f1de8-4617-49ca-ac00-72ceec4b48e5", "node_type": "1", "metadata": {"window": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26b5e483e8e28c1c36b3e31c131ca617afcd1da7ec745b39da2351a6ecf84b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f0b2377-ee22-49b9-af27-672093bea19b", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22"}, "hash": "891961aeb3e69f816c2a79ed74f11e600493cc7d17b5f5ece188d6ce7d746ecd", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f0b2377-ee22-49b9-af27-672093bea19b": {"__data__": {"id_": "3f0b2377-ee22-49b9-af27-672093bea19b", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84e1ca6a-98f0-412b-8f2a-39fca4af8589", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56b1669ec85ddecee1df9cca615185cdb16ed2a4c94d4c58e300ee028b6a36f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9643655f-e3c1-4718-984b-b503530db308", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6370110949e624809e7ff20a6df5d6543a1e159a239bb0e5ec441dfa929064f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926420dd-a9d9-40b1-9fd8-b6aaf69b95c6", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "original_text": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23"}, "hash": "5c2f240b8b0424e69c5e3cbda925ee55b084bf5bfb034bbce2cf6f9166b7ff98", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "start_char_idx": 354, "end_char_idx": 1040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926420dd-a9d9-40b1-9fd8-b6aaf69b95c6": {"__data__": {"id_": "926420dd-a9d9-40b1-9fd8-b6aaf69b95c6", "embedding": null, "metadata": {"window": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "original_text": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f64e3259-5ffb-4d34-a2e2-dde3e6a1b004", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdd9f06980a40d4c5ed7d4e78b635832b4c3021f011880a4aa5ecbc8ed7ff8cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f0b2377-ee22-49b9-af27-672093bea19b", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "212a6bf05b5f3beeb49c68cd9494e99f3ab94cb69a5116b38d97e98901e9dfc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "301f8a3c-628a-4688-b6c2-1ceb93c8167e", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c7662e6f6d9191ac5baafe0e79aacfba8ee3ea07b15912c669e7a6b9904b8f64", "class_name": "RelatedNodeInfo"}}, "text": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "start_char_idx": 0, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "301f8a3c-628a-4688-b6c2-1ceb93c8167e": {"__data__": {"id_": "301f8a3c-628a-4688-b6c2-1ceb93c8167e", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30ca6010-c542-48bf-8f83-c0eda9fdcbfb", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "871f3612c4ad259dfc15aebb3e4ea595b9fceeba355f8a598f59cff9103070db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926420dd-a9d9-40b1-9fd8-b6aaf69b95c6", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "original_text": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de13a15dba54bed7588cd18a5b26fc924fde8f1c2c99d8792f08d49e7be339e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11913a23-6cb2-4a23-a183-06e156c7e701", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24"}, "hash": "aea4509c98d40a9e9fc67fba57d59593c471989e989720e333b4c2a95b4efadf", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11913a23-6cb2-4a23-a183-06e156c7e701": {"__data__": {"id_": "11913a23-6cb2-4a23-a183-06e156c7e701", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30ca6010-c542-48bf-8f83-c0eda9fdcbfb", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "871f3612c4ad259dfc15aebb3e4ea595b9fceeba355f8a598f59cff9103070db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "301f8a3c-628a-4688-b6c2-1ceb93c8167e", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea13cdd03c5f0cd398ba3922c2378d7ba4e3fe73e1f4ef3938ca3001a428799e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a297227f-cd3c-49ea-b529-2cbc2b0c47c7", "node_type": "1", "metadata": {"window": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "original_text": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25"}, "hash": "133fa02e9f62b53ec89f9754fcea53e2df58c6da29fc5e1af3a5dc3aa931a745", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "start_char_idx": 354, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a297227f-cd3c-49ea-b529-2cbc2b0c47c7": {"__data__": {"id_": "a297227f-cd3c-49ea-b529-2cbc2b0c47c7", "embedding": null, "metadata": {"window": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "original_text": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "page_label": "25", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b748d157-5abd-407a-b589-973fbe7166ae", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cd418364770b17901ef867c22fdce1071d4bd07112e919f49c4436281b124d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11913a23-6cb2-4a23-a183-06e156c7e701", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "104968a5a5cfdca7dac16e55bfbb9665f0155c048d463824f5b9492d067b64ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d89b570-dd30-467f-84e2-fba82f89df20", "node_type": "1", "metadata": {"window": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "original_text": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26"}, "hash": "146a0c2c97b27ce70b21889c7e7503909fb58f0b693cff9354dffd01b22b2ac8", "class_name": "RelatedNodeInfo"}}, "text": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "start_char_idx": 0, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d89b570-dd30-467f-84e2-fba82f89df20": {"__data__": {"id_": "4d89b570-dd30-467f-84e2-fba82f89df20", "embedding": null, "metadata": {"window": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "original_text": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fdc3d6a-0d61-4995-928e-f92d09e35c62", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41862493b4ae392dc155f90897465fc5ffd7922e7b92bd566a172f6c4d98d5a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a297227f-cd3c-49ea-b529-2cbc2b0c47c7", "node_type": "1", "metadata": {"window": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "original_text": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "page_label": "25", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eae15b5b0d1dd8e479d8196d9bfb9157d3c3cafd5e7c3bf7571a58e884eb1de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a321c71a-110e-4153-8368-ed02bede86f3", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "original_text": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020. "}, "hash": "fda4213ee140504b147707815e3a1fe0cec9d743c58017881dd58a4501eceb4f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "start_char_idx": 0, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a321c71a-110e-4153-8368-ed02bede86f3": {"__data__": {"id_": "a321c71a-110e-4153-8368-ed02bede86f3", "embedding": null, "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "original_text": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d89b570-dd30-467f-84e2-fba82f89df20", "node_type": "1", "metadata": {"window": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "original_text": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1233c56333b970b3b389d74f9bcf4faa61ecdf2b7a2679693ea6f027708e54f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "original_text": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n"}, "hash": "21f7ac7972dae3398f75f446ae2fc725c4842f368e8ebf61892cd5b07d670711", "class_name": "RelatedNodeInfo"}}, "text": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020. ", "start_char_idx": 0, "end_char_idx": 549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1": {"__data__": {"id_": "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1", "embedding": null, "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "original_text": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a321c71a-110e-4153-8368-ed02bede86f3", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "original_text": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "142ed8b99cf148fb0268b7ce6d4d3af6a436342462f429600c98651419073159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e468c82c-e572-4f68-82f3-07e84b6becaf", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "original_text": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020. "}, "hash": "0fd7ee24b7fcfdb1795d6db7e401f1bc1235c938ce97077dd3b33e09867fa994", "class_name": "RelatedNodeInfo"}}, "text": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n", "start_char_idx": 549, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e468c82c-e572-4f68-82f3-07e84b6becaf": {"__data__": {"id_": "e468c82c-e572-4f68-82f3-07e84b6becaf", "embedding": null, "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "original_text": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "original_text": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b140dfe8e5471b49a935dcbb87f904245f246035cfa3d5a2a9a5e14a517ffe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93300160-99c0-426a-90a8-573959e73321", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n"}, "hash": "d8cadbbf45d39404bb15129df5acaaec03a89f3beb2fdf0cfdf6ed44cb01705d", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020. ", "start_char_idx": 693, "end_char_idx": 814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93300160-99c0-426a-90a8-573959e73321": {"__data__": {"id_": "93300160-99c0-426a-90a8-573959e73321", "embedding": null, "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e468c82c-e572-4f68-82f3-07e84b6becaf", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "original_text": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "694235aada42ac8d741b301980ef6bd5c8b86a1c9d99693c2bf43d3ad0e4a915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d76e686b-e258-46bf-96f3-0a5574b9b346", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. "}, "hash": "1b64ae7226da2d41e7154ae38a9fc1143dde27035462b5e78000265f6ce5c69a", "class_name": "RelatedNodeInfo"}}, "text": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "start_char_idx": 814, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d76e686b-e258-46bf-96f3-0a5574b9b346": {"__data__": {"id_": "d76e686b-e258-46bf-96f3-0a5574b9b346", "embedding": null, "metadata": {"window": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93300160-99c0-426a-90a8-573959e73321", "node_type": "1", "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ecbaad3b23cffdfa15a7e28f62836e9801bd6406ddfa9538822d5ea0f37f120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c000b21-2d65-46d7-acf8-61db328126a5", "node_type": "1", "metadata": {"window": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n"}, "hash": "6994fff87e623343d9cc15eaecad8d94e54c4f49be878c3cdf8f361b9787bdd8", "class_name": "RelatedNodeInfo"}}, "text": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "start_char_idx": 993, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c000b21-2d65-46d7-acf8-61db328126a5": {"__data__": {"id_": "5c000b21-2d65-46d7-acf8-61db328126a5", "embedding": null, "metadata": {"window": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d76e686b-e258-46bf-96f3-0a5574b9b346", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c8deccc09b7b757bfbc80cf851113908aa5c8cdc797c6c1c948f0f362719421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20434f49-6ddf-4fe6-abcb-29d6b462a246", "node_type": "1", "metadata": {"window": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "e8d72ad37a541f2bdaf25f696bc0d63fee0c49a206c4a563dd7e72144d33b66c", "class_name": "RelatedNodeInfo"}}, "text": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "start_char_idx": 1150, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20434f49-6ddf-4fe6-abcb-29d6b462a246": {"__data__": {"id_": "20434f49-6ddf-4fe6-abcb-29d6b462a246", "embedding": null, "metadata": {"window": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c000b21-2d65-46d7-acf8-61db328126a5", "node_type": "1", "metadata": {"window": "2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cb44d87a2446f539ed76a78ef91205481289eaa03f490ffeb3068138f5dc8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b254378d-d2f7-4558-85d5-5c206251c37e", "node_type": "1", "metadata": {"window": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "6f1d1d607108ed954906d736e897c8b22ee920a8b25a05bcfaad502bc4678ff1", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 1395, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b254378d-d2f7-4558-85d5-5c206251c37e": {"__data__": {"id_": "b254378d-d2f7-4558-85d5-5c206251c37e", "embedding": null, "metadata": {"window": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20434f49-6ddf-4fe6-abcb-29d6b462a246", "node_type": "1", "metadata": {"window": "Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n 3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "652c834ec4415478847042193a4eb0cf4e741077d40f6b44434c73fee7dc63ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ee9d17-6f3c-4c9c-a2dd-9e0150981868", "node_type": "1", "metadata": {"window": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "0e207bc7d7fe38754b3ef1af956c63171f01c76f813dea4bf7567233a74e1fa0", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1531, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ee9d17-6f3c-4c9c-a2dd-9e0150981868": {"__data__": {"id_": "78ee9d17-6f3c-4c9c-a2dd-9e0150981868", "embedding": null, "metadata": {"window": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b254378d-d2f7-4558-85d5-5c206251c37e", "node_type": "1", "metadata": {"window": "3Purchases of common stock in the fiscal year ended September 30, 2020 includes $14.8 million of September 2019 purchases\nthat cash settled in October 2019.  Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e29ea42a095fc980fd6a8fe50d3996b885822b2d8e8d39bc8ed9b55a8ff5b6d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "c8836ac02cf4000e4de6922c3463e824fb706b0c605847c43920b81936ee7755", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1646, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2": {"__data__": {"id_": "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78ee9d17-6f3c-4c9c-a2dd-9e0150981868", "node_type": "1", "metadata": {"window": "Purchases of common stock in the fiscal year ended September 30, 2019 includes $24.0\nmillion of September 2018 purchases that cash settled in October 2018 and excludes $14.8 million of September 2019\npurchases that cash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04fb6bfb3a7ce695da58cac5eee0a21b982c3e28feb90cbee87c2b35b6f1c0e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ada95e0-36fa-4ce0-a677-1210812735e9", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "cec07a9b80ed3b76e051b0370c8a6a880cd41017a84aacfc312c30347bcd6289", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1786, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ada95e0-36fa-4ce0-a677-1210812735e9": {"__data__": {"id_": "8ada95e0-36fa-4ce0-a677-1210812735e9", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING\nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c431991e90e5cc49981c2fe03c60b2a226885f9b42e536de15bffac098718489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcdcc45e-b067-4da0-b193-87d7f599d0f5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "b7f817e04d3d9f29e9ddcbcfa76a17208d1e09c3324971d863a8782a8db5f30a", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1905, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcdcc45e-b067-4da0-b193-87d7f599d0f5": {"__data__": {"id_": "dcdcc45e-b067-4da0-b193-87d7f599d0f5", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ada95e0-36fa-4ce0-a677-1210812735e9", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d2889db064b501d1b3b9508511d06c8bef994789a061be5825e21fb644c805e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f28c544-62ed-48ae-98e0-2cfac7da54b1", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "f9b1b54a961a52ad38ab4d7f07ada2324657ff1f4d0268cc65174138b6b0fd2a", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 2124, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f28c544-62ed-48ae-98e0-2cfac7da54b1": {"__data__": {"id_": "6f28c544-62ed-48ae-98e0-2cfac7da54b1", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcdcc45e-b067-4da0-b193-87d7f599d0f5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e0ca5990788f8ba5ea2a7f168da0a09739b2b99b918691306415372d440a54c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e46d3d7b-1d6d-4529-9426-a1199d27c744", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). "}, "hash": "e3f37508e175003155dc46f1c611d6b7c4de8f42128e6521148e8152b34d233b", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 2306, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e46d3d7b-1d6d-4529-9426-a1199d27c744": {"__data__": {"id_": "e46d3d7b-1d6d-4529-9426-a1199d27c744", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f28c544-62ed-48ae-98e0-2cfac7da54b1", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1d75773c57a33c77ec0d965091db9938f15392591f59f16259da0cea48c50d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57b598a4-0081-4d83-9545-77fd1524e8e9", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. "}, "hash": "aace905a62df96527abb50d29aed683f9ebb070b4d24a62fe358c6d845c954bc", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "start_char_idx": 2587, "end_char_idx": 3051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57b598a4-0081-4d83-9545-77fd1524e8e9": {"__data__": {"id_": "57b598a4-0081-4d83-9545-77fd1524e8e9", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e46d3d7b-1d6d-4529-9426-a1199d27c744", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d91ada3dbba579d4db97fa7e755e80dc6af9cedd24acb16b1d7d42fc5139cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e033b38-b8d1-46be-8779-54884ed0a48c", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\n27"}, "hash": "ef87050327ac1287f4fed428cd4df7c273b42f8ad9908622a20adef2d9b4ece7", "class_name": "RelatedNodeInfo"}}, "text": "Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "start_char_idx": 3051, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e033b38-b8d1-46be-8779-54884ed0a48c": {"__data__": {"id_": "5e033b38-b8d1-46be-8779-54884ed0a48c", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\n27", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9215f02ef97bd9774997be21a7e5fc9324561a946993e2e6476a75c4123c70b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57b598a4-0081-4d83-9545-77fd1524e8e9", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f37e0381b67470e87693ca02e1f1d84d75c21d4d4937d72ff90f3c962667b0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe20c2e-e71e-4346-a0ba-684e413c968f", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "original_text": "expenses. "}, "hash": "05ef5ae3a1fc19f44640763efe2bda3fa5d494a458bcf2aaf3bffbc4796ab374", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they were unpredictable\n27", "start_char_idx": 3217, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe20c2e-e71e-4346-a0ba-684e413c968f": {"__data__": {"id_": "6fe20c2e-e71e-4346-a0ba-684e413c968f", "embedding": null, "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "original_text": "expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e033b38-b8d1-46be-8779-54884ed0a48c", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the expense (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain\nfrom antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\n27", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\n27", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9db4b8b14b7ccf5816d2d46cf53795afc445d24747b3e2488e3a81e5c24a495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0638315-3faa-420d-b140-e565e7426baa", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring. "}, "hash": "5a7b290fb8b33ccc07bcb3deca1b420ba96b6a1005928a576a6ead1a307a53bc", "class_name": "RelatedNodeInfo"}}, "text": "expenses. ", "start_char_idx": 0, "end_char_idx": 10, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0638315-3faa-420d-b140-e565e7426baa": {"__data__": {"id_": "f0638315-3faa-420d-b140-e565e7426baa", "embedding": null, "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe20c2e-e71e-4346-a0ba-684e413c968f", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "original_text": "expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e152ef59496488752016f208b26c2395a2e7cdea679384e861eb59d742d0dee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f4704b1-2a76-4011-af34-a6420c90659c", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n"}, "hash": "704d7b279b500425cc4c958e1f31b1255fb79b54e18e7668195e8e1aec5379df", "class_name": "RelatedNodeInfo"}}, "text": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring. ", "start_char_idx": 10, "end_char_idx": 148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f4704b1-2a76-4011-af34-a6420c90659c": {"__data__": {"id_": "3f4704b1-2a76-4011-af34-a6420c90659c", "embedding": null, "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0638315-3faa-420d-b140-e565e7426baa", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2465cd32d0ee6fc53e34991af0a042193f0afbc24c568f002a228489e392022b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b5bd722-8c50-4e75-871f-9b565b662249", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. "}, "hash": "afa3d528f5223f09c288b1cd9025483b045cf8e1147ff77906f2c589b658a9c7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n", "start_char_idx": 148, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b5bd722-8c50-4e75-871f-9b565b662249": {"__data__": {"id_": "5b5bd722-8c50-4e75-871f-9b565b662249", "embedding": null, "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f4704b1-2a76-4011-af34-a6420c90659c", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba746befdb6ece579a5932118ba82aeb8e5cdfab2d4b893d7fe1da276067774d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cab9bf4c-e745-4769-9300-b8ae41b53c66", "node_type": "1", "metadata": {"window": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "931eb6bc471b0ad2aea293ec4c7ba21ed7888132e5b80e526acef7389aed397c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "start_char_idx": 233, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cab9bf4c-e745-4769-9300-b8ae41b53c66": {"__data__": {"id_": "cab9bf4c-e745-4769-9300-b8ae41b53c66", "embedding": null, "metadata": {"window": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b5bd722-8c50-4e75-871f-9b565b662249", "node_type": "1", "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "345114b311e5c0f72b419462ee9f32035ea6768146e2a639cb9caa50149a8271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35c95969-f58a-458e-91d2-14e9ee16892b", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. "}, "hash": "8e84d0938f951cc2eba8e9d5ff21c8aa888e18dd41b2dda847dfb4644c8a29e0", "class_name": "RelatedNodeInfo"}}, "text": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 390, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35c95969-f58a-458e-91d2-14e9ee16892b": {"__data__": {"id_": "35c95969-f58a-458e-91d2-14e9ee16892b", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cab9bf4c-e745-4769-9300-b8ae41b53c66", "node_type": "1", "metadata": {"window": "The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be471685790986561df531195afbc71d0ee62ba928c1bed9bb6176c55c2a94e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51f0a62d-434a-4fbd-a1e7-4e6ef5826763", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "original_text": "Food and Drug\nAdministration inspections. "}, "hash": "d3a8abecf2aa3284b407928bd16e0ba3d840dd2c95914b004261ff942cd5c5d4", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "start_char_idx": 690, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51f0a62d-434a-4fbd-a1e7-4e6ef5826763": {"__data__": {"id_": "51f0a62d-434a-4fbd-a1e7-4e6ef5826763", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "original_text": "Food and Drug\nAdministration inspections. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35c95969-f58a-458e-91d2-14e9ee16892b", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a25c8c63788251bb4f0d47941475e3387dd8b2170371c1de549decfc5d9f7427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dadbc79-37f4-47b0-864d-78b294ccd489", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. "}, "hash": "688eda4ec1966c6320cdc451a62cd725d96082b5df9af50d73131ee8da81876c", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug\nAdministration inspections. ", "start_char_idx": 815, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dadbc79-37f4-47b0-864d-78b294ccd489": {"__data__": {"id_": "5dadbc79-37f4-47b0-864d-78b294ccd489", "embedding": null, "metadata": {"window": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51f0a62d-434a-4fbd-a1e7-4e6ef5826763", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance.  The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "original_text": "Food and Drug\nAdministration inspections. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73e815aec514066def6d493850487fae8579a91375cb8021cadac8894c61ff8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93dbed1b-b51f-4521-aa86-b6a7ad2833f1", "node_type": "1", "metadata": {"window": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. "}, "hash": "5a0beeeaf36ea979d26599cdb1fe9d4da3b7746f3bb122a17bfbf8104bfab33d", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "start_char_idx": 857, "end_char_idx": 972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93dbed1b-b51f-4521-aa86-b6a7ad2833f1": {"__data__": {"id_": "93dbed1b-b51f-4521-aa86-b6a7ad2833f1", "embedding": null, "metadata": {"window": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dadbc79-37f4-47b0-864d-78b294ccd489", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements relates to the settlement of\nlawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5eb36648f10671780368405746e26262c0f20b29ef0de5226697f59d3ff2bc3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acf3bb9b-b1d6-4217-b217-43a0552f3183", "node_type": "1", "metadata": {"window": "Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. "}, "hash": "64910ae48d0d214e656d711a3b2ce9139938900c55e25de0c06f38950ebeaac4", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "start_char_idx": 972, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acf3bb9b-b1d6-4217-b217-43a0552f3183": {"__data__": {"id_": "acf3bb9b-b1d6-4217-b217-43a0552f3183", "embedding": null, "metadata": {"window": "Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93dbed1b-b51f-4521-aa86-b6a7ad2833f1", "node_type": "1", "metadata": {"window": "The PharMEDium\nremediation costs related to costs incurred in connection with suspended production activities following U.S.  Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73b9864036e9a8db16e5f436bd99f31fc3a715d29bb88a58a0bd13ff733b192f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9d9249c-b721-4f5b-bfda-4ef77f5898a7", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. "}, "hash": "e2cadef18aeab9f7ae14dcc4bb737c6ccb8442c8bee83684c50598643874a74b", "class_name": "RelatedNodeInfo"}}, "text": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "start_char_idx": 1154, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9d9249c-b721-4f5b-bfda-4ef77f5898a7": {"__data__": {"id_": "c9d9249c-b721-4f5b-bfda-4ef77f5898a7", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acf3bb9b-b1d6-4217-b217-43a0552f3183", "node_type": "1", "metadata": {"window": "Food and Drug\nAdministration inspections.  PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea96af12194a76c66f45d236c3a3c6db63182772b6e8723572e68cadaf7f64c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22140291-af52-476e-84d8-3096fb2f7028", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n"}, "hash": "fedba576fd96ec9a0978520d93187a13b04e9cd8020fc00d1c52b268baf9bc54", "class_name": "RelatedNodeInfo"}}, "text": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "start_char_idx": 1410, "end_char_idx": 1486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22140291-af52-476e-84d8-3096fb2f7028": {"__data__": {"id_": "22140291-af52-476e-84d8-3096fb2f7028", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9d9249c-b721-4f5b-bfda-4ef77f5898a7", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with the permanent shutdown of\nthe PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c93377dfbd4b7406c0e8424e7f7a853f15b2a0b6cdd0abcbea12953c1e4a39e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c8163b5-212a-40d6-b06e-ec5b90cd26d1", "node_type": "1", "metadata": {"window": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. "}, "hash": "e5542d999279e6114307e6e35e41ae8ba5fb7cced8eacdde80e5b9c7b0c3c3dc", "class_name": "RelatedNodeInfo"}}, "text": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "start_char_idx": 1486, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c8163b5-212a-40d6-b06e-ec5b90cd26d1": {"__data__": {"id_": "7c8163b5-212a-40d6-b06e-ec5b90cd26d1", "embedding": null, "metadata": {"window": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22140291-af52-476e-84d8-3096fb2f7028", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product mix, and\nmanufacturer pricing practices, which may be impacted by market and other external influences.  The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f954878f7f1a876ca3ae3e1e91064e54f2ece6074a41fd0a6015f62016cdd2b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e20b16f-5c00-4280-8d5a-0ae797798217", "node_type": "1", "metadata": {"window": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n"}, "hash": "462c038743899316f2e09b78a80c25127a516013e2f890c3d5ea695b263287f0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "start_char_idx": 1661, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e20b16f-5c00-4280-8d5a-0ae797798217": {"__data__": {"id_": "6e20b16f-5c00-4280-8d5a-0ae797798217", "embedding": null, "metadata": {"window": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c8163b5-212a-40d6-b06e-ec5b90cd26d1", "node_type": "1", "metadata": {"window": "The NYS Opioid Act, which\nwent into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and\nimporters to ratably share the assessment based upon opioids sold or distributed to or within New York state.  In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdc3109c21bf28d848e048ef28b2d4daf738931fef16f1b2d8b5746a237c7513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b1f5a3e-2f19-4df0-be33-efc98829b2f8", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. "}, "hash": "cf70bc24b2e8a876cea1a3715bfa6f349d3185495c6aece182cf74fe6aaa51fe", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "start_char_idx": 2040, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b1f5a3e-2f19-4df0-be33-efc98829b2f8": {"__data__": {"id_": "9b1f5a3e-2f19-4df0-be33-efc98829b2f8", "embedding": null, "metadata": {"window": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e20b16f-5c00-4280-8d5a-0ae797798217", "node_type": "1", "metadata": {"window": "In December\n2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd8fbb0334e4cfeb69788b458497d50926c288628c4fc6fff8fe91ff9c7e76c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f18043a-7704-4e56-a608-69a002879271", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. "}, "hash": "b264cba164bbb42f5ba90da327fb5a4fb2f7ed9e1cc02c6c13966a3b5d8e5b2a", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "start_char_idx": 2136, "end_char_idx": 2297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f18043a-7704-4e56-a608-69a002879271": {"__data__": {"id_": "0f18043a-7704-4e56-a608-69a002879271", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b1f5a3e-2f19-4df0-be33-efc98829b2f8", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York but, in\nSeptember 2020, the United States Court of Appeals for the Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86d7f050c9135e869c80e9580db794c0411c0d733b3314c8f94ad8e7812022af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00acd40a-0ee3-4115-8049-25a73c6b6a04", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. "}, "hash": "ccbeb0a8b6c9fe3d262a9e497987e0f996cb2df262adb274218184aa50551fa1", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "start_char_idx": 2297, "end_char_idx": 2411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00acd40a-0ee3-4115-8049-25a73c6b6a04": {"__data__": {"id_": "00acd40a-0ee3-4115-8049-25a73c6b6a04", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f18043a-7704-4e56-a608-69a002879271", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5deff7c28983574280305cdc3171bfdba9e0ff1575b0c1d0d7f873f60b0d1b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a0812da-6a6b-4b4a-9122-c3f130b5f39e", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n"}, "hash": "ae7b5e7203bb53193a4dbf9ad7cc72f9b29b9cece5d8ddb84062e7386675f269", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "start_char_idx": 2411, "end_char_idx": 2877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a0812da-6a6b-4b4a-9122-c3f130b5f39e": {"__data__": {"id_": "2a0812da-6a6b-4b4a-9122-c3f130b5f39e", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00acd40a-0ee3-4115-8049-25a73c6b6a04", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a9c5df54bd541be39f28f8b660d1033008ce75baa615008c47301742a67186", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f31508-54bc-4626-b0bd-550fd9132c98", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "59ac994d86766a127b58fb26707bb894e559ac9eeb0091762dad8bbc41281c18", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "start_char_idx": 2877, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f31508-54bc-4626-b0bd-550fd9132c98": {"__data__": {"id_": "a1f31508-54bc-4626-b0bd-550fd9132c98", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a0812da-6a6b-4b4a-9122-c3f130b5f39e", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9dbb51e7bdf3b54575334c6effbd375d4e810a5e072c5c7b2d898f70e7f489e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "4542b5e711c5a67423c095c166e81e99ec1a329e910156d17ca06da467ccdd6a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3171, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3": {"__data__": {"id_": "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f31508-54bc-4626-b0bd-550fd9132c98", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e163f7c28b3b26246d245d5e0dc69a33337884e0cf29359c6f3eefe01c23ac88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8a770be-c35f-4013-b204-678c6ad02cc8", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "3f996b39c03042efb1a41a9370e89dd0b4341022475c2cb754457954dd6d73df", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3420, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8a770be-c35f-4013-b204-678c6ad02cc8": {"__data__": {"id_": "a8a770be-c35f-4013-b204-678c6ad02cc8", "embedding": null, "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual\nrelated to opioid lawsuits and investigations, as well as PharMEDium remediation costs, PharMEDium shutdown costs, a\ncontingent consideration adjustment and the impairment of PharMEDium assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a64f0d24d64f853c5cabaedabbd8d35157fddb9078bb8e1a2ab2c1a921780ae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3f4037c-5f63-4263-96ab-744e772537f0", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "bd92b91b5ba4abf47f69452862808c2b22be84a1c68fd4ee23f588eeb3766599", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3513, "end_char_idx": 3760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3f4037c-5f63-4263-96ab-744e772537f0": {"__data__": {"id_": "e3f4037c-5f63-4263-96ab-744e772537f0", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8a770be-c35f-4013-b204-678c6ad02cc8", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s\nnon-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be5a8f35b55f081d2c442e66155b40773961d14ea467cf18117233f5592011bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c00d39d0-29b5-47cd-9735-7b266287022e", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "a909ca192d2f598c54e338fb19ffeff8869fcc5d6cf59e4525db1d7fecde5492", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3760, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c00d39d0-29b5-47cd-9735-7b266287022e": {"__data__": {"id_": "c00d39d0-29b5-47cd-9735-7b266287022e", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3f4037c-5f63-4263-96ab-744e772537f0", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2ce938c5b14b62a0d8d38f00a7313a4ef1092402497b22d710fb3782da98aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff63881a-ea5b-46ed-9095-67492b194c18", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n"}, "hash": "0bd78605a283f314b90bfd38ba081378ee203990de2f221da50bf5a9ee65bcfb", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 3965, "end_char_idx": 4213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff63881a-ea5b-46ed-9095-67492b194c18": {"__data__": {"id_": "ff63881a-ea5b-46ed-9095-67492b194c18", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c00d39d0-29b5-47cd-9735-7b266287022e", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cd9d449ab444f6135bd6533fad43c2b5e321b5668c4881f472e7b5e254e70d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65001cc5-3d27-4793-a8cd-40e12c1699ec", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "59c752c4baa9b94a0dafb1006af0a76f314180f8a48e73a4d23862b44a40765c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "start_char_idx": 4213, "end_char_idx": 4378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65001cc5-3d27-4793-a8cd-40e12c1699ec": {"__data__": {"id_": "65001cc5-3d27-4793-a8cd-40e12c1699ec", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff63881a-ea5b-46ed-9095-67492b194c18", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39dc0b515663e244ac9b5f5fb15b368f09d3e8e6439b72e8186997a8977a1c8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dbb718a-761c-4aef-9a3c-ef5c8be45b93", "node_type": "1", "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "47b27eb14e4951c240d7fdfb7c8ac17fe2c2dce01d20bda33f9bf9f70b6904a4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 4378, "end_char_idx": 4575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dbb718a-761c-4aef-9a3c-ef5c8be45b93": {"__data__": {"id_": "8dbb718a-761c-4aef-9a3c-ef5c8be45b93", "embedding": null, "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65001cc5-3d27-4793-a8cd-40e12c1699ec", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a9838a27bbbdecf2e7802c6df72a36b800ef871bce40036c0e82dfaf5252cb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e828304-aa5c-44ab-912f-2444294dda92", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "3e0ce6d578a5128f991f96bb1cf329914d1e66569424f6e86b8d9ba173d29218", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 4575, "end_char_idx": 4847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e828304-aa5c-44ab-912f-2444294dda92": {"__data__": {"id_": "6e828304-aa5c-44ab-912f-2444294dda92", "embedding": null, "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dbb718a-761c-4aef-9a3c-ef5c8be45b93", "node_type": "1", "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d3147bed3dcef334e26c7fcbbd7819f0758c72ceff78cff8f6b2a843bdffe47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80bcff5f-fe39-458b-a609-c88d04f325ec", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. "}, "hash": "766fa65097472cca057e827375c05aaec89fb2a2d97fa8c5a788ab4c6f8ffdf4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4847, "end_char_idx": 5085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80bcff5f-fe39-458b-a609-c88d04f325ec": {"__data__": {"id_": "80bcff5f-fe39-458b-a609-c88d04f325ec", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e828304-aa5c-44ab-912f-2444294dda92", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cae9ba3ba08251840da6c2a13769da53abf21156ef1d7e4a0555a2bff53e51b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2e344a7-07c7-4b03-b945-dac2f7d52543", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. "}, "hash": "05796bb327361954bb5dfed3ba6a78beae57aba411a8a3014305b440f1392768", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "start_char_idx": 5085, "end_char_idx": 5430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2e344a7-07c7-4b03-b945-dac2f7d52543": {"__data__": {"id_": "b2e344a7-07c7-4b03-b945-dac2f7d52543", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80bcff5f-fe39-458b-a609-c88d04f325ec", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cea59998fc817b472ac5a4cfa1d22d048c03b772845158b80837e8f82518d36f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a73b18e-b686-44df-9d62-409ed8aaf04a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "In addition, the final U.S. "}, "hash": "d729ac53fc8019625ed30e0a53bb20e91980c8e6c61db918b26222f22aebb229", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "start_char_idx": 5430, "end_char_idx": 5603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a73b18e-b686-44df-9d62-409ed8aaf04a": {"__data__": {"id_": "6a73b18e-b686-44df-9d62-409ed8aaf04a", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "In addition, the final U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2e344a7-07c7-4b03-b945-dac2f7d52543", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2018e142f1c186bf8b534a4645bf397f36204313ddb74e64a569d970b0f63622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f462f269-b39c-4db8-8fa8-446b41e255af", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28"}, "hash": "eda71d13ab52846cfa3ed8c9ccebca0e4f2cfa5b2b53b43938e6a6cedcb996e6", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the final U.S. ", "start_char_idx": 5603, "end_char_idx": 5631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f462f269-b39c-4db8-8fa8-446b41e255af": {"__data__": {"id_": "f462f269-b39c-4db8-8fa8-446b41e255af", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b98c11b-968e-4c02-bb95-5adef919d78e", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62bfb437535aebb9055f6bbc2080d8b406e02f10417121b337ba8b4023a82a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a73b18e-b686-44df-9d62-409ed8aaf04a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "In addition, the final U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a99274d08751e5368139fd63f8a8cc3769e8f4a1eef48ff3c4100819ed90851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e47efa82-ba5e-4e7e-af00-e274008099eb", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "adjusted income tax expense for the fiscal year ended September 30, 2019. "}, "hash": "a4fef2201b5afc7cb070d1fb27879c91f560222a20003b885644b3e075418eb7", "class_name": "RelatedNodeInfo"}}, "text": "tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "start_char_idx": 5631, "end_char_idx": 5816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e47efa82-ba5e-4e7e-af00-e274008099eb": {"__data__": {"id_": "e47efa82-ba5e-4e7e-af00-e274008099eb", "embedding": null, "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "adjusted income tax expense for the fiscal year ended September 30, 2019. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f462f269-b39c-4db8-8fa8-446b41e255af", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months and fiscal year ended September 30, 2020.  Further, certain\nbenefits relating to tax reform in Switzerland are excluded from adjusted income tax expense for the three months and fiscal\nyear ended September 30, 2020.  In addition, the final U.S.  tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "original_text": "tax reform measurement period adjustment to the one-time\ntransition tax liability on historical foreign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from\n28", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ac80cec4a3b3613fec72caa47c5426eff9ef00f5030e560804958b70cdd242d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "a66d4791ad1b0c87477200d93a2848dccceaba7a83bf6494d26b2784f8695404", "class_name": "RelatedNodeInfo"}}, "text": "adjusted income tax expense for the fiscal year ended September 30, 2019. ", "start_char_idx": 0, "end_char_idx": 74, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f": {"__data__": {"id_": "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f", "embedding": null, "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e47efa82-ba5e-4e7e-af00-e274008099eb", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "adjusted income tax expense for the fiscal year ended September 30, 2019. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d47a4364683f579d881eb396b07a4ee7f5d5d2d6da6134df4759f784e155b32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb48123f-31e1-42e9-b855-ccbfceead542", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "9daffa15b9b6cdb5c7c6bff38cdd31a92d3cce4470a28b6562e8cec122ac507c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 74, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb48123f-31e1-42e9-b855-ccbfceead542": {"__data__": {"id_": "fb48123f-31e1-42e9-b855-ccbfceead542", "embedding": null, "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77513fb165e0bd1f83aa8e56bac81a18add622da78d9fb2af4d00bc97c52b3cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b0173c-3f8c-4585-95f2-25221d2e1d43", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "2e512e6758c976e30167815352e655e286561402ca18a9af8184180e2b14a7dc", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 318, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b0173c-3f8c-4585-95f2-25221d2e1d43": {"__data__": {"id_": "73b0173c-3f8c-4585-95f2-25221d2e1d43", "embedding": null, "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb48123f-31e1-42e9-b855-ccbfceead542", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61da9ae998163137fac2a51d943098513ee95075e3ae6dccca12b32045b82fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "073eac4d-74b8-4843-a262-c10c198e52a6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "849438980694bc0c4625eae90a3c88357fef2131accfe92bfe890728453cf35e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 586, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "073eac4d-74b8-4843-a262-c10c198e52a6": {"__data__": {"id_": "073eac4d-74b8-4843-a262-c10c198e52a6", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b0173c-3f8c-4585-95f2-25221d2e1d43", "node_type": "1", "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad3142d4e7b3ea7c9204bf3b97dc792a7ed29de868beff138cd8554b0c2fb9b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e083cb90-d228-4735-8b81-8dfd0aea2e79", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "59013662b3add1640ab21a57849109adad5ed9006a8503f1f345c963b378902b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 749, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e083cb90-d228-4735-8b81-8dfd0aea2e79": {"__data__": {"id_": "e083cb90-d228-4735-8b81-8dfd0aea2e79", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "073eac4d-74b8-4843-a262-c10c198e52a6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18e71ea30de34ec0ad5c0678d0e637cc66433db0e652888d4d33832c377a5d2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "764b26c0-f283-4ce6-95e2-e66063fe75d6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. "}, "hash": "97760a8563da9f6eb4839bb979b096431069df55a538ea7d91e79ad655767a50", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 918, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "764b26c0-f283-4ce6-95e2-e66063fe75d6": {"__data__": {"id_": "764b26c0-f283-4ce6-95e2-e66063fe75d6", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e083cb90-d228-4735-8b81-8dfd0aea2e79", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d5af899f668198bf964268b6ad350d073129eac0561f05b86923b3ba1996f61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0f67162-bca4-49a7-bb38-dab39b2f6a24", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. "}, "hash": "9a4c6c97dbb33f0007ab74482a262a172f38a0321c9e398af4593bd640d92679", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "start_char_idx": 1163, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0f67162-bca4-49a7-bb38-dab39b2f6a24": {"__data__": {"id_": "d0f67162-bca4-49a7-bb38-dab39b2f6a24", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "764b26c0-f283-4ce6-95e2-e66063fe75d6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "459e7ad65f567da8dc56caaaf3b3f4e6e00b09aab66a43a8b366ac501a405e77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8990f384-ad18-4cfc-9584-19a82a52acfa", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "original_text": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. "}, "hash": "f0c6e13ef349b01f76ab9b13a488c1c450099aead5ee226956ab48d2e08b9dac", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "start_char_idx": 1807, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8990f384-ad18-4cfc-9584-19a82a52acfa": {"__data__": {"id_": "8990f384-ad18-4cfc-9584-19a82a52acfa", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "original_text": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0f67162-bca4-49a7-bb38-dab39b2f6a24", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "109cbf16bffcdc07ae5ff93adbc84c371818af919f1e38215b84b6005311a9ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85088b18-07c1-43f5-9c95-08f7d2490994", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. "}, "hash": "55ee90150cf809b5053570b62d60bb528671cdb7e5228dc7ffd32632993105cc", "class_name": "RelatedNodeInfo"}}, "text": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "start_char_idx": 1954, "end_char_idx": 2356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85088b18-07c1-43f5-9c95-08f7d2490994": {"__data__": {"id_": "85088b18-07c1-43f5-9c95-08f7d2490994", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8990f384-ad18-4cfc-9584-19a82a52acfa", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "original_text": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8debc61e60e2e947dfa52d821dafa36f58b2c2f43034559c8aab8644b63d1733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "844e632f-60a1-405c-8677-d526ce2d105b", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n"}, "hash": "7f5396e644314db8dd208135ed0a7c74d351ad8c27137d3dca808269aa6eba9c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "start_char_idx": 2356, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "844e632f-60a1-405c-8677-d526ce2d105b": {"__data__": {"id_": "844e632f-60a1-405c-8677-d526ce2d105b", "embedding": null, "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85088b18-07c1-43f5-9c95-08f7d2490994", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the expense (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early\nretirement of debt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1d17e481ac9e0881e1fab8e50a9921dd3667aedcde510f9c6dde7dd2620f94d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b075ba1d-769e-457f-a081-fc288bdec389", "node_type": "1", "metadata": {"window": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n"}, "hash": "480e640c4e0ba34d9a443b819da79008b4c4a0bbdc5b7f91aefffb025b504eb5", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "start_char_idx": 2710, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b075ba1d-769e-457f-a081-fc288bdec389": {"__data__": {"id_": "b075ba1d-769e-457f-a081-fc288bdec389", "embedding": null, "metadata": {"window": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "844e632f-60a1-405c-8677-d526ce2d105b", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings\nper share for the fiscal year ended September 30, 2019.  The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd9bc0a792b855f898aeb088f111de072cad4e1caef08b2a079422c174171bcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45e6943d-9067-4564-b1e6-4ea78d6f6706", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "b33b790657ffb5e1c02f64a5cee80c600358efdc8d4eed33dac3bd965cba50bc", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "start_char_idx": 2987, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45e6943d-9067-4564-b1e6-4ea78d6f6706": {"__data__": {"id_": "45e6943d-9067-4564-b1e6-4ea78d6f6706", "embedding": null, "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b075ba1d-769e-457f-a081-fc288bdec389", "node_type": "1", "metadata": {"window": "The per share impact of certain discrete tax benefits primarily\nattributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as\nthe CARES Act and the per share impact of certain benefits relating to tax reform in Switzerland are also excluded from\nadjusted diluted earnings per share for the three months and fiscal year ended September 30, 2020.  Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a929f92accb2dad3a0c808f46de46869cae695e926b14289887fdbed01b3d93d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da11392b-7442-45ed-bf82-2aea21bf5061", "node_type": "1", "metadata": {"window": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. "}, "hash": "3c93c8bfce9cc41a5dc80a597f285a40031c0a2e38d36bd9f1c0663ecf3b1e0a", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 3150, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da11392b-7442-45ed-bf82-2aea21bf5061": {"__data__": {"id_": "da11392b-7442-45ed-bf82-2aea21bf5061", "embedding": null, "metadata": {"window": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45e6943d-9067-4564-b1e6-4ea78d6f6706", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are\noutside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to\ntheir inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "134ed1affef2d2c10ae79c00a7ea769fd7250dd81ecf912b331e134a16020e79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b3ef72-41d8-47d2-8188-19fcd9a5c135", "node_type": "1", "metadata": {"window": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. "}, "hash": "3869f89dc156294edfadb7e603962760931594c000d5943017fb65b861e9ab7d", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "start_char_idx": 3600, "end_char_idx": 3680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b3ef72-41d8-47d2-8188-19fcd9a5c135": {"__data__": {"id_": "68b3ef72-41d8-47d2-8188-19fcd9a5c135", "embedding": null, "metadata": {"window": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da11392b-7442-45ed-bf82-2aea21bf5061", "node_type": "1", "metadata": {"window": "Diluted weighted average common\nshares outstanding has been adjusted to include the impact of the stock options and restricted stock units that were anti-\ndilutive for the GAAP presentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.\n Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "447216caeaf5c1a730c091c5453e75ad5acffa1f08a02380642d5e860950819b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d1547bc-3317-4c97-8e0a-8a3f428c40c5", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. "}, "hash": "1db23d8735c8dde6e99503a4fcac62fb492d52edfcf2d8b873c37e09b905198b", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "start_char_idx": 3680, "end_char_idx": 3966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d1547bc-3317-4c97-8e0a-8a3f428c40c5": {"__data__": {"id_": "6d1547bc-3317-4c97-8e0a-8a3f428c40c5", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b3ef72-41d8-47d2-8188-19fcd9a5c135", "node_type": "1", "metadata": {"window": "Management believes that adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of\nadjusted diluted earnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71579d16f4debbe625485924b476af712fe080f88efb44b0473e04212dbba2ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "8c6ed15f4f8bb46a418482a6a472d582710f7ba42da4ef5c4d12afb005b80790", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "start_char_idx": 3966, "end_char_idx": 4202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8": {"__data__": {"id_": "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8", "embedding": null, "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d1547bc-3317-4c97-8e0a-8a3f428c40c5", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c75cf42be4fcab05c53dcf10865711da924d0ad10968f67cd208bb194574add", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e23def1-9f23-48da-82dd-dd070f618f8a", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n"}, "hash": "df1e33fc095e1d883d6eebf0224768ef13b268e08bcc9f0caccaf4f352f167d1", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 4202, "end_char_idx": 4518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e23def1-9f23-48da-82dd-dd070f618f8a": {"__data__": {"id_": "5e23def1-9f23-48da-82dd-dd070f618f8a", "embedding": null, "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1b0d650515d0692d45a6c97f11c7b06a671ea85ceb73883f663ab34f04d16df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "108f2b36-25e5-4d82-86c0-662726ecdf70", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29"}, "hash": "9a4ba34e5f6b98705073e56c99569748d8afc84076d920fc76fd5beb89527433", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "start_char_idx": 4518, "end_char_idx": 4613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "108f2b36-25e5-4d82-86c0-662726ecdf70": {"__data__": {"id_": "108f2b36-25e5-4d82-86c0-662726ecdf70", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "066464df-b033-4822-abd5-2642c8d71f08", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0e6eeb324e6b69e6491eef46224121e8d5b33f9a8b67f1fc8652e9aec53984", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e23def1-9f23-48da-82dd-dd070f618f8a", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  The Company does not provide forward looking guidance on a GAAP basis for such\nmetrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot\nbe reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and\ngeneric pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the\ntiming and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "Similarly, the timing and amount of litigation\nsettlements is unpredictable and non-recurring.\n", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef5650580c359301ecc947febab38f8462a9a18cfb16cf0b3126c4b1dd14e842", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20201105005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "start_char_idx": 4613, "end_char_idx": 4863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"bd9c8945-0f61-43a4-a05a-98f04983f080": {"doc_hash": "f6ff26a9a1671185fb400653e8752f9d5ab9aa242177ae9377ee9a8b45d8f2d1", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "7fe2206e-cade-4790-bea9-72a6d79b8cdc": {"doc_hash": "5a3e93f414ff178b2e108fcaef23d5a1a217752dd71d4e2c8571ba474dc4692a", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511": {"doc_hash": "b3bd51cc8ab3dc6a86004dd4625d74979e9bad49bc7ae0b53c6a030859d0d616", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "c863004e-c2df-4eb7-b406-d25e4e24c40d": {"doc_hash": "601517cbba7902f11a20664fcda9cd0fcdb750c23c21f3c9fa3301a139a7d07d", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "d1ee7199-20bd-428b-8d8f-e8f51dcd268d": {"doc_hash": "8e1768e8d59ba10575ba33ffcac21380b83386ca2b986add52d27dc12c4f9c32", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "6e619bf4-1178-4c12-a56a-39f3afff092d": {"doc_hash": "0b2dba2523a382a5726913020a367f2b223639a6951f81f8a8c923a103a29de9", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "c9d0e3e4-1ee5-4446-b42b-493a19fa1586": {"doc_hash": "761f573e8eded99e17231b60e26280a6743fd614216f6c300ac4df4058ebda22", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "dae1d640-4b0c-4614-8046-eff77ea08555": {"doc_hash": "3c7c884dd6c2c87fa7186ad671909d6322cc2232b74408585cdb768d6e433336", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "a40f42ca-8ad8-485f-9fad-7f97a40ecba7": {"doc_hash": "76dbd1d9878a6048aa5cb1b6f8e63797fb93ba193709e01506c54d5d1a3b19d5", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "0f740528-ed5c-4cd7-adf4-55f71c3f7545": {"doc_hash": "373683d858d28ce1bc3d947cb07af8ac33ff278f0bfd1676ace318333cec8e6c", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "db457551-07ce-4033-af2f-3dbaab0f83ee": {"doc_hash": "e84f4609a1cf920891d8c54cf9f831c6ba9dd96ddcb6d6d3f18aa1fddc957224", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "d7cea242-b704-4816-95b7-4ad2e1e960bd": {"doc_hash": "145c850b87b8d69547e0fc0e2a15d95a07f3ec2fbafad4d1f5a6ed9f5864638d", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "27911437-bb74-415a-84ca-b624092d5b20": {"doc_hash": "22c169fa571bc65ed2ace51ab0a45382cfff1b022dab6614f67d904e7e104125", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "74089d77-d17a-4c63-ab9a-cbbbaf69ffed": {"doc_hash": "480a93a46447a47ba0f1cb2861eee368f6bec9efa6524401b3566b9ee0c606ae", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de": {"doc_hash": "53edd5bbb4f76308cac86eb3b8d51d6eb361d1463b1fa8f51557e58527d7a01e", "ref_doc_id": "7a2e2f1a-e74e-4aca-857b-a60243a9b406"}, "24daad0f-2890-4b79-9bb7-785941a91e58": {"doc_hash": "af53727a7645c22ec494abb802ce8998523b9f95e8b5622db6003e8dd8f6d1b6", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "0aa870e0-e8ed-4c3a-b8da-51a7de61021d": {"doc_hash": "5b82aaee2ee20849ed05ec935bd6324b013959cb671f360f6fc33a7a9dbdf629", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce": {"doc_hash": "56538633050861189744a9c0f73bb5fe684c86b82ecbfecee3e68d91a6c37712", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "137ef58a-ac1a-4da7-81f8-af9d95634ee1": {"doc_hash": "8060c4947f9d603ba98c753eee13a83f9c65f9a296bcd3d3ff2d60a5e0503a45", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7": {"doc_hash": "3355ecb92139df4b310daaac68ec0e5301fd4fa4ece3a34b3f5b6d0c2406a082", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "22c7e601-577f-49cb-8ed8-c30ec89692fc": {"doc_hash": "1560b5aa0429b27762122abf3bc5bce2b7a3ea3b0b376ef76eb79ba6e9c9e371", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "853b7cb6-a361-474e-8570-325da0038bca": {"doc_hash": "8de759e8a7fc46a12a030c58e73d36dfdd91ae11004d69951744a1aba55870e2", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "703f156d-862c-4d3c-86e1-fe8cc9082600": {"doc_hash": "ac584563aa46c8731ca76e23eb9477173a00fbb41cae1b7ffd9e6903942260a0", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "19b8e792-cd8f-4953-9151-be3bba46648e": {"doc_hash": "97a9de6f884ddf1b7ec68f4990b91746e26b08e263dc483a666d331ca8820111", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "efa888d4-7245-4a31-86a6-6e150d54c524": {"doc_hash": "ce56cd200178d628e28678c920a48fc20258b7a6a7fc81291cf2da5314406627", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "1317e049-f628-47d4-975c-a8f2cccf1f18": {"doc_hash": "00723d5576a5ed47f0d5a714c03228fe0592bf61d3817b0d16d011e785afaa3a", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "811378d9-6c2f-4b92-8f6b-23abc41d1bc2": {"doc_hash": "c895c5b66de4d15a320e7536412dddf54b8a4163836c705d7fde08254d9bbd3f", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "77dda154-9f67-46c3-888f-84d4c097adb4": {"doc_hash": "4568ffff360f930ee9cb8e8eb7568e9be8d2059f7ed997d305fbd76426a8ca0b", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "c3193c05-42bb-4696-b21b-32c94195a431": {"doc_hash": "95a93f2b6eb299c418e0546bfc8478bb4731b5b4deb954d618ea4efa77b7d487", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "28228a07-16f7-47aa-99be-946156a6be6e": {"doc_hash": "64a92fc479cb6be27ccc850f717ac5feff9f2bf02fe5447e62d5ca1206a88582", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2": {"doc_hash": "a57c90a597f2022d02ab64bb11a78e216e204663b313c8780c3d2dd3b887fa4c", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "e0953262-5102-4766-a52a-88e5d3a74d93": {"doc_hash": "f6fe1bc2de94781d13b953fb863a6a95b0e4e7e7e90ab8f95961612c216c65c8", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "753e5b41-f83f-4a6f-a21c-7757eb54cbb6": {"doc_hash": "ce2dbbef2c6aa892aace5acdde74db4111ef935d8361b2cc490b1ce9d5fdab04", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "e08d95df-585d-4b6b-9538-a95f2bb28bc4": {"doc_hash": "bd0ab9e6ffae6313d392cf397db56d48bb9c18c0459df9acf0c3716981538820", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "6060e495-18c1-4b8a-8294-eef50ef76848": {"doc_hash": "bb2d2b1079bccac88a9f5dc3c99ba49ca05c2bc044cb2182e5f725bc36945311", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "5b966424-52e8-4901-80c6-249c7e6c4bb6": {"doc_hash": "095f97aaf56032938be3f097b7f6ac6bb96cba4738eda0cb713ce9885f2e0ece", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "0a90a22f-e1dd-4627-a240-cd0120f510b1": {"doc_hash": "495a24aae7bf9278ee790744fbe3b64af28ced20047c41163b8c12f3d3272d0c", "ref_doc_id": "6e2e2375-2056-44d1-9211-acb187caa717"}, "7b1fe49a-b2b9-454f-b50c-63a831ac8f61": {"doc_hash": "a25f7be28e08c66cb04ee0c13a716116ba1dcb14f845db58aed857fd70279546", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "04e3da42-b9d5-4e07-b739-23b3b628f366": {"doc_hash": "2caad1b8959442c0e9c9dedce036d62199f3a35c7da03979ec925377268f7257", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "99e179fe-68db-4e44-a38c-acb7bcb75617": {"doc_hash": "76f8cd049b052c06861e28d957b93a328095a6c1c9b773dede38c322397abdb5", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "eb10ce1e-8d0a-456e-a978-64bc1d579b06": {"doc_hash": "4a89cc437f2c908313502921b81d2b671b4695255a49de57b16bf5038a2b75d1", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1": {"doc_hash": "35f1d0db46db5ea25bbc15491d073354fdbd344361294307e83f52eddafffe2a", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "81d75f35-e706-4bb9-9430-6e9062754085": {"doc_hash": "518d65b8de40426fc4418988a47e7d1d71eb9261dceab5dfbd01d7e49bc061aa", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "998631c3-b098-42e5-91d5-768746b3a302": {"doc_hash": "0c031f8e6da06b0892e1a6b124dd630262a3b119d5f738ff4fdc1402e465441e", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "bbd00dd1-4e58-4a2d-b793-9b75af047e8c": {"doc_hash": "b439c0ce00c9f74be87d6db4e180c772beb4bdc3ea8c1dec911e0de2d89e84d6", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4": {"doc_hash": "37be534a09d7c492e4915b4a94a2a373a1f7cd330304d2a44143f7d5a8ad09b0", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb": {"doc_hash": "88d0585488dd0e3a497c447741695c2b64f9e2ad60e14ce04a5de20958eb603c", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "e75a5724-6375-4162-95c1-70dcc0c69310": {"doc_hash": "08f749a142e359bbb43bb1a3c540b33fd0a5848e03205e540d6a8364e9ab38bc", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "5d60c2ad-0116-478e-b81b-196add31126a": {"doc_hash": "8052ab208e226d3d3093b30d82b14d3643f329517cdf24c1f513966f0a04b8eb", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "b1937eb6-0d16-4339-99f5-2d6a21c20b36": {"doc_hash": "62b4175719f9304707f35faee406d8157c79042617398d2f52b6028c6ecccd52", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "2e29ef5e-5a02-4e05-b21d-fdd155b4b239": {"doc_hash": "f9587ef3691778d949669d601c2cabaaa53f2c1d23a30d62359847152405c2a4", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "49a57206-6a64-4021-97a1-4465ac16c9c2": {"doc_hash": "5c34af694783ad27aa7e5064e11c9574ac51e08fb8b5ce4d42bf3720bc3ea74c", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "f2ffb482-19c0-4a52-af31-5448e8784b92": {"doc_hash": "9694ebd35c6dacb02470a130380fe2e5a075cb8bc71a4f8de1b4ce04b399d700", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "233093d7-e34a-41c9-b82e-0afe621fdb7e": {"doc_hash": "2ed0015a109419c77ca68d3c448cfc4f23ad34e2ba3a20eb3c723d92c4b83e2b", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93": {"doc_hash": "49c21b2eb726277eadf3da98e2b2b61e3703307e3e1ee2b3550f35bf94ffc622", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "697037c2-9329-44c0-bf10-e08a208c408e": {"doc_hash": "c178d476ceea10b713fa091f7cc76762d6f31c271c1703a7ac04c6ad2f83167a", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195": {"doc_hash": "687c7f7c988aa56c1757beff955e3d265110e5a4f9c20de6860edc37f09918f6", "ref_doc_id": "99f35340-e798-462c-b301-84023a5e8668"}, "29e955cb-e530-481d-bbef-55d17d883fee": {"doc_hash": "270316b629b331223b27be89a5f27ebc762454e6aed8aff797aa2381dfb100ba", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "e06309f5-3821-4dda-bf3e-62ad4e02f0f9": {"doc_hash": "ae10328861bef94933167af01f66381766660931eb1d382e870f1f0c23d8c651", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "b1e7885d-ada5-48da-a274-c3b5cdad066e": {"doc_hash": "abc80a5cb4139c4669feb21f0d1259d21de790f2cba8923967dcb4dc1a36e77a", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "ea3bb1ee-ebf2-435e-86a3-7f314ba46755": {"doc_hash": "18c213b3c2e903e776b0a747d66d26db93370a46d102d501e326294523bdd146", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "62e5e62e-0326-4aac-b93b-51983f257c7b": {"doc_hash": "cc88d25b2f3735381a611a607d5caf59819a5f4a2d8a9d9fa7e7eaa59576fada", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368": {"doc_hash": "8a147038e28583a27b39b77546a9b7d56853653562bcf3236d975f029eed1a83", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "00a31cca-1242-4d5e-bcf6-9dcba5899389": {"doc_hash": "aac9e1ba5d6d6316e6c568293064dcb48ec116143c29884c17295430726d507e", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1": {"doc_hash": "89bb3d96785f82bda8b5d9d4b5f538687d4dafbc95220c2b292d1fc5f356610d", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "8460cdfe-2644-4618-a626-71c31f6f72b4": {"doc_hash": "ba99e8cfd36344489c0d3d587054ca0f45e30168e496338657b2439f476252f5", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "03930657-2bab-400f-8f04-2239491ddf1c": {"doc_hash": "954ecf6d6880fc4f83db9ce116355a7659591aff4b92efb8fd53c71e42d5394a", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "2d05beb9-cd19-42a8-be58-379f86d222fe": {"doc_hash": "1f0aaa675202b3ced54ed82a6414d656e1685f3c305846f0d7ea51b5d99772fc", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "68e2f6e8-32b2-466c-aa25-c2f5824234e6": {"doc_hash": "5eb807010f5f3d3ab2265bb2131277ca291b4b33c5c0272c8f6a78e6ca225db5", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "f703977b-1992-460f-bcdf-52877cce03e0": {"doc_hash": "9fbd6d2c2e83990e8bf614e52e417183ea5c5cd8261644d661880edf0ffce441", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "b595c98b-2a4b-47f3-9a39-dd224ed59c4a": {"doc_hash": "e25cb52b3faf57fde1d6e72d5aafe08fb7d10414fcf44eea715b36111e739e9c", "ref_doc_id": "29ab8946-edfd-4590-9f3c-e369f1c3048b"}, "79033148-2632-4cd2-9863-a4402bc06bae": {"doc_hash": "d282e887e38b0a5754ce7645a5ccb7dcde83371057a9148147b91424c26431cf", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "f6409f3c-ff47-462a-a7ec-66cf92f2fd95": {"doc_hash": "fc10e8e5d966da7acdaef7005262224e256704e059e63dd7dda53dca2384ff0f", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "6674f685-60a1-40f6-9f9d-b7b99a8cace2": {"doc_hash": "2eaaa82d6b8eb8fcaf465e423177b0d78095de919d25ed15d00404255680eeba", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "6acb175c-fb63-45e2-8608-e3f0de0d211d": {"doc_hash": "9cad1cc10f96661219c7743d7c07ebcd2e9c838bc1569606d9ed2c702cf4dc73", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "a3de57fb-6252-4b24-9ecc-5593485b4bf3": {"doc_hash": "91b4d2f3d9f8d5870762698cf4488ee411e51e3ffa12ca9355ef750c046d66f1", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "6428ae8a-19f4-467f-a065-c5f63f2f572b": {"doc_hash": "2bda45d7f20649b34247a894453ed396985778d59b05daea3a548d506ed59c46", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "b49d5fba-1923-40c3-9e17-9ec4fa31e63b": {"doc_hash": "50fa7272045fb490608d21f51b3eb8bab319ee6509b0fafb81c446eac56d9e8f", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "500faac5-cf18-41c0-9231-516d8856c4a4": {"doc_hash": "bb4c6047f21a4c39e4010d076a41455d86ea9c9c0c80cdbd0789850375c149c5", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "866e6947-6464-4a49-a482-f1c957f57805": {"doc_hash": "a423297da32194d1150e182a7f610679a2b287d37534add1c856c84d606bc384", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "31a8441d-4b4b-42fe-80de-7b6f096851f2": {"doc_hash": "1136d75c23e020a373b02ab9a0fe4ef60370ddc8e2ce4c6e92d24b043c499a02", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09": {"doc_hash": "55d11ea64090ea35e88988bb0242c48a6b53f02e66952d8c68ee446e09e4c801", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "87ddd624-a21e-4c76-8276-eadc950e1f7d": {"doc_hash": "bca4eba75e6d2ce337a08c3c42b04acadc268f15698639c0228e85c5e5ce6ca8", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "ee2ad3f9-75ce-4c66-8b12-b4227face72f": {"doc_hash": "e874fbb77a40c101c515040bb7e11c3528f38d49ed368176b120c0b7c8992ec0", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "cecc850b-e060-488d-b771-80dbce91a03d": {"doc_hash": "41b8e680bc62983c9c5931861220f4dfd232e7a28fe63375731daf96ae8f1593", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "4be0d65a-6f85-4270-a079-3512e2c95ccf": {"doc_hash": "677b62521cb3821d1e2259aafa6b7857845cb87863aef75decd344eb01e8570b", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "83626644-f406-4e61-99dd-b68510e8f5fc": {"doc_hash": "d7573612fdbea70b71bf4c68e83e0475a9ca0a26fe6cb5b037bf234b882ca9d2", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "1f25c9f8-14b6-43f9-8626-15527dd2e5c8": {"doc_hash": "cf1e60702bd23c2962e841d970c95473eab972774f32cc220bf6b79766e9a381", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "765a1777-bcd2-469f-ae04-a6805f4df07e": {"doc_hash": "f5a1275c72713360fab73bc0c89aaf28309b6c18ee887c33e4d8afd33a3b2838", "ref_doc_id": "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115"}, "dde9fd5f-f402-46b6-a9fa-424facae070f": {"doc_hash": "80d3652cad590dfde9d8e3e41d547f6ed81c016883e84977b0716ccd7a9265b4", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "07585bae-966a-470e-bd35-e22a0030963b": {"doc_hash": "b78730783a23755e0e46210c6281e69934cd8890fefd4d8d5ef0284d670f4d97", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "81e94f23-93ee-42db-96a0-04e6516c4447": {"doc_hash": "7d6c67aa97355ae7f90679b123a80f7f64780c6e838f5fca94ea67ae92106941", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "a9cd29b5-2317-4b85-9ab5-34dea7819d47": {"doc_hash": "ed532b412ab5f7d39b0e6bc985ed0ebb06a254725ec57279e068f10395d1c45f", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "60f65129-7de7-4671-87c8-f434bfc260f6": {"doc_hash": "482e8ab9ff2ea2e9a783add99fc443b10e138fff0af09e29a58d80ef153b9038", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "f8e9fdef-2257-4b0b-bae8-0730b5700343": {"doc_hash": "258a656bc56ceba5fbcd455c7a93df9f2fdd016d49155b63c25242e3aa3c7c80", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "d4036928-dbf0-4ebe-b527-6a92e7fe5991": {"doc_hash": "66a9ba66522d446dfe19e2b491b27ead3e67ffc0e9c0f8b11d19b360060adb0e", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "84729ce8-2556-4a14-a8fc-cbd0c034ab0a": {"doc_hash": "942ba4169ac4fc328ebcaa4b1e92dc4aa207df68021c8611bd5d0e1099af1cda", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4": {"doc_hash": "7f2401437b3a2066659ce8450823f3d3338b249f077adca26e43f22151215298", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30": {"doc_hash": "ce9e631471851f6eda2f8768c5895e47bf87796e8815985d463b9d0b04536f84", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "bc43260a-110e-4d63-b6ad-187cae692264": {"doc_hash": "bb50c5d11598b7332f7931f906a548f9cba931b72daccd4db692227ef4985660", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "f2d2cc54-21a1-4da2-a446-4d3c904f3292": {"doc_hash": "3edcbe89c78998ec1b1a525b0ef8694357123473c7e6a8aa85cbdcf18467454d", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "ff3864ea-ad97-45ec-81cb-8c98d659e985": {"doc_hash": "c5c0081ba631fc3029a2f729af852cdf0427ad875ad80776bd85a897f2f984d2", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "9f374e57-cf72-405e-a78a-2a72ab0617da": {"doc_hash": "96c3f16741f376ee19be37bd4312318bdec8e4358e448037c52baf9b0a420a2b", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "6078699d-35c6-46c8-afa9-1a4b71e86aa9": {"doc_hash": "670428972d4ac31eaf12a4eb2340ac66994a95842db8553cc1ca3ea725e7d880", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "28bf0b91-05e3-48fb-8ee9-72ff5042b156": {"doc_hash": "dea153f01bb3c0673421a543dc2d4797b0aa116bf23ce89abf5c1ad576650347", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "9c4f8d91-83a4-4ad1-8aee-98280e608a63": {"doc_hash": "02c509f946d7edd2435620a136ae023105bef2cd1aefb9da9d1d84de89e699ee", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "f25f6784-733e-42c5-9155-010533818f64": {"doc_hash": "763303493a39dce6fa60201aec19d30c647da7f3ad459734ad5dad2914820a50", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "bee2999e-f602-4bd0-b336-c3b158f01198": {"doc_hash": "deac45fa5c070f4c535556c5f39142e13bbf4e7f4ff21ec2dec68d50db46ddc3", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "48205464-ecaa-4855-bd83-fc93bc2f3fd1": {"doc_hash": "3faa95387f5679af9db8ec72f158a7d2debbf2ae74c4874febad8b6b24036d41", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "f7aecefb-1258-4e55-9eb1-cea2b184246f": {"doc_hash": "ba3c2414fdb129b53b319dcff7e127583d9cbf19b9f9d9430f78ded7ce2a2fae", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "44a32c10-3c5a-48a6-b529-ede5dfe9d401": {"doc_hash": "e66f7c4ff794f78775f8ae2629f1c1ad768feb408c766e37ad2f938850b8de39", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "e956ebc2-ce30-4736-b167-993c78d3d6ea": {"doc_hash": "f532dcd9f21230b5b7bafd8c3e17706dc392311bb19547cd1c889072b96a7e8b", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9": {"doc_hash": "e9dc1d095439a1523ae9bfba524363daaa7fa6f3b7d684a21663293e14bea4aa", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "82b2e5c6-29bc-40d4-8c01-74821aba62ce": {"doc_hash": "57d2b42ce15f2a6a9cbed634715715ffcae997fe0e7bbdbc11f9253012384bd7", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "6146dc7f-1150-4c10-92da-17d421bb698c": {"doc_hash": "21211131b60e71ddc0c0be6ab44effbacb841ad31c20249c6dae543d11f02d6a", "ref_doc_id": "991b5740-edca-4251-803c-f1bd2f8fbe44"}, "e06cdf83-31db-4e84-9ed9-9cead65c9a82": {"doc_hash": "a15120eec6e23974efe19a2247759c44a70fb0f34bcd0202cd9bd7cb5c32f674", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "ce95df4d-f082-42ba-b9a2-6a67e51b7343": {"doc_hash": "4dbfd5bad3ab41c03f790a4a3379eb326aa65506db52cbe516d489e1f2203a69", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "ca5de92a-a310-4b8a-8c78-ee81c10362ae": {"doc_hash": "30b0c413648934a7394ba8e111f0207f3532278ac749ad574852f16af73f5729", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "a6752793-e8e7-42ec-975d-e10c701bdad7": {"doc_hash": "71bb648e52b2e11f09b9b7950c368a76796f6c49e548bdb122efa54ea74230e8", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "ea19e11a-5561-4789-8adb-ab3d226c3b1a": {"doc_hash": "9a7caa0c1eb9f05c0fd32f25086d3c25563f2287b4bafdfec09515413a3f9ac4", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "1b018d3c-554c-4a9b-ada4-7638c41ecf48": {"doc_hash": "5ab3136f8b90d74d509a8d263d5f8f811a54b21b474f45431bb80f39a644e0bc", "ref_doc_id": "79a4aa0b-df42-4135-848a-9dd211bde65c"}, "d7d8433e-2694-4a57-9fc4-d9b9908e8780": {"doc_hash": "4df646c7be7c7d670fc8cf243342d280ea0a08847fd85316e87c3943bfa67f21", "ref_doc_id": "3e77b5f4-6b57-426c-af63-3312e27915f5"}, "d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49": {"doc_hash": "34d6bfc2403daf5526bb10cc9bda839f8367a4034093d9b33fb4fc36af7faddb", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "1239d4d9-95e0-4f90-bb4f-866fca49fa81": {"doc_hash": "a2cd43cd1b071fbe08e2ec8e6f15ed519bac15a4fdabcd574033a3a213fbf509", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "bdcd009d-4abc-42e5-88d3-b514fe89b91d": {"doc_hash": "acac24f42b6e330dd8ac915ac35a6915589aba92406bf8eb54bf92c5712a35e9", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "b2d590ae-7639-416f-b2df-d6ddc00a7e12": {"doc_hash": "0e21c8ec39a4ac5100e448d5d002b8a5eb214499e462b449d01fa7fe248ae4f1", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "adf39649-b52f-44d3-b623-d5d75944c70c": {"doc_hash": "2aeb2b99a5c1f0bb77949930ae29dda012fb249eee9abd82d8b0f6278aaf4753", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "e4a3b046-2445-4a61-8ce6-1c432806072b": {"doc_hash": "43e9d42b13ef8c41ce359ea474f131d6f7abcfe7a6eb8d2cd1f36ddb0d1f11c1", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e": {"doc_hash": "c3dcb37c231caad3e26a59953fb89e3ab04d0a36b7df744043da654d923f63f8", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9": {"doc_hash": "1c5aa59385aafd85a54dac150e5e4e2a8983cc33a57ad0fbbe2066b0f66555c6", "ref_doc_id": "551079b5-a5a6-4d61-bd6e-479afab2ec50"}, "18a6f189-e253-4cf7-be1c-216e3f675a49": {"doc_hash": "deca29841d641e84a22d5ff82a56b71e3efa4b280158afc2471a2265b8f559a3", "ref_doc_id": "67637666-07f6-46ca-95ff-6e0322dfdf1f"}, "c31585bb-0952-4944-afe8-79e7825b740c": {"doc_hash": "28c2b9119186796cf90a1be56e0c8e040fd4bb8b83bd2c684c56c7f83c106917", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "c28c0c6b-18ca-4530-a187-63a3ed8f09d0": {"doc_hash": "5b4c265f8a006afb04d566d0240ad42e7f47fc3a80d81f57c842541a32b801c0", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "77db1781-36f1-4da5-835f-642ef764dff0": {"doc_hash": "b0f8c6db752c45612ca4900e246524fdcb3f3f70d2de52ef450fb778ab3f8818", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0": {"doc_hash": "cf40cadac81d24a08f9bd30df9c5e73020ed6c21edd45aea7f253629d54b3f2e", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "df81b0ff-8496-4d0a-89eb-c99a33fdfea3": {"doc_hash": "834d69c3261890d8b7a733a8620bf924cb8022a85e5a4917affe60a7a24b895e", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "626f011a-0058-44cf-9b87-5b26be8490ca": {"doc_hash": "0fa8aa6a58a27f938d76f5984b28cd2a9062d17177dca17321990f0447ac7549", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "953a2da6-014f-45cf-97a6-2f19b54731da": {"doc_hash": "a7c39810053d207958f717ace4fb99ca352182d425b5efcbb517b922609790c1", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5": {"doc_hash": "8dae7a71d30fc583e364e6380fb412834ac51043d4458277920168ce14bbe42b", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "3d59d0c7-96c3-4074-97f7-c453383a3420": {"doc_hash": "5960feeddebde5372c0531c9fe2f25500c3294b39348f89193095758580a7850", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "b02135bc-b68e-4eba-97f1-b1c218ff1914": {"doc_hash": "e679936466cf975d5af58d4015a318bd6654436f41c9b94d65a91608d037b6ed", "ref_doc_id": "d3dc6679-af14-4823-bb3a-9e97e000459a"}, "5114b368-cc2e-4189-9a49-72b3a73431f6": {"doc_hash": "0bec4eecf7db665e84b55a2e587637b3c0ee5ade80b0ba40709bd789415f71e2", "ref_doc_id": "8687204e-d0a7-4da4-9432-1f376b32802d"}, "e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1": {"doc_hash": "976f66d536526cde61ee2dd682b38baf1a66da5d4125fad794f4db25607cae5f", "ref_doc_id": "e870ba2f-9b27-47a8-894e-26192a7e6020"}, "584d9df2-6136-47df-ab81-481061fe64e6": {"doc_hash": "a9f2c686232b925abd1ad1546d60508214e51dee0fd2d0d41dc5526341767ce6", "ref_doc_id": "e870ba2f-9b27-47a8-894e-26192a7e6020"}, "1037c6f5-913a-4149-87e3-81628ac1288a": {"doc_hash": "9fc992efc500e76b28b1271a43c4996f2515fb6f00ffe0a264d160b0617108e8", "ref_doc_id": "e870ba2f-9b27-47a8-894e-26192a7e6020"}, "64d4fbaa-3b73-4868-bc38-fd58c44822bd": {"doc_hash": "4785297fca091df1477c34954715ec523e3526742dadababdcd51547310d3ad6", "ref_doc_id": "e870ba2f-9b27-47a8-894e-26192a7e6020"}, "938ee48a-47f2-4c4e-84e7-0db3571470fb": {"doc_hash": "96df47657f022b0394db7a13331a79817560f4bdce0c0c73848a53e3f2a5742b", "ref_doc_id": "e870ba2f-9b27-47a8-894e-26192a7e6020"}, "a9bc7192-8d8f-4256-a1f4-9ac2e396b394": {"doc_hash": "55b69803bf3f2db508b6a78a595bc5a2191b2ce11d7b185c75a6b6a8c173c5d3", "ref_doc_id": "09e81d7a-2548-4447-9283-300df9fa2a91"}, "593093f1-7746-4452-b0f6-b027dd72e045": {"doc_hash": "381c08538f7a29693c2e06aaea62070931409779afa1d1c0f33e663e190fe778", "ref_doc_id": "09e81d7a-2548-4447-9283-300df9fa2a91"}, "a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7": {"doc_hash": "bae420d5a826802a0ffaf7766f898a960135b27f70b37a81c187691b832119f3", "ref_doc_id": "520772ff-bae5-432b-bead-06f23fabe510"}, "69906f47-04e7-410b-a4eb-9ab883932e32": {"doc_hash": "9677db30597d4a49460e19094e41250d3785ebbd79054332c92d4a78b85e92d2", "ref_doc_id": "520772ff-bae5-432b-bead-06f23fabe510"}, "195f806c-1005-48d0-9817-5c5dc51c8b40": {"doc_hash": "6281902f7982657029d824f7da20cf388dbdff70f4109d58fc096ff77719fa92", "ref_doc_id": "bff91b8c-9e20-4fae-9c1c-7b15b45748fa"}, "008b954c-ebdd-44b7-86b2-42648c81b6cd": {"doc_hash": "797f7014de6b6deb28d84d42a4bbf87a35feba19f7022d5a3df3044878b37393", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "1d154778-ddf4-4be8-a6ac-472d32ec92eb": {"doc_hash": "d0815e608cdc5a8ad4d5bfaeae64a1af36a313babcc34d83f3461cdc7e4aba22", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "00838776-fb73-4c0a-8ec0-257d95e87699": {"doc_hash": "d344fdc44facf642fceab2584086925c5a684cc8353db2374f26b4140cd25c83", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "4b7ac312-11b2-4f0b-8c2d-c944f7884b76": {"doc_hash": "67ea4e6d39de81ec96e7d540c001c1f313e2d2549819a61eb218a2bda4a43408", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "16eba2a1-0d4f-4284-ae85-be5d91c485db": {"doc_hash": "41616f1b24a2e0fc138b4c95945a954e82f42a4579db172ec7061f0874ef029c", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "686b71b0-c938-47bb-add6-b4efca6ae1cd": {"doc_hash": "8d51df37019e32f335893fc3d47d0bbab0e95673e23dc4380356c8196780b626", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "7e933621-0bc5-4d60-ab78-9d8803e4473b": {"doc_hash": "0f9da51945b4a02d8384360bc04126f5c771a5297ba208db4bfbccdf27f224ce", "ref_doc_id": "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050"}, "e6c393c3-c8f3-48c0-98e1-deed4f005d81": {"doc_hash": "ce2c1c10e8445bbaf13fa084ccaaeb0b027ae7c896f45a910f792f316cf231ec", "ref_doc_id": "999b7c0b-7db0-4420-af0a-464508fe1c2f"}, "587cea1a-8fd6-43bb-9684-79e46bead2b2": {"doc_hash": "9dd5758aae1ccd5db5da719a557311a31ae6e3b9d9fcd16b5e1f19511b818597", "ref_doc_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8"}, "b4e17012-e68d-4ada-a614-f725bf534812": {"doc_hash": "fd96fcc9651af3b930706b4ebf21434ebb063a9383f638f5ca2da207da721ea6", "ref_doc_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8"}, "db92de59-0145-479e-8f9d-ce49d37fba70": {"doc_hash": "31226054468bac8d253ace36d5ee1fc160ecd6dd04466dc8c569eb976fe5d4dc", "ref_doc_id": "c8749d25-13fa-44a8-9a83-e9471d8112d8"}, "0f113148-d3d7-4043-a9eb-0a6c7e543a09": {"doc_hash": "aa87746e46993e60a0345d2355ddec907d185231326c43a282b4e10761a6b506", "ref_doc_id": "2340d502-3472-4d1d-822e-89910f10693e"}, "24def10d-99c8-4d09-94e4-dbd2846b7bd3": {"doc_hash": "f64519c7c117e36f70c1fe85e98d902fe99f95b65ea0a9f3db0d7170deeb0651", "ref_doc_id": "2340d502-3472-4d1d-822e-89910f10693e"}, "cff161fb-93fd-484e-9282-ba9d179d248f": {"doc_hash": "15c323043b53be4b036a8ab7d3160e5e9482e0aff0f86abf5bcb3e610749823b", "ref_doc_id": "2340d502-3472-4d1d-822e-89910f10693e"}, "9f3f1de8-4617-49ca-ac00-72ceec4b48e5": {"doc_hash": "b26b5e483e8e28c1c36b3e31c131ca617afcd1da7ec745b39da2351a6ecf84b7", "ref_doc_id": "7a250ca7-4948-488e-bec3-03bd2a36811b"}, "9643655f-e3c1-4718-984b-b503530db308": {"doc_hash": "6370110949e624809e7ff20a6df5d6543a1e159a239bb0e5ec441dfa929064f9", "ref_doc_id": "84e1ca6a-98f0-412b-8f2a-39fca4af8589"}, "3f0b2377-ee22-49b9-af27-672093bea19b": {"doc_hash": "212a6bf05b5f3beeb49c68cd9494e99f3ab94cb69a5116b38d97e98901e9dfc1", "ref_doc_id": "84e1ca6a-98f0-412b-8f2a-39fca4af8589"}, "926420dd-a9d9-40b1-9fd8-b6aaf69b95c6": {"doc_hash": "de13a15dba54bed7588cd18a5b26fc924fde8f1c2c99d8792f08d49e7be339e3", "ref_doc_id": "f64e3259-5ffb-4d34-a2e2-dde3e6a1b004"}, "301f8a3c-628a-4688-b6c2-1ceb93c8167e": {"doc_hash": "ea13cdd03c5f0cd398ba3922c2378d7ba4e3fe73e1f4ef3938ca3001a428799e", "ref_doc_id": "30ca6010-c542-48bf-8f83-c0eda9fdcbfb"}, "11913a23-6cb2-4a23-a183-06e156c7e701": {"doc_hash": "104968a5a5cfdca7dac16e55bfbb9665f0155c048d463824f5b9492d067b64ca", "ref_doc_id": "30ca6010-c542-48bf-8f83-c0eda9fdcbfb"}, "a297227f-cd3c-49ea-b529-2cbc2b0c47c7": {"doc_hash": "4eae15b5b0d1dd8e479d8196d9bfb9157d3c3cafd5e7c3bf7571a58e884eb1de", "ref_doc_id": "b748d157-5abd-407a-b589-973fbe7166ae"}, "4d89b570-dd30-467f-84e2-fba82f89df20": {"doc_hash": "1233c56333b970b3b389d74f9bcf4faa61ecdf2b7a2679693ea6f027708e54f4", "ref_doc_id": "5fdc3d6a-0d61-4995-928e-f92d09e35c62"}, "a321c71a-110e-4153-8368-ed02bede86f3": {"doc_hash": "142ed8b99cf148fb0268b7ce6d4d3af6a436342462f429600c98651419073159", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1": {"doc_hash": "2b140dfe8e5471b49a935dcbb87f904245f246035cfa3d5a2a9a5e14a517ffe5", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "e468c82c-e572-4f68-82f3-07e84b6becaf": {"doc_hash": "694235aada42ac8d741b301980ef6bd5c8b86a1c9d99693c2bf43d3ad0e4a915", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "93300160-99c0-426a-90a8-573959e73321": {"doc_hash": "5ecbaad3b23cffdfa15a7e28f62836e9801bd6406ddfa9538822d5ea0f37f120", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "d76e686b-e258-46bf-96f3-0a5574b9b346": {"doc_hash": "6c8deccc09b7b757bfbc80cf851113908aa5c8cdc797c6c1c948f0f362719421", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "5c000b21-2d65-46d7-acf8-61db328126a5": {"doc_hash": "1cb44d87a2446f539ed76a78ef91205481289eaa03f490ffeb3068138f5dc8c9", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "20434f49-6ddf-4fe6-abcb-29d6b462a246": {"doc_hash": "652c834ec4415478847042193a4eb0cf4e741077d40f6b44434c73fee7dc63ea", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "b254378d-d2f7-4558-85d5-5c206251c37e": {"doc_hash": "e29ea42a095fc980fd6a8fe50d3996b885822b2d8e8d39bc8ed9b55a8ff5b6d7", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "78ee9d17-6f3c-4c9c-a2dd-9e0150981868": {"doc_hash": "04fb6bfb3a7ce695da58cac5eee0a21b982c3e28feb90cbee87c2b35b6f1c0e6", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2": {"doc_hash": "c431991e90e5cc49981c2fe03c60b2a226885f9b42e536de15bffac098718489", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "8ada95e0-36fa-4ce0-a677-1210812735e9": {"doc_hash": "6d2889db064b501d1b3b9508511d06c8bef994789a061be5825e21fb644c805e", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "dcdcc45e-b067-4da0-b193-87d7f599d0f5": {"doc_hash": "2e0ca5990788f8ba5ea2a7f168da0a09739b2b99b918691306415372d440a54c", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "6f28c544-62ed-48ae-98e0-2cfac7da54b1": {"doc_hash": "c1d75773c57a33c77ec0d965091db9938f15392591f59f16259da0cea48c50d5", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "e46d3d7b-1d6d-4529-9426-a1199d27c744": {"doc_hash": "7d91ada3dbba579d4db97fa7e755e80dc6af9cedd24acb16b1d7d42fc5139cfd", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "57b598a4-0081-4d83-9545-77fd1524e8e9": {"doc_hash": "9f37e0381b67470e87693ca02e1f1d84d75c21d4d4937d72ff90f3c962667b0e", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "5e033b38-b8d1-46be-8779-54884ed0a48c": {"doc_hash": "d9db4b8b14b7ccf5816d2d46cf53795afc445d24747b3e2488e3a81e5c24a495", "ref_doc_id": "8d6d58f6-5aa1-420b-88a9-9b14ee27334a"}, "6fe20c2e-e71e-4346-a0ba-684e413c968f": {"doc_hash": "4e152ef59496488752016f208b26c2395a2e7cdea679384e861eb59d742d0dee", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "f0638315-3faa-420d-b140-e565e7426baa": {"doc_hash": "2465cd32d0ee6fc53e34991af0a042193f0afbc24c568f002a228489e392022b", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "3f4704b1-2a76-4011-af34-a6420c90659c": {"doc_hash": "ba746befdb6ece579a5932118ba82aeb8e5cdfab2d4b893d7fe1da276067774d", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "5b5bd722-8c50-4e75-871f-9b565b662249": {"doc_hash": "345114b311e5c0f72b419462ee9f32035ea6768146e2a639cb9caa50149a8271", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "cab9bf4c-e745-4769-9300-b8ae41b53c66": {"doc_hash": "be471685790986561df531195afbc71d0ee62ba928c1bed9bb6176c55c2a94e0", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "35c95969-f58a-458e-91d2-14e9ee16892b": {"doc_hash": "a25c8c63788251bb4f0d47941475e3387dd8b2170371c1de549decfc5d9f7427", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "51f0a62d-434a-4fbd-a1e7-4e6ef5826763": {"doc_hash": "73e815aec514066def6d493850487fae8579a91375cb8021cadac8894c61ff8b", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "5dadbc79-37f4-47b0-864d-78b294ccd489": {"doc_hash": "5eb36648f10671780368405746e26262c0f20b29ef0de5226697f59d3ff2bc3e", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "93dbed1b-b51f-4521-aa86-b6a7ad2833f1": {"doc_hash": "73b9864036e9a8db16e5f436bd99f31fc3a715d29bb88a58a0bd13ff733b192f", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "acf3bb9b-b1d6-4217-b217-43a0552f3183": {"doc_hash": "ea96af12194a76c66f45d236c3a3c6db63182772b6e8723572e68cadaf7f64c3", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "c9d9249c-b721-4f5b-bfda-4ef77f5898a7": {"doc_hash": "9c93377dfbd4b7406c0e8424e7f7a853f15b2a0b6cdd0abcbea12953c1e4a39e", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "22140291-af52-476e-84d8-3096fb2f7028": {"doc_hash": "f954878f7f1a876ca3ae3e1e91064e54f2ece6074a41fd0a6015f62016cdd2b1", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "7c8163b5-212a-40d6-b06e-ec5b90cd26d1": {"doc_hash": "cdc3109c21bf28d848e048ef28b2d4daf738931fef16f1b2d8b5746a237c7513", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "6e20b16f-5c00-4280-8d5a-0ae797798217": {"doc_hash": "bd8fbb0334e4cfeb69788b458497d50926c288628c4fc6fff8fe91ff9c7e76c4", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "9b1f5a3e-2f19-4df0-be33-efc98829b2f8": {"doc_hash": "86d7f050c9135e869c80e9580db794c0411c0d733b3314c8f94ad8e7812022af", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "0f18043a-7704-4e56-a608-69a002879271": {"doc_hash": "5deff7c28983574280305cdc3171bfdba9e0ff1575b0c1d0d7f873f60b0d1b7f", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "00acd40a-0ee3-4115-8049-25a73c6b6a04": {"doc_hash": "82a9c5df54bd541be39f28f8b660d1033008ce75baa615008c47301742a67186", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "2a0812da-6a6b-4b4a-9122-c3f130b5f39e": {"doc_hash": "d9dbb51e7bdf3b54575334c6effbd375d4e810a5e072c5c7b2d898f70e7f489e", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "a1f31508-54bc-4626-b0bd-550fd9132c98": {"doc_hash": "e163f7c28b3b26246d245d5e0dc69a33337884e0cf29359c6f3eefe01c23ac88", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3": {"doc_hash": "a64f0d24d64f853c5cabaedabbd8d35157fddb9078bb8e1a2ab2c1a921780ae5", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "a8a770be-c35f-4013-b204-678c6ad02cc8": {"doc_hash": "be5a8f35b55f081d2c442e66155b40773961d14ea467cf18117233f5592011bc", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "e3f4037c-5f63-4263-96ab-744e772537f0": {"doc_hash": "b2ce938c5b14b62a0d8d38f00a7313a4ef1092402497b22d710fb3782da98aa1", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "c00d39d0-29b5-47cd-9735-7b266287022e": {"doc_hash": "4cd9d449ab444f6135bd6533fad43c2b5e321b5668c4881f472e7b5e254e70d5", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "ff63881a-ea5b-46ed-9095-67492b194c18": {"doc_hash": "39dc0b515663e244ac9b5f5fb15b368f09d3e8e6439b72e8186997a8977a1c8e", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "65001cc5-3d27-4793-a8cd-40e12c1699ec": {"doc_hash": "8a9838a27bbbdecf2e7802c6df72a36b800ef871bce40036c0e82dfaf5252cb9", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "8dbb718a-761c-4aef-9a3c-ef5c8be45b93": {"doc_hash": "0d3147bed3dcef334e26c7fcbbd7819f0758c72ceff78cff8f6b2a843bdffe47", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "6e828304-aa5c-44ab-912f-2444294dda92": {"doc_hash": "3cae9ba3ba08251840da6c2a13769da53abf21156ef1d7e4a0555a2bff53e51b", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "80bcff5f-fe39-458b-a609-c88d04f325ec": {"doc_hash": "cea59998fc817b472ac5a4cfa1d22d048c03b772845158b80837e8f82518d36f", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "b2e344a7-07c7-4b03-b945-dac2f7d52543": {"doc_hash": "2018e142f1c186bf8b534a4645bf397f36204313ddb74e64a569d970b0f63622", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "6a73b18e-b686-44df-9d62-409ed8aaf04a": {"doc_hash": "0a99274d08751e5368139fd63f8a8cc3769e8f4a1eef48ff3c4100819ed90851", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "f462f269-b39c-4db8-8fa8-446b41e255af": {"doc_hash": "8ac80cec4a3b3613fec72caa47c5426eff9ef00f5030e560804958b70cdd242d", "ref_doc_id": "3b98c11b-968e-4c02-bb95-5adef919d78e"}, "e47efa82-ba5e-4e7e-af00-e274008099eb": {"doc_hash": "6d47a4364683f579d881eb396b07a4ee7f5d5d2d6da6134df4759f784e155b32", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f": {"doc_hash": "77513fb165e0bd1f83aa8e56bac81a18add622da78d9fb2af4d00bc97c52b3cf", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "fb48123f-31e1-42e9-b855-ccbfceead542": {"doc_hash": "61da9ae998163137fac2a51d943098513ee95075e3ae6dccca12b32045b82fc3", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "73b0173c-3f8c-4585-95f2-25221d2e1d43": {"doc_hash": "ad3142d4e7b3ea7c9204bf3b97dc792a7ed29de868beff138cd8554b0c2fb9b2", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "073eac4d-74b8-4843-a262-c10c198e52a6": {"doc_hash": "18e71ea30de34ec0ad5c0678d0e637cc66433db0e652888d4d33832c377a5d2c", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "e083cb90-d228-4735-8b81-8dfd0aea2e79": {"doc_hash": "7d5af899f668198bf964268b6ad350d073129eac0561f05b86923b3ba1996f61", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "764b26c0-f283-4ce6-95e2-e66063fe75d6": {"doc_hash": "459e7ad65f567da8dc56caaaf3b3f4e6e00b09aab66a43a8b366ac501a405e77", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "d0f67162-bca4-49a7-bb38-dab39b2f6a24": {"doc_hash": "109cbf16bffcdc07ae5ff93adbc84c371818af919f1e38215b84b6005311a9ec", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "8990f384-ad18-4cfc-9584-19a82a52acfa": {"doc_hash": "8debc61e60e2e947dfa52d821dafa36f58b2c2f43034559c8aab8644b63d1733", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "85088b18-07c1-43f5-9c95-08f7d2490994": {"doc_hash": "a1d17e481ac9e0881e1fab8e50a9921dd3667aedcde510f9c6dde7dd2620f94d", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "844e632f-60a1-405c-8677-d526ce2d105b": {"doc_hash": "cd9bc0a792b855f898aeb088f111de072cad4e1caef08b2a079422c174171bcd", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "b075ba1d-769e-457f-a081-fc288bdec389": {"doc_hash": "a929f92accb2dad3a0c808f46de46869cae695e926b14289887fdbed01b3d93d", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "45e6943d-9067-4564-b1e6-4ea78d6f6706": {"doc_hash": "134ed1affef2d2c10ae79c00a7ea769fd7250dd81ecf912b331e134a16020e79", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "da11392b-7442-45ed-bf82-2aea21bf5061": {"doc_hash": "447216caeaf5c1a730c091c5453e75ad5acffa1f08a02380642d5e860950819b", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "68b3ef72-41d8-47d2-8188-19fcd9a5c135": {"doc_hash": "71579d16f4debbe625485924b476af712fe080f88efb44b0473e04212dbba2ee", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "6d1547bc-3317-4c97-8e0a-8a3f428c40c5": {"doc_hash": "8c75cf42be4fcab05c53dcf10865711da924d0ad10968f67cd208bb194574add", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8": {"doc_hash": "c1b0d650515d0692d45a6c97f11c7b06a671ea85ceb73883f663ab34f04d16df", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "5e23def1-9f23-48da-82dd-dd070f618f8a": {"doc_hash": "ef5650580c359301ecc947febab38f8462a9a18cfb16cf0b3126c4b1dd14e842", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}, "108f2b36-25e5-4d82-86c0-662726ecdf70": {"doc_hash": "7846791138eb9d5e03704c450ef6b94d433d0370a9d617ef04a9452eba5b28ee", "ref_doc_id": "066464df-b033-4822-abd5-2642c8d71f08"}}, "docstore/ref_doc_info": {"7a2e2f1a-e74e-4aca-857b-a60243a9b406": {"node_ids": ["bd9c8945-0f61-43a4-a05a-98f04983f080", "7fe2206e-cade-4790-bea9-72a6d79b8cdc", "4d2107bf-4f5f-4469-b8c9-c7de7f3bf511", "c863004e-c2df-4eb7-b406-d25e4e24c40d", "d1ee7199-20bd-428b-8d8f-e8f51dcd268d", "6e619bf4-1178-4c12-a56a-39f3afff092d", "c9d0e3e4-1ee5-4446-b42b-493a19fa1586", "dae1d640-4b0c-4614-8046-eff77ea08555", "a40f42ca-8ad8-485f-9fad-7f97a40ecba7", "0f740528-ed5c-4cd7-adf4-55f71c3f7545", "db457551-07ce-4033-af2f-3dbaab0f83ee", "d7cea242-b704-4816-95b7-4ad2e1e960bd", "27911437-bb74-415a-84ca-b624092d5b20", "74089d77-d17a-4c63-ab9a-cbbbaf69ffed", "5cfe3972-d4a9-4ec4-8aeb-dfbf3961e2de"], "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.  Revenue increased 5.7 percent to $189.9\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$(23.74) for the September quarter of fiscal 2020, compared to $0.63 in the prior year quarter. ", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Four th Quar ter and Y ear End R esults\n11/5/2020\nRevenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year\nFourth Quarter GAAP Diluted EPS of $(23.74) and Adjusted Diluted EPS of $1.89\nRevenue of $189.9 Billion for Fiscal Year 2020, a 5.7 Percent Increase Year-Over-Year\nFiscal Year 2020 GAAP Diluted EPS of $(16.65) and Adjusted Diluted EPS of $7.90\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nfourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6e2e2375-2056-44d1-9211-acb187caa717": {"node_ids": ["24daad0f-2890-4b79-9bb7-785941a91e58", "0aa870e0-e8ed-4c3a-b8da-51a7de61021d", "ff3daf94-fdd1-46b4-8c48-2c0720dd25ce", "137ef58a-ac1a-4da7-81f8-af9d95634ee1", "ae2ea183-92e9-45a1-ae66-bbbce4a55bd7", "22c7e601-577f-49cb-8ed8-c30ec89692fc", "853b7cb6-a361-474e-8570-325da0038bca", "703f156d-862c-4d3c-86e1-fe8cc9082600", "19b8e792-cd8f-4953-9151-be3bba46648e", "efa888d4-7245-4a31-86a6-6e150d54c524", "1317e049-f628-47d4-975c-a8f2cccf1f18", "811378d9-6c2f-4b92-8f6b-23abc41d1bc2", "77dda154-9f67-46c3-888f-84d4c097adb4", "c3193c05-42bb-4696-b21b-32c94195a431", "28228a07-16f7-47aa-99be-946156a6be6e", "6eb63018-6c57-4d9f-9a7b-bb3f4d076ec2", "e0953262-5102-4766-a52a-88e5d3a74d93", "753e5b41-f83f-4a6f-a21c-7757eb54cbb6", "e08d95df-585d-4b6b-9538-a95f2bb28bc4", "6060e495-18c1-4b8a-8294-eef50ef76848", "5b966424-52e8-4901-80c6-249c7e6c4bb6", "0a90a22f-e1dd-4627-a240-cd0120f510b1"], "metadata": {"window": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2020, revenue was $49.2 billion, up 7.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 7.8 percent increase in Pharmaceutical Distribution Services revenue and a 10.8 percent\nincrease in revenue within Other.\n", "original_text": "Net (Loss) Income A ttributable t o ABC $(4.8)B $389M\nDilut ed Earnings P er Shar e $(23.74) $1.89\nDilut ed Shar es Outstanding 204.1M 206.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "99f35340-e798-462c-b301-84023a5e8668": {"node_ids": ["7b1fe49a-b2b9-454f-b50c-63a831ac8f61", "04e3da42-b9d5-4e07-b739-23b3b628f366", "99e179fe-68db-4e44-a38c-acb7bcb75617", "eb10ce1e-8d0a-456e-a978-64bc1d579b06", "2f75c2c4-53a1-4b0f-98e4-9c1d18c7a7e1", "81d75f35-e706-4bb9-9430-6e9062754085", "998631c3-b098-42e5-91d5-768746b3a302", "bbd00dd1-4e58-4a2d-b793-9b75af047e8c", "22346f65-df2b-4f3f-9c6e-eaf1dba9fda4", "f4503d4c-1c21-45ae-bff3-13a8dc2b00bb", "e75a5724-6375-4162-95c1-70dcc0c69310", "5d60c2ad-0116-478e-b81b-196add31126a", "b1937eb6-0d16-4339-99f5-2d6a21c20b36", "2e29ef5e-5a02-4e05-b21d-fdd155b4b239", "49a57206-6a64-4021-97a1-4465ac16c9c2", "f2ffb482-19c0-4a52-af31-5448e8784b92", "233093d7-e34a-41c9-b82e-0afe621fdb7e", "f62e0cbf-f0d4-46c0-bb79-f46a8572bf93", "697037c2-9329-44c0-bf10-e08a208c408e", "4ceed96e-b614-4b9d-9c5d-95a5eb2cb195"], "metadata": {"window": "forward.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2020, revenue was\n$49.2 billion, up 7.9 percent compared to the same quarter in the previous fiscal year, reflecting a 7.8 percent increase in\nPharmaceutical Distribution Services revenue and a 10.8 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 fourth quarter was $1.3 billion, which was up 6.4 percent\ncompared to the same period in the previous year, due to the increases in gross profit within Pharmaceutical Distribution\nServices and Other primarily resulting from higher revenue. ", "original_text": "forward.\n", "page_label": "3", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "29ab8946-edfd-4590-9f3c-e369f1c3048b": {"node_ids": ["29e955cb-e530-481d-bbef-55d17d883fee", "e06309f5-3821-4dda-bf3e-62ad4e02f0f9", "b1e7885d-ada5-48da-a274-c3b5cdad066e", "ea3bb1ee-ebf2-435e-86a3-7f314ba46755", "62e5e62e-0326-4aac-b93b-51983f257c7b", "20e56d2a-0cc0-43eb-a2e6-ac5aa3ad7368", "00a31cca-1242-4d5e-bcf6-9dcba5899389", "f90ce0b7-6a63-4ea6-bb04-5070fbfe17b1", "8460cdfe-2644-4618-a626-71c31f6f72b4", "03930657-2bab-400f-8f04-2239491ddf1c", "2d05beb9-cd19-42a8-be58-379f86d222fe", "68e2f6e8-32b2-466c-aa25-c2f5824234e6", "f703977b-1992-460f-bcdf-52877cce03e0", "b595c98b-2a4b-47f3-9a39-dd224ed59c4a"], "metadata": {"window": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 20.5 percent to $104.5 million in the fourth quarter of fiscal 2020 primarily due to an increase at World Courier.\n Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $189.9B $189.9B\nGross Pr ofit $5.2B $5.2B\nOperating Expenses $10.3B $3.0B\nOperating (Loss) Income $(5.1)B $2.2B\nInterest Expense, Net $138M $138M\nEffectiv e Tax Rat e 35.8% 20.8%\nNet (Loss) Income A ttributable t o ABC $(3.4)B $1.6B\nDilut ed Earnings P er Shar e $(16.65) $7.90\nDilut ed Shar es Outstanding 204.8M 206.6M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2020, GAAP diluted EPS was $(16.65), compared to $4.04 in the prior year.  Revenue of $189.9 billion was up 5.7 percent\nover the last fiscal year. ", "original_text": "Other\nRevenue in Other was $2.0 billion in the fourth quarter of fiscal 2020, an increase of 10.8 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "4", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7d2a82f1-58ef-49fb-97d1-d08d2dd2c115": {"node_ids": ["79033148-2632-4cd2-9863-a4402bc06bae", "f6409f3c-ff47-462a-a7ec-66cf92f2fd95", "6674f685-60a1-40f6-9f9d-b7b99a8cace2", "6acb175c-fb63-45e2-8608-e3f0de0d211d", "a3de57fb-6252-4b24-9ecc-5593485b4bf3", "6428ae8a-19f4-467f-a065-c5f63f2f572b", "b49d5fba-1923-40c3-9e17-9ec4fa31e63b", "500faac5-cf18-41c0-9231-516d8856c4a4", "866e6947-6464-4a49-a482-f1c957f57805", "31a8441d-4b4b-42fe-80de-7b6f096851f2", "ed50ec2e-f61d-488b-a2ef-cb40ff37bf09", "87ddd624-a21e-4c76-8276-eadc950e1f7d", "ee2ad3f9-75ce-4c66-8b12-b4227face72f", "cecc850b-e060-488d-b771-80dbce91a03d", "4be0d65a-6f85-4270-a079-3512e2c95ccf", "83626644-f406-4e61-99dd-b68510e8f5fc", "1f25c9f8-14b6-43f9-8626-15527dd2e5c8", "765a1777-bcd2-469f-ae04-a6805f4df07e"], "metadata": {"window": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n Good Neighbor Pharmacy, AmerisourceBergen's national independent pharmacy network, hosted ThoughtSpot, its annual\nconference and tradeshow.  Thousands of independent pharmacists participated in ThoughtSpot 2020 which included a virtual\ngeneral session and keynote address, more than 40 on-demand continuing education sessions, and a selection of live\nwebinars hosted on AmerisourceBergen's new virtual event platform.\n AmerisourceBergen hosted its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty and generic manufacturers. ", "original_text": "AmerisourceBergen was selected by the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "page_label": "5", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "991b5740-edca-4251-803c-f1bd2f8fbe44": {"node_ids": ["dde9fd5f-f402-46b6-a9fa-424facae070f", "07585bae-966a-470e-bd35-e22a0030963b", "81e94f23-93ee-42db-96a0-04e6516c4447", "a9cd29b5-2317-4b85-9ab5-34dea7819d47", "60f65129-7de7-4671-87c8-f434bfc260f6", "f8e9fdef-2257-4b0b-bae8-0730b5700343", "d4036928-dbf0-4ebe-b527-6a92e7fe5991", "84729ce8-2556-4a14-a8fc-cbd0c034ab0a", "0b30e4e9-b5fc-42c8-a111-eff9b1d0c0f4", "e9bd3959-5a6f-4fbe-bd5a-7a6a03c37d30", "bc43260a-110e-4d63-b6ad-187cae692264", "f2d2cc54-21a1-4da2-a446-4d3c904f3292", "ff3864ea-ad97-45ec-81cb-8c98d659e985", "9f374e57-cf72-405e-a78a-2a72ab0617da", "6078699d-35c6-46c8-afa9-1a4b71e86aa9", "28bf0b91-05e3-48fb-8ee9-72ff5042b156", "9c4f8d91-83a4-4ad1-8aee-98280e608a63", "f25f6784-733e-42c5-9155-010533818f64", "bee2999e-f602-4bd0-b336-c3b158f01198", "48205464-ecaa-4855-bd83-fc93bc2f3fd1", "f7aecefb-1258-4e55-9eb1-cea2b184246f", "44a32c10-3c5a-48a6-b529-ede5dfe9d401", "e956ebc2-ce30-4736-b167-993c78d3d6ea", "d0ad6d6f-c890-4391-b21c-d37e4c7ea1b9", "82b2e5c6-29bc-40d4-8c01-74821aba62ce", "6146dc7f-1150-4c10-92da-17d421bb698c"], "metadata": {"window": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Steven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "6", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "79a4aa0b-df42-4135-848a-9dd211bde65c": {"node_ids": ["e06cdf83-31db-4e84-9ed9-9cead65c9a82", "ce95df4d-f082-42ba-b9a2-6a67e51b7343", "ca5de92a-a310-4b8a-8c78-ee81c10362ae", "a6752793-e8e7-42ec-975d-e10c701bdad7", "ea19e11a-5561-4789-8adb-ab3d226c3b1a", "1b018d3c-554c-4a9b-ada4-7638c41ecf48"], "metadata": {"window": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including principally with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt\nPractices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material\nreduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss,\nbankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and\nability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate\nfluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax,\nregulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic,\nlong-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3e77b5f4-6b57-426c-af63-3312e27915f5": {"node_ids": ["d7d8433e-2694-4a57-9fc4-d9b9908e8780"], "metadata": {"window": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "original_text": "Depreciation and amortization \u00a097,337 \u00a0\u00a00.20 %\u00a0108,545 \u00a0\u00a00.24 %\u00a0(10.3 )%\nEmployee severance, litigation, and other 3 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0174,407 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a07,459,984 \u00a0\u00a015.15 %\u00a01,004,896 \u00a0\u00a02.20 %\u00a0642.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(6,113,137 )\u00a0(12.41 )%\u00a0179,841 \u00a0\u00a00.39 %\u00a0(3,499.2 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0(4,387 )\u00a0\u00a0 \u00a0(1,213 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,707 \u00a0\u00a0\u00a0 \u00a036,403 \u00a0\u00a0\u00a0 \u00a0(4.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(6,143,457 )\u00a0(12.48 )%\u00a0144,651 \u00a0\u00a00.32 %\u00a0(4,347.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 4 \u00a0(1,298,952 )\u00a0\u00a0 \u00a012,344 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(4,844,505 )\u00a0(9.84 )%\u00a0132,307 \u00a0\u00a00.29 %\u00a0(3,761.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterest \u00a0(1,567 )\u00a0\u00a0 \u00a0312 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(4,846,072 )\u00a0(9.84 )%\u00a0$132,619 \u00a0\u00a00.29 %\u00a0(3,754.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.64 \u00a0\u00a0\u00a0 \u00a0(3,809.4 )%\nDiluted \u00a0$(23.74 )\u00a0\u00a0 \u00a0$0.63 \u00a0\u00a0\u00a0 \u00a0(3,868.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0207,979 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0204,094 \u00a0\u00a0\u00a0 \u00a0209,680 \u00a0\u00a0\u00a0 \u00a0(2.7 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "551079b5-a5a6-4d61-bd6e-479afab2ec50": {"node_ids": ["d1b9f343-00dd-49dd-9cb8-ad39ce1c4c49", "1239d4d9-95e0-4f90-bb4f-866fca49fa81", "bdcd009d-4abc-42e5-88d3-b514fe89b91d", "b2d590ae-7639-416f-b2df-d6ddc00a7e12", "adf39649-b52f-44d3-b623-d5d75944c70c", "e4a3b046-2445-4a61-8ce6-1c432806072b", "17c8c4ed-abb7-439c-9cb8-8fd649f03a5e", "5bd389c8-7aac-4ecf-82e3-3c9f957d4bf9"], "metadata": {"window": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020.  Includes a $57.2 million LIFO expense, $6.7 million of PharMEDium\nremediation costs, and a $3.1 million gain from antitrust litigation settlements in the three months ended September 30, 2019.\n\u00a0\n 2Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.  Includes $7.0\nmillion of PharMEDium remediation costs in the three months ended September 30, 2019.\n\u00a0\n", "original_text": "________________________________________\n1Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State Opioid Stewardship\nAct (for the period covering January 1, 2017 through December 31, 2018), and a $0.5 million gain from antitrust litigation\nsettlements in the three months ended September 30, 2020. ", "page_label": "9", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "67637666-07f6-46ca-95ff-6e0322dfdf1f": {"node_ids": ["18a6f189-e253-4cf7-be1c-216e3f675a49"], "metadata": {"window": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Distribution, selling, and administrative 2 \u00a02,767,217 \u00a0\u00a01.46 %\u00a02,663,508 \u00a0\u00a01.48 %\u00a03.9 %\nDepreciation and amortization \u00a0391,062 \u00a0\u00a00.21 %\u00a0462,407 \u00a0\u00a00.26 %\u00a0(15.4 )%\nEmployee severance, litigation, and other 3 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0330,474 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a010,327,238 \u00a0\u00a05.44 %\u00a04,026,389 \u00a0\u00a02.24 %\u00a0156.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating (loss) income \u00a0(5,135,354 )\u00a0(2.70 )%\u00a01,111,923 \u00a0\u00a00.62 %\u00a0(561.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(1,581 )\u00a0\u00a0 \u00a0(12,952 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0137,883 \u00a0\u00a0\u00a0 \u00a0157,769 \u00a0\u00a0\u00a0 \u00a0(12.6 )%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Loss) income before income taxes \u00a0(5,293,831 )\u00a0(2.79 )%\u00a0967,106 \u00a0\u00a00.54 %\u00a0(647.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(1,894,273 )\u00a0\u00a0 \u00a0112,971 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income \u00a0(3,399,558 )\u00a0(1.79 )%\u00a0854,135 \u00a0\u00a00.48 %\u00a0(498.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(9,158 )\u00a0\u00a0 \u00a01,230 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (loss) income attributable to AmerisourceBergen\nCorporation \u00a0$(3,408,716 )\u00a0(1.80 )%\u00a0$855,365 \u00a0\u00a00.48 %\u00a0(498.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.07 \u00a0\u00a0\u00a0 \u00a0(509.1 )%\nDiluted \u00a0$(16.65 )\u00a0\u00a0 \u00a0$4.04 \u00a0\u00a0\u00a0 \u00a0(512.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d3dc6679-af14-4823-bb3a-9e97e000459a": {"node_ids": ["c31585bb-0952-4944-afe8-79e7825b740c", "c28c0c6b-18ca-4530-a187-63a3ed8f09d0", "77db1781-36f1-4da5-835f-642ef764dff0", "1d7c5e21-9d02-4bcf-ab6b-5fe5a8bf24f0", "df81b0ff-8496-4d0a-89eb-c99a33fdfea3", "626f011a-0058-44cf-9b87-5b26be8490ca", "953a2da6-014f-45cf-97a6-2f19b54731da", "f33cd36d-1b6d-4a7b-8d97-14d6502f6ce5", "3d59d0c7-96c3-4074-97f7-c453383a3420", "b02135bc-b68e-4eba-97f1-b1c218ff1914"], "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.  Includes\na $145.9 million gain from antitrust litigation settlements, $48.6 million of PharMEDium remediation costs, a $22.5 million LIFO\ncredit, and a $22.0 million reversal of a prior period estimated assessment relating to the New York State Opioid Stewardship\nAct in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes $46.8 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended\nSeptember 30, 2020.  Includes $20.8 million of PharMEDium remediation costs in the fiscal year ended September 30, 2019.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0210,165 \u00a0\u00a0\u00a0 \u00a0(2.6 )%\nDiluted \u00a0204,783 \u00a0\u00a0\u00a0 \u00a0211,840 \u00a0\u00a0\u00a0 \u00a0(3.3 )%\n________________________________________\n1Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the period covering\nJanuary 1, 2017 through December 31, 2018), $12.6 million of PharMEDium remediation and shutdown costs, a $9.1 million\ngain from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020. ", "page_label": "11", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8687204e-d0a7-4da4-9432-1f376b32802d": {"node_ids": ["5114b368-cc2e-4189-9a49-72b3a73431f6"], "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0Income \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss) \n Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per\nShare\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0327 \u00a0\u00a0189 \u00a0\u00a0(138 )\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e870ba2f-9b27-47a8-894e-26192a7e6020": {"node_ids": ["e8fe8ed8-037b-4e6a-a8aa-d8e839067ac1", "584d9df2-6136-47df-ab81-481061fe64e6", "1037c6f5-913a-4149-87e3-81628ac1288a", "64d4fbaa-3b73-4868-bc38-fd58c44822bd", "938ee48a-47f2-4c4e-84e7-0db3571470fb"], "metadata": {"window": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a06.4 %\u00a00.8 %\u00a016.2 %\u00a018.7 %\u00a031.5 %\u00a0\u00a0 \u00a015.1 %\u00a017.4 %\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Loss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(595 )\u00a0\u2014 \u00a0\u00a0595 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "09e81d7a-2548-4447-9283-300df9fa2a91": {"node_ids": ["a9bc7192-8d8f-4256-a1f4-9ac2e396b394", "593093f1-7746-4452-b0f6-b027dd72e045"], "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,184,737 \u00a0\u00a0$1,004,896 \u00a0\u00a0$179,841 \u00a0\u00a0$144,651 \u00a0\u00a0$12,344 \u00a0\u00a0$ 312 \u00a0\u00a0$132,619 \u00a0\u00a0$0.63 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust\nlitigation\nsettlements \u00a0(3,137 )\u00a0\u2014 \u00a0\u00a0(3,137 )\u00a0(3,137 )\u00a0(764 )\u00a0\u2014 \u00a0\u00a0(2,373 )\u00a0(0.01 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a057,203 \u00a0\u00a0\u2014 \u00a0\u00a057,203 \u00a0\u00a057,203 \u00a0\u00a014,956 \u00a0\u00a0\u2014 \u00a0\u00a042,247 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation costs \u00a06,660 \u00a0\u00a0(7,027 )\u00a013,687 \u00a0\u00a013,687 \u00a0\u00a03,550 \u00a0\u00a0\u2014 \u00a0\u00a010,137 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,078 )\u00a034,078 \u00a0\u00a034,078 \u00a0\u00a08,844 \u00a0\u00a0(438 )\u00a024,796 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance, litigation,\nand other \u00a0\u2014 \u00a0\u00a0(174,407 )\u00a0174,407 \u00a0\u00a0174,407 \u00a0\u00a043,855 \u00a0\u00a0\u2014 \u00a0\u00a0130,552 \u00a0\u00a00.62 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(204 )\u00a0\u2014 \u00a0\u00a0204 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$1,245,463 \u00a0\u00a0$789,384 \u00a0\u00a0$456,079 \u00a0\u00a0$420,889 \u00a0\u00a0$82,581 \u00a0\u00a0$ (126 )\u00a0$338,182 \u00a0\u00a0$1.61 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "520772ff-bae5-432b-bead-06f23fabe510": {"node_ids": ["a7e79ba0-69a1-46ea-b708-fb81e2d1fcd7", "69906f47-04e7-410b-a4eb-9ab883932e32"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\n(Loss) \n Income \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit)\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net (Loss)\nIncome \n Attributable\nto \n ABC \u00a0Dilut ed \n Earnings \n Per\nShare \u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354 )\u00a0$(5,293,831 )\u00a0$(1,894,273 )\u00a0$(9,158 )\u00a0$(3,408,716 )\u00a0$(16.65 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(9,076 )\u00a0\u2014 \u00a0\u00a0(9,076 )\u00a0(9,076 )\u00a0(1,988 )\u00a0\u2014 \u00a0\u00a0(7,088 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\n15", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.60% \u00a02.73%\nOperating expenses \u00a02.20% \u00a01.73%\nOperating income \u00a00.39% \u00a01.00%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bff91b8c-9e20-4fae-9c1c-7b15b45748fa": {"node_ids": ["195f806c-1005-48d0-9817-5c5dc51c8b40"], "metadata": {"window": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "costs \u00a012,556 \u00a0\u00a0(46,815 )\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478 )\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745 )\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307 )\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,660 )\u00a05,867 \u00a0\u00a0(3,626 )\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590 )\u00a0(3.49 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036 )\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c51fbe87-a9e5-4d7e-bfe7-34e3d8dc2050": {"node_ids": ["008b954c-ebdd-44b7-86b2-42648c81b6cd", "1d154778-ddf4-4be8-a6ac-472d32ec92eb", "00838776-fb73-4c0a-8ec0-257d95e87699", "4b7ac312-11b2-4f0b-8c2d-c944f7884b76", "16eba2a1-0d4f-4284-ae85-be5d91c485db", "686b71b0-c938-47bb-add6-b4efca6ae1cd", "7e933621-0bc5-4d60-ab78-9d8803e4473b"], "metadata": {"window": "Adjusted\nNon-GAAP %\nchange vs.\n prior year \u00a04.4 %\u00a02.3 %\u00a07.5 %\u00a09.3 %\u00a010.5 %\u00a0\u00a0 \u00a08.7 %\u00a011.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 3Represents a tax benefit relating to Swiss tax reform.\n\u00a0\n", "original_text": "Adjusted\nNon-GAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "999b7c0b-7db0-4420-af0a-464508fe1c2f": {"node_ids": ["e6c393c3-c8f3-48c0-98e1-deed4f005d81"], "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare\nGAAP \u00a0$5,138,312 \u00a0\u00a0$4,026,389 \u00a0\u00a0$1,111,923 \u00a0\u00a0$967,106 \u00a0\u00a0$112,971 \u00a0\u00a0$1,230 \u00a0\u00a0$855,365 \u00a0\u00a0$4.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(145,872 )\u00a0\u2014 \u00a0\u00a0(145,872 )\u00a0(145,872 )\u00a0(38,063 )\u00a0\u2014 \u00a0\u00a0(107,809 )\u00a0(0.51 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(22,544 )\u00a0\u2014 \u00a0\u00a0(22,544 )\u00a0(22,544 )\u00a0(5,883 )\u00a0\u2014 \u00a0\u00a0(16,661 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a048,603 \u00a0\u00a0(20,820 )\u00a069,423 \u00a0\u00a069,423 \u00a0\u00a018,115 \u00a0\u00a0\u2014 \u00a0\u00a051,308 \u00a0\u00a00.24 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014 \u00a0\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,741 )\u00a0\u2014 \u00a0\u00a0(16,259 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(159,848 )\u00a0159,848 \u00a0\u00a0159,848 \u00a0\u00a041,710 \u00a0\u00a0(1,821 )\u00a0116,317 \u00a0\u00a00.55 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0\u00a0(330,474 )\u00a0330,474 \u00a0\u00a0330,474 \u00a0\u00a084,638 \u00a0\u00a0\u2014 \u00a0\u00a0245,836 \u00a0\u00a01.16 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000 )\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,734 \u00a0\u00a0\u2014 \u00a0\u00a0421,266 \u00a0\u00a01.99 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692 )\u00a0(3,573 )\u00a0\u2014 \u00a0\u00a0(10,119 )\u00a0(0.05 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n18", "page_label": "18", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c8749d25-13fa-44a8-9a83-e9471d8112d8": {"node_ids": ["587cea1a-8fd6-43bb-9684-79e46bead2b2", "b4e17012-e68d-4ada-a614-f725bf534812", "db92de59-0145-479e-8f9d-ce49d37fba70"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0Three Months Ended \nSeptember 30, \u00a0Fiscal Y ear Ended \nSeptember 30,\n\u00a0 \u00a02020 \u00a02019 \u00a02020 \u00a02019\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0204,094 \u00a0\u00a0207,979 \u00a0\u00a0204,783 \u00a0210,165\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a0\u2014 \u00a0\u00a01,701 \u00a0\u00a0\u2014 \u00a0\u00a01,675 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0204,094 \u00a0\u00a0209,680 \u00a0\u00a0204,783 \u00a0\u00a0211,840 \u00a0\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$4,996,499 \u00a0\u00a0$2,945,247 \u00a0\u00a0$2,051,252 \u00a0\u00a0$1,892,743 \u00a0\u00a0$389,905 \u00a0\u00a0$(591 )\u00a0$1,502,247 \u00a0\u00a0$7.09 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.86% \u00a02.78%\nOperating expenses \u00a02.24% \u00a01.64%\nOperating income \u00a00.62% \u00a01.14%\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2340d502-3472-4d1d-822e-89910f10693e": {"node_ids": ["0f113148-d3d7-4043-a9eb-0a6c7e543a09", "24def10d-99c8-4d09-94e4-dbd2846b7bd3", "cff161fb-93fd-484e-9282-ba9d179d248f"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,288,572 \u00a0\u00a0$43,865,440 \u00a0\u00a07.8 %\nOther \u00a01,990,992 \u00a0\u00a01,797,436 \u00a0\u00a010.8 %\nIntersegment eliminations \u00a0(34,796 )\u00a0(25,074 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,244,768 \u00a0\u00a0$45,637,802 \u00a0\u00a07.9 %\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$425,567 \u00a0\u00a0$369,303 \u00a0\u00a015.2 %\nOther \u00a0104,525 \u00a0\u00a086,737 \u00a0\u00a020.5 %\nIntersegment eliminations \u00a0(118 )\u00a039 \u00a0\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0206,356 \u00a0\u00a0209,680 \u00a0\u00a0206,622 \u00a0\u00a0211,840 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for GAAP presentation.\n\u00a0\n", "page_label": "20", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7a250ca7-4948-488e-bec3-03bd2a36811b": {"node_ids": ["9f3f1de8-4617-49ca-ac00-72ceec4b48e5"], "metadata": {"window": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Total segment operating income \u00a0529,974 \u00a0\u00a0456,079 \u00a0\u00a016.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0530 \u00a0\u00a03,137 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a035,773 \u00a0\u00a0(57,203 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a02,200 \u00a0\u00a0(13,687 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,133 )\u00a0(34,078 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,641,681 )\u00a0(174,407 )\u00a0\u00a0\nOperating (loss) income \u00a0$(6,113,137 )\u00a0$179,841 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.05 %\u00a02.07 %\u00a0\u00a0\nOperating expenses \u00a01.15 %\u00a01.23 %\u00a0\u00a0\nOperating income \u00a00.90 %\u00a00.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.08 %\u00a018.76 %\u00a0\u00a0\nOperating expenses \u00a012.83 %\u00a013.93 %\u00a0\u00a0\nOperating income \u00a05.25 %\u00a04.83 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.74 %\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a015.15 %\u00a02.20 %\u00a0\u00a0\nOperating (loss) income \u00a0(12.41 )%\u00a00.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "84e1ca6a-98f0-412b-8f2a-39fca4af8589": {"node_ids": ["9643655f-e3c1-4718-984b-b503530db308", "3f0b2377-ee22-49b9-af27-672093bea19b"], "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$182,467,189 \u00a0\u00a0$172,813,537 \u00a0\u00a05.6 %\nOther \u00a07,525,102 \u00a0\u00a06,868,341 \u00a0\u00a09.6 %\nIntersegment eliminations \u00a0(98,365 )\u00a0(92,757 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$189,893,926 \u00a0\u00a0$179,589,121 \u00a0\u00a05.7 %\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating (loss) income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,807,001 \u00a0\u00a0$1,671,251 \u00a0\u00a08.1 %\nOther \u00a0400,139 \u00a0\u00a0380,660 \u00a0\u00a05.1 %\nIntersegment eliminations \u00a0(2,693 )\u00a0(659 )\u00a0\u00a0\nTotal segment operating income \u00a02,204,447 \u00a0\u00a02,051,252 \u00a0\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.69 %\u00a02.73 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.62 %\u00a01.73 %\u00a0\u00a0\nAdjusted operating income \u00a01.08 %\u00a01.00 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f64e3259-5ffb-4d34-a2e2-dde3e6a1b004": {"node_ids": ["926420dd-a9d9-40b1-9fd8-b6aaf69b95c6"], "metadata": {"window": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "original_text": "Gain from antitrust litigation settlements \u00a09,076 \u00a0\u00a0145,872 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(7,422 )\u00a022,544 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(59,371 )\u00a0(69,423 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0(14,800 )\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(110,478 )\u00a0(159,848 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(6,807,307 )\u00a0(330,474 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating (loss) income \u00a0$(5,135,354 )\u00a0$1,111,923 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10 %\u00a02.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 %\u00a01.16 %\u00a0\u00a0\nOperating income \u00a00.99 %\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.60 %\u00a019.13 %\u00a0\u00a0\nOperating expenses \u00a013.28 %\u00a013.59 %\u00a0\u00a0\nOperating income \u00a05.32 %\u00a05.54 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73 %\u00a02.86 %\u00a0\u00a0\nOperating expenses \u00a05.44 %\u00a02.24 %\u00a0\u00a0\nOperating (loss) income \u00a0(2.70 )%\u00a00.62 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "30ca6010-c542-48bf-8f83-c0eda9fdcbfb": {"node_ids": ["301f8a3c-628a-4688-b6c2-1ceb93c8167e", "11913a23-6cb2-4a23-a183-06e156c7e701"], "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 13,846,301 \u00a0\u00a012,386,879 \u00a0\nInventories 12,589,278 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,344,649 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 452,579 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 189,300 \u00a0\u00a0157,385 \u00a0\nTotal current assets 33,019,853 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,484,808 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,592,826 \u00a0\u00a09,000,343 \u00a0\nDeferred income taxes 70,522 \u00a0\u00a0\u2014 \u00a0\n24", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.75 %\u00a02.78 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 %\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a01.16 %\u00a01.14 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b748d157-5abd-407a-b589-973fbe7166ae": {"node_ids": ["a297227f-cd3c-49ea-b529-2cbc2b0c47c7"], "metadata": {"window": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "original_text": "Other long-term assets 779,854 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,705,055 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 1,646,763 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 501,259 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 33,853,077 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,618,261 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 644,363 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes \u2014 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 472,855 \u00a0\u00a0419,330 \u00a0\nCommitments and contingencies 6,198,943 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal (deficit) equity (839,636 )\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and (deficit) equity $43,947,863 \u00a0\u00a0$39,171,980 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n25", "page_label": "25", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5fdc3d6a-0d61-4995-928e-f92d09e35c62": {"node_ids": ["4d89b570-dd30-467f-84e2-fba82f89df20"], "metadata": {"window": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "original_text": "\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet (loss) income $(3,399,558 )\u00a0$854,135 \u00a0\nAdjustments to reconcile net (loss) income to net cash provided by operating activities 1(1,057,797 )\u00a01,120,690 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (1,628,991 )\u00a0(1,241,890 )\nInventories (1,621,143 )\u00a0(167,990 )\nAccounts payable 3,300,832 \u00a0\u00a01,561,048 \u00a0\nOther, net 2 6,613,697 \u00a0\u00a0218,030 \u00a0\nNet cash provided by operating activities 2,207,040 \u00a0\u00a02,344,023 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (369,677 )\u00a0(310,222 )\nCost of equity investments and acquired companies, net of cash acquired (56,080 )\u00a0(63,951 )\nOther 45,886 \u00a0\u00a0(1,659 )\nNet cash used in investing activities (379,871 )\u00a0(375,832 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (32,006 )\u00a0(133,073 )\nPayment of premium on early retirement of debt (21,448 )\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449 )\u00a0(674,031 )\nExercises of stock options 159,533 \u00a0\u00a076,234 \u00a0\nCash dividends on common stock (343,578 )\u00a0(338,974 )\nOther 54,331 \u00a0\u00a0(16,669 )\nNet cash used in financing activities (603,617 )\u00a0(1,086,513 )\n\u00a0 \u00a0 \u00a0\u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8d6d58f6-5aa1-420b-88a9-9b14ee27334a": {"node_ids": ["a321c71a-110e-4153-8368-ed02bede86f3", "fddb7a59-f8ba-4de8-8cda-20fcd1c770b1", "e468c82c-e572-4f68-82f3-07e84b6becaf", "93300160-99c0-426a-90a8-573959e73321", "d76e686b-e258-46bf-96f3-0a5574b9b346", "5c000b21-2d65-46d7-acf8-61db328126a5", "20434f49-6ddf-4fe6-abcb-29d6b462a246", "b254378d-d2f7-4558-85d5-5c206251c37e", "78ee9d17-6f3c-4c9c-a2dd-9e0150981868", "dab18f92-7a3b-4728-8d90-a8aa32ae2ee2", "8ada95e0-36fa-4ce0-a677-1210812735e9", "dcdcc45e-b067-4da0-b193-87d7f599d0f5", "6f28c544-62ed-48ae-98e0-2cfac7da54b1", "e46d3d7b-1d6d-4529-9426-a1199d27c744", "57b598a4-0081-4d83-9545-77fd1524e8e9", "5e033b38-b8d1-46be-8779-54884ed0a48c"], "metadata": {"window": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020.  Includes a LIFO credit of $22.5 million and an impairment of PharMEDium assets of\n$570.0 million in the fiscal year ended September 30, 2019.\n\u00a0\n 2Includes a $6.6 billion expense accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.  Also\nincludes a $446.7 million increase in income tax receivable in the fiscal year ended September 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\n", "original_text": "Increase in cash and cash equivalents 1,223,552 \u00a0\u00a0881,678 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of year 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of year $4,597,746 \u00a0\u00a0$3,374,194 \u00a0\n________________________________________\n1Includes a LIFO expense of $7.4 million, an impairment of PharMEDium assets of $361.7 million, and a $1,940.3 million benefit\nfor deferred income taxes primarily attributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the\nfiscal year ended September 30, 2020. ", "page_label": "27", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3b98c11b-968e-4c02-bb95-5adef919d78e": {"node_ids": ["6fe20c2e-e71e-4346-a0ba-684e413c968f", "f0638315-3faa-420d-b140-e565e7426baa", "3f4704b1-2a76-4011-af34-a6420c90659c", "5b5bd722-8c50-4e75-871f-9b565b662249", "cab9bf4c-e745-4769-9300-b8ae41b53c66", "35c95969-f58a-458e-91d2-14e9ee16892b", "51f0a62d-434a-4fbd-a1e7-4e6ef5826763", "5dadbc79-37f4-47b0-864d-78b294ccd489", "93dbed1b-b51f-4521-aa86-b6a7ad2833f1", "acf3bb9b-b1d6-4217-b217-43a0552f3183", "c9d9249c-b721-4f5b-bfda-4ef77f5898a7", "22140291-af52-476e-84d8-3096fb2f7028", "7c8163b5-212a-40d6-b06e-ec5b90cd26d1", "6e20b16f-5c00-4280-8d5a-0ae797798217", "9b1f5a3e-2f19-4df0-be33-efc98829b2f8", "0f18043a-7704-4e56-a608-69a002879271", "00acd40a-0ee3-4115-8049-25a73c6b6a04", "2a0812da-6a6b-4b4a-9122-c3f130b5f39e", "a1f31508-54bc-4626-b0bd-550fd9132c98", "aefdd8d5-3144-4e7c-9d67-1b061cf36ca3", "a8a770be-c35f-4013-b204-678c6ad02cc8", "e3f4037c-5f63-4263-96ab-744e772537f0", "c00d39d0-29b5-47cd-9735-7b266287022e", "ff63881a-ea5b-46ed-9095-67492b194c18", "65001cc5-3d27-4793-a8cd-40e12c1699ec", "8dbb718a-761c-4aef-9a3c-ef5c8be45b93", "6e828304-aa5c-44ab-912f-2444294dda92", "80bcff5f-fe39-458b-a609-c88d04f325ec", "b2e344a7-07c7-4b03-b945-dac2f7d52543", "6a73b18e-b686-44df-9d62-409ed8aaf04a", "f462f269-b39c-4db8-8fa8-446b41e255af"], "metadata": {"window": "expenses.  The expense (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they\nare unusual and non-recurring.  Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the\nCompany\u2019s ongoing operating performance. ", "original_text": "expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "066464df-b033-4822-abd5-2642c8d71f08": {"node_ids": ["e47efa82-ba5e-4e7e-af00-e274008099eb", "aeea6d3f-b9cd-4544-b573-83cf02b3fa8f", "fb48123f-31e1-42e9-b855-ccbfceead542", "73b0173c-3f8c-4585-95f2-25221d2e1d43", "073eac4d-74b8-4843-a262-c10c198e52a6", "e083cb90-d228-4735-8b81-8dfd0aea2e79", "764b26c0-f283-4ce6-95e2-e66063fe75d6", "d0f67162-bca4-49a7-bb38-dab39b2f6a24", "8990f384-ad18-4cfc-9584-19a82a52acfa", "85088b18-07c1-43f5-9c95-08f7d2490994", "844e632f-60a1-405c-8677-d526ce2d105b", "b075ba1d-769e-457f-a081-fc288bdec389", "45e6943d-9067-4564-b1e6-4ea78d6f6706", "da11392b-7442-45ed-bf82-2aea21bf5061", "68b3ef72-41d8-47d2-8188-19fcd9a5c135", "6d1547bc-3317-4c97-8e0a-8a3f428c40c5", "eda2f6ae-9e51-43f8-8f6d-22f006ef7cd8", "5e23def1-9f23-48da-82dd-dd070f618f8a", "108f2b36-25e5-4d82-86c0-662726ecdf70"], "metadata": {"window": "adjusted income tax expense for the fiscal year ended September 30, 2019.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "adjusted income tax expense for the fiscal year ended September 30, 2019. ", "page_label": "29", "file_name": "CEN-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220281, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}